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Abstract 
The objective of this work was to develop suitable delivery systems for 
biological agents that have antimicrobial activities using biocompatible polymers, 
aiming to reduce their toxicity when administered. Two biological agents, colistin as 
an antibacterial agent and nystatin (Nys) as an antifungal agent, are the focus of this 
thesis as they are potent treatments for current pathogen infections, especially to the 
multidrug-resistant (MDR) bacteria/fungi, but have potential toxicity to human. 
Polymeric drug delivery systems, including prodrug, hydrogel and micelle 
formulations, have been developed and discussed for their potential as topical and 
systemic regimes. 
The majority of the work was focused on the effect of the covalently attachment 
of   synthetic polymers onto the biological agents upon their antimicrobial activities 
and the toxicity. The conjugation between colistin and polymers was achieved 
successfully through either irreversible or releasable linkages. Although irreversible 
polymer modifications on colistin showed no antimicrobial activity (chapter 2), an 
acceptable antibacterial activity was observed from the polymer-colistin conjugates 
with a releasable linkage through either ‘grafting-to’ (chapter 3) or ‘grafting-from’ 
(chapter 4) approaches. On the other hand, even though the pure polymer-Nys 
conjugate with a releasable imine linkage cannot be obtained due to the nature of the 
labile imine bond, the crude conjugate showed an excellent antifungal activity and a 
reduced toxicity compared to the native Nys (chapter 6).  
Other polymeric delivery systems were also discussed in this thesis. The 
incorporation of colistin within a developed hydrogel delivery system as an 
antibacterial patch for burn infections was investigated through in vitro and in vivo 
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studies, showing a similar antibacterial activity as the native colistin solution against 
MDR Gram-negative bacteria with no systemic toxicity (chapter 5). Finally, an 
amphiphilic polymer containing boronic acid groups on the side chains was 
synthesised and used to target the hydroxyl groups on Nys, expecting to build up an 
environmental responsive micelle through dynamic boronate ester bond (chapter 7). 
Although more work is still needed, this system showed a potential to improve Nys 
solubility.
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 Introduction  
1.1 Biological Antimicrobial Agents 
Biological antimicrobial agents are the biomolecules that are generated or 
discovered from a living organism or its products which can be used for human 
therapeutics against pathogenic microorganisms. Ever since the very first biological 
antimicrobial agent, penicillin,1 was discovered by Alexander Fleming in 1928 and 
then applied clinically to treat infectious diseases, the long drawn fight between the 
micro-world and humans has not relented.2, 3 Over the last decades, the infections 
caused by microorganisms, especially bacterial and fungal infections, remain a great 
physical and financial burden to all human beings.4-11 Unfortunately, due to the 
increased use of these antimicrobial agents in recent years, more and more of these 
microorganisms have developed resistance to them. The emergence of multidrug-
resistant (MDR) strains of bacteria/fungi has become a worrying prospect for all 
humanity.7-9, 11, 12 While there is an urgent need for more novel antimicrobial agents, 
the development of new drugs normally takes years.10, 13-15 Thus, some ‘old’ 
antimicrobial agents, e.g. colistin as an antibacterial agent and amphotericin B 
(AmB)/nystatin (Nys) as an antifungal agent, have now been reappraised and reused 
as ‘last-line’ treatments for microbial infections.16-19 These agents are effective and 
incidents to resistance, to date, have been rare.20 However, the use of these drugs is 
limited by concerns regarding systemic toxicity in humans, especially to the kidney, 
during administration.21-23 Therefore, methods to reduce their toxicity while retaining 
activity were developed and discussed in this thesis. 
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1.1.1 MDR Gram-negative bacteria infections and colistin 
Bacterial infections, especially drug-resistant infections are a major global 
health issue.7-11, 19 The emergence of MDR Gram-negative ‘superbugs’ including 
Pseudomonas aeruginosa, Acinetobacter baumanii, and Klebsiella pneumoniae, 
threatens to undermine the efficacy of treatments in both the developed and developing 
world.24-26 These problematic bacteria can easily spread within confined environments 
such as hospitals to immunodeficient patients,27, 28 making the treatment of these 
patients more complex and problematic. A recent report suggests failing to control 
drug-resistant infections may cause in excess of 10 million deaths per year and cost 
up to US$ 100 trillion by 2050.11 P. aeruginosa, for example, is a particularly 
problematic pathogen that is of concern worldwide.26-30 These ‘superbugs’ are 
particularly difficult to treat due to the nature of their robust outer membrane.31 
Polymyxin, a type of anitibacterial lipopeptide, are one of the only few effective 
treatment options for these MDR Gram-negative infections.32-35 
1.1.1.1 Chemical structure and the related activity of colistin  
Colistin (polymyxin E), one important member of the polymyxin family, is a 
peptide-based antibiotic produced by Gram-positive bacteria such as Paenibacillus 
polymyxa.20 It was first discovered in 1949 and had been used clinically in a salt form 
of colistin sulfate or in a prodrug form of colistimethate sodium (CMS) from the 
1950s.20, 36  Although it was later banned for use since in the 1980s due to the high 
incidence of nephrotoxicity,34 it is now applied as a last-line therapy against infections, 
as a result of increased cases of resistance in less toxic therapeutics and limited 
discovery of new antibiotics.33  
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Figure 1.1 The chemical structure of the two major subgroups of colistin, colistin A (left) and colistin 
B (right). 
Colistin is a cyclic lipopeptide constructed of an intramolecular hydrophilic 
peptide-based loop with a N-terminal fatty acyl group.33, 37 The commercial colistin 
source contains two major active components, colistin A and colistin B, of which the 
only difference is on the N-terminal fatty acyl group; a 6-methyloctanoic acid for 
colistin A and isooctanoic acid for colistin B (Figure 1.1).38 Both compounds are 
biologically active against Gram-negative bacteria, therefore, the mixture of colistin 
A and B are used directly in clinical colistin treatments. 
The mechanism of colistin activity takes place at the bacterial outer membrane 
of the Gram-negative bacteria. The insertion of colistin can disrupt the barrier function 
of the Gram-negative outer membrane that ultimately cause the cell death.18, 20, 37, 39 
The amphiphilic structure formed by the hydrophilic amino acid residues (2,4-
diaminobutyric acid (Dab) and threonine (Thr) residues) and two hydrophobic 
domains (the N-terminal fatty acyl group and the two hydrophobic residues) on colistin 
helps it to fold into a more compacted surfactant-like structure to achieve a better 
binding to the bacterial outer membrane. The five primary amine groups on the Dab 
residues of colistin, which are protonated under physiological condition, can recognise 
and electrostatically interact with the phosphorylated sugars on the lipid A component 
of the lipopolysaccharide (LPS), the major constituent of the outer membrane of 
Gram-negative bacteria. This interaction will displace the divalent cations (Mg2+ and 
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Ca2+) within the LPS, causing the disruption of the bacteria outer membrane, further 
leading to bacteria lysis.  
1.1.1.2 Potential toxicity of colistin  
Even though colistin is a potent antibiotic against most Gram-negative bacteria, 
the potential toxicity is always of concern.40-42 The major adverse effects of the 
administration of colistin are neurotoxicity (~7%) and nephrotoxicity (15-55%), 
particularly acute renal failure. Most patients that experience neurotoxicity are likely 
to have also had renal failure. Thus, many studies have focused on colistin 
nephrotoxicity to elucidate its mechanism. So far, several pathways including 
oxidative damage and inflammatory caspase (Caspase 1) have been reported to be 
involved in the nephrotoxicity mechanism.42 The main cause of toxicity is considered 
to be closely related to its antimicrobial activity, with the five primary amine groups 
on the Dab residues and the N-terminal fatty acyl group of colistin being implicated. 
Although the clearance pathway of colistin is not fully understood, it is believed that 
colistin undergoes renal tubular reabsorption during the the clearance process, where 
it can also bind and be inserted into the tubular epithelial cell membrane. Thus, it 
would increase the permeability of the cell membrane causing cell swelling and cell 
lysis.  
However, it is still possible to maintain the colistin antimicrobial activity and 
reduce its potential nephrotoxicity. One straightforward method is to alter the structure 
of colistin. Thanks to the development of automated solid-phase peptide synthesis, 
many polymyxin analogues have been synthesised and screened for their activity and 
toxicity.37 Unfortunately, it was found many analogues possessed no or low 
antibacterial activity, indicating the interaction between colistin and the bacterial outer 
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membrane is crucially influenced by the chemical structure of colistin. Due to the 
small molecular weight of colistin as well as most functional groups are involved 
during the binding process, a single change on one residue can cause a dramatic change 
on the binding affinity, and result in a loss of its activity. To evaluate the effect of 
polymer modification on colistin, several approaches have been developed and will be 
discussed in chapter 2.  
 
Figure 1.2 The possible modification sites for polymyxins, Dab amines (blue), hydroxyl groups (red), 
and terminal amine (green). 
 In order to modify the chemical structure of colistin while maintaining its 
activity, an alternative approach involves formulation of polymyxins into prodrugs.43 
The possible modification sites, terminal amine, Dab amines and hydroxyl groups, 
have been labelled in different colours in Figure 1.2. The terminal amine on colistin 
can be recovered through enzyme degradation on the N-terminal fatty acyl group.44 
The resultant polymyxin nonapeptide analogue exhibits a much lower toxicity with an 
acceptable antibacterial acitivty.37 Therefore, it can be potentially fabricated into a 
prodrug.45 However, the polymyxin nonapeptide analogue itself has a lower 
antibacterial activity compared to the native polymyxins, thus, no clinical product has 
been developed. The modification on polymyxin Dab residues is also possible and 
CMS, or colistimethate sodium, is one successful example. As an FDA approved 
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prodrug of colistin, it can be used intravenously in the clinic.36 The prodrug is prepared 
by modification of the five primary amines to form methanesulfonate groups, which 
reduce the possibility of the interactions between colistin and the healthy human cells 
during the delivery process, making it is less toxic compared to the native colistin.46 
Despite this CMS still has some limitations that will be elaborated in chapter 3. To 
date, this is the only FDA approved colistin-based prodrug therapy available for clinic 
use. Another possible modification site that has been underestimated is to modify the 
hydroxyl groups on polymyxins. Although no prodrug has been developed through the 
hydroxyl group modification, the chemical engineering on polymyxin hydroxyl 
group(s) can potentially become a useful tool for formulation into a prodrug and has 
some advantages compared the other two modification methods. To demonstrate this 
possibility, two approaches for the development of polymeric colistin prodrugs have 
been addressed in chapter 3 and 4. 
As nephrotoxicity is dose-dependant, an alternative approach to reducing the 
risk is to lower the dosage and therefore the overall systematic colistin concentration. 
40, 42, 47  Owing to the differences between the bacteria and human cell membrane, it is 
possible to kill the bacteria at a low enough colistin concentration to avoid or limit the 
toxicity. The clinical studies suggested the potential risk of colistin nephrotoxicity can 
be suppressed by lowing the dose of colistin (in CMS prodrug form) during the 
administration, while the colistin concentration remains effective against the 
infection.35 Alternatively, delivery of colistin through a topical delivery system in 
principle may also help to reduce the overall systematic colistin concentration while 
keeping the local colistin concentration high enough to kill the bacteria. To explore 
this concept, a hydrogel-based localised delivery system is developed in this thesis as 
well, which will be elaborated in chapter 5.  
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1.1.2 Fungal infection and polyene antimycotics  
Although a large population of fungal species (> 5 million species) lives on the 
Earth,48 less than 2 per mille (around 600 species) of them are considered to be human 
pathogens.23 Some fungal infections (i.e., superficial and cutaneous infections) are 
mild and easy to treat thanks to the development of antifungal treatments,  however, 
other fungal infections can sometimes be life-threatening.23, 49-52 For example, 
Candida albicans, one of the most common fungi pathogens in clinic, is able to infect 
every human organ through the bloodstream, causing severe systematic damage to the 
patients.53 Furthermore, the opportunistic invasive fungal infections, especially by 
Canadida pathogens, can easily cause cross-infection in immunocompromised patients 
in hospitals, which burdens the medical care and increases the cost of treatment.54 
Before the other less-toxic synthetic antifungal drugs such as azoles and 
pyrimidine analogues have been developed over the last decades, the natural product 
polyene drugs, AmB in particular, was the standard treatment against these pathogens 
like Candida species.23 
1.1.2.1 Structure and pharmaceutical behaviours of polyene 
antimycotics 
Polyene antifungal agents are primarily produced by Streptomyces bacteria, a 
genus of actinomycete Gram-positive bacteria.21, 23, 55-57 Although there are more than 
200 analogues that have a similar antifungal activity, amongst them, AmB and Nys 
are the two most widely used polyene antifungal agents because of their acceptable 
clinical toxicity.23 Both compounds are cyclic amphiphilic macrolides containing eight 
hydroxyl groups, a carboxyl group and a glycoside group on the main ring (Figure 
1.3).58, 59 The difference of the two structures is that AmB is a heptaene macrolide 
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(seven conjugated double bonds within the main ring) with two hydroxyl residues on 
position 5 and 6 while Nys is tetraene diene macrolide (two sets of conjugated double 
bonds, two and four, within the main ring) with two hydroxyl residues on position 4 
and 7.  
 
Figure 1.3 The difference between the chemical structures of the two polyene antifungal agents, AmB 
and Nys. 
The colour difference between the two compounds (AmB has an orange colour 
while Nys is light yellow) is likely caused by the difference in the conjugation double 
bonds system of Nys, the similar chemical structure of AmB and Nys instils in them a 
similar physical and biological behaviour, i.e., low solubility in aqueous media, similar 
antifungal activity and mode of action.60, 61  
Although different models have been suggested to explain the mechanism, 
which can vary in some fungal strains, it is widely accepted that the binding to 
ergosterol, the major sterol component of the fungal membrane, is very crucial to this 
process.23, 56, 62 Thanks to the hydrophobic polyene structure and the polar glycoside 
group, AmB and Nys can target and bind ergosterol on the fungal membrane.61, 62 
Their amphiphilic structures can further help AmB and Nys insert into the cell 
membrane, disrupting the integrity of the cell membrane, resulting in changes in 
permeability and cell lysis.23, 61 Thus, both drugs have a broad antifungal activity 
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although AmB is more effective in most cases which is attributed to its rigid 
structure.60  
1.1.2.2 Current available formulation of polyene drugs to improve 
their solubility and reduce toxicity 
Due to the similar structure between ergosterol and cholesterol (the sterol 
existence on human cell membrane), these polyene drugs also have an affinity, albeit 
lower, towards cholesterol.21, 23 It is considered to be one of the main reasons that these 
drugs produce a high toxicity, especially to human kidneys, when administrated. The 
solubility of AmB and Nys is also a big issue.62, 63 In addition to the difficulties that 
arise in clinical applications, the low solubility of these polyene drugs will induce the 
non-selectively formation of aggregates onto both fungal and mammalian cells, 
resulting in unwanted cell damage. 
In order to improve the solubility of AmB as well as to reduce its toxicity, it has 
been formulated with solubilizing agents prior to administration.17, 56, 64-68 The 
common formulation includes of AmB micellar deoxycholate complex (AmBd, 
FungizoneTM, solubiliser: sodium deoxycholate), lipid complex (ABLC, solubiliser: 
dimyristoylphosphatidylcholine and dimyristoyl phosphatidylglycerol), liposome (L-
AmB, i.e., AmBisome®, solubiliser: hydrogenated soy phosphatidylcholine, 
cholesterol and distearoylphosphatidylglycerol) and AmB colloidal dispersion 
(ABCD, solubiliser: sodium cholesteryl sulfate).56 The concept of formulating AmB 
into a prodrug has also been raised recently.66, 69-71 The sugar amine and the carboxyl 
group on AmB are often targeted for site-specific modification. With various 
physical/biological behavior, all these formulations reduce the toxicity of AmB but 
retain all or part of its antifungal activity.56, 64 
Chapter 1 
Chongyu Zhu  10 
Conversley, formulation of Nys is not as well developed since it is mainly used 
as a topical treatment.57, 60 Systemic administrations have been avoided due to the low 
systemic activity caused by the poor gastrointestinal absorption.6, 60, 72 Of the two 
antimycotic agents, Nys is less active than AmB and is also less toxic. More 
interestingly, it shows activity against some Candida species that have resistance 
against AmB, suggesting its potential as an alternative to AmB in systemic 
administration.53, 60, 73 Thus far, some initial studies have been developed on the 
formulation of Nys into a micelle or liposome to improve its aqueous solubility.16, 60, 
74-76 
 
Figure 1.4 The possible modification sites for Nys, sugar amines (red), hydroxyl groups (blue), 1,2-
/1,3- diols (highlighted) and carboxyl group (green).   
Similarly to AmB, the sugar amine and the carboxyl group on Nys are also the 
possible modification sites for it to form a prodrug (Figure 1.4).77 To emphasise the 
possibility of modifying Nys on its amine group with a polymer to improve its 
chemical and biological performances, a prodrug approach has been developed in 
chapter 6. Although the hydroxyl groups on Nys can also potentially be targeted 
(Figure 1.4), it has not been well-evaluated due to the multiple possible reaction sites. 
Fortunately, when applying the reversible covalent boronic acid-1,2/1,3-diol 
interaction,78-80 the possible reaction sites can be in principle narrow down to two. 
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Through this environment-responsive interaction, Nys can be attached through a 
polymer delivery system with boronic acid units and can be released with stimuli, 
which will be discussed in chapter 7. 
1.2 Polymer-Based Delivery System for Antimicrobial 
Biological Agents 
As mentioned previously, the administration of these antimicrobial agents with 
the help of a suitable delivery system can increase their solubility, reduce their 
potential toxicity while maintaining their biological activity.16, 17, 56, 60, 64-68, 74, 76, 77 
However, unlike the delivery some other drugs such as antitumor agents, the initial 
concentration of the antimicroibial agents in the first few hours is crucial to their 
antimicrobial activity (especially against these MDR microorganisms) due to the fast 
(re)growth and resistance response of these microorganisms. Thus, the effective 
release of the antimicrobial agents is an important consideration when selecting an 
appropriate delivery system. 
Two main approaches have been successfully applied in clinic: 1) reaction of 
the antimicrobial agents with some biocompatible (bio)molecules, formulating them 
into prodrugs;81, 82 2) encapsulating these drugs into macro/micro-carriers (i.e., 
hydrogels, emulsions, suspensions, and aerosols) or nano-complexes (i.e., micelles, 
vesicles/liposomes, and nanogels) ahead of administration.83, 84 Although many small 
molecules such as sugars, lipids, and some other natural products have been 
successfully applied for drug delivery, more and more polymer-based drug delivery 
systems have been developed in order to benefit from the notable advantages of using 
polymers, especially synthetic polymer, over the small molecules.85, 86 Due to the 
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diversification of polymer selection and the development of polymerisation 
techniques, cheap polymers with high functionality, low toxicity and higher chemo-
/bio- stability can be synthesised and purified in economical ways.81, 87, 88 
1.2.1 Biological agent-polymer conjugates 
Although the biological agents are effective therapies, they normally have poor 
bioavailability. Unlike the common synthetic small molecular drugs, many 
peptide/protein-based drugs only have short half-lives in the human body due to the 
biodegradable nature caused by the proteolytic degradation.81, 82, 89  The poor solubility 
of some of the biological agents like the polyene antimycotics and some lipopeptides 
is sometimes problematic and limits their use.63, 66, 90, 91 Moreover, the functional 
groups on the biological agents may also trigger immune response, producing toxicity 
or other side effects.82, 92 One approach that has been developed to address these 
limitation is to modify these therapeutic biological molecules with polymers and has 
attracted increasingly attention in the past few years.81, 86  
1.2.1.1 Poly(ethylene glycol) (PEG) and PEGylation 
Amongst all the polymers, poly(ethylene glycol) (PEG), a polymer approved by 
the FDA, is most well-studied conferring high stability and good biocompatibility in 
the human body.81, 86, 89 Attachment of PEG to biological agents, known as 
PEGylation, can improve the pharmacokinetic and pharmacodynamic properties of 
these fragile biocompounds.93 The PEG chains on these agents will help them bypass 
enzymatic recognition, avoiding antigenic/immunogenic recognition92 and proteolytic 
degradation.81 PEGylation of these biological drugs also increases the total 
hydrodynamic volume of these drugs, changing their bio-distribution in the human 
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body.81, 89 Due to the unique structure of PEG, PEGylation can also prevent 
unnecessary fouling of these drugs during the delivery.94 It can also, to some extent, 
reduce the toxicity caused by therapeutic biomolecules during the drug delivery.93 
Furthermore, PEG has a molecular weight-dependent clearance property in the human 
body,81 which means that the PEG conjugated biological agents can have increased 
half-lives and circulation times can be controlled by tuning the size of the PEG 
attached. In addition, PEGylation is well studied since most PEG derivatives are 
commercial available or easily obtained. Up until now, a few PEGylated protein 
products like Adagen®, Oncospar®, and PEG-Intron® have been introduced to the 
market.81 
1.2.1.2 Controlled radical polymerisation (CRP) and their 
conjugates with antimicrobial agents 
Although PEGylation is a commonly used method to achieve biological 
antimicrobial agent conjugates, other synthetic functional polymers can provide more 
versatility and functionalisation.95-100 Controlled radical polymerisation (CRP) is a 
powerful tool to synthesize biocompatible polymers, stimuli responsive polymers and 
other function polymers with controlled molecular weights and narrow dispersities 
(Đ). Examples include, but are not limited to, poly(poly(ethylene glycol) methyl ether 
(meth)acrylate) (PPEGA/PPEGMA),97-99 poly(N-(2-hydroxypropyl) methacrylamide 
(PHPMA)),100 poly(N-isopropylacrylamide) (PNIPAM)95 and glycopolymers.96 
Furthermore, some CRP methods, such as reversible addition−fragmentation chain 
transfer (RAFT) polymerisation,95, 101 atom transfer radical polymerisation 
(ATRP),102, 103 single-electron transfer living radical polymerisation (SET-LRP),104, 105 
and copper-mediated photoinduced living radical polymerisation (CP-LRP)106, 107 can 
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now be conducted in water, buffer, or even physiological environment, which make it 
possible to perform polymerisation and conjugation in one pot under biologically 
relevant conditions. Through careful selection of the initiator and by selecting the 
appropriate conditions, conjugates between biological agents and desired polymers 
with various architectures and high end-group fidelity can be achieved.70 The 
biological agents can be attached on the end-group as well as the side chains of the 
polymers. 
1.2.1.3 Polymer conjugation methods and sites 
As the biological agents are usually complex structures with an array of 
functionality, the selection and control over the conjugation site is important during 
the modification. As amine groups are exist in many natural biological products, 
especially in peptides/proteins, it is the most commonly targeted site for the polymer 
conjugation.66, 81, 98, 108 The high nucleophilicity of the amine groups allows the 
conjugation to proceed smoothly with high yields in aqueous media. Thus, numerous 
functional groups, including aldehyde, dichlorotriazine, carbonylimidazole and 
activated ester/carbonate (1-hydroxybenzotriazole ester or N-hydroxysuccinimidyl 
ester), have been developed for this type of conjugation.81, 108 Other functional groups 
such as thiol, carboxyl and hydroxyl groups are also targeted as more specific 
alternatives.81, 96, 97, 99 
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Figure 1.5 Three approaches for biological agent-polymer conjugation. a) ‘Grafting-to’ approach is the 
conjugation of polymer directly onto a biological agent. b) ‘Grafting-from’ approach is the 
polymerisation of monomers from the initiator derivative from a biological agent. c) ‘Grafting-through’ 
approach is the polymerisation of the monomers derivative from a biological agent. 
Three approaches that are classified as ‘grafting-from’, ‘grafting-to’ and 
‘grafting-through’ are mainly applied for the polymer conjugation (Figure 1.5).109, 110 
The ‘grafting-to’ approach has been widely explored to conjugate the biomolecules 
with α–functional polymers, especially PEG, typically through an efficient reaction 
(i.e., ‘click’ reaction) under a mild conditions such as water/buffer system at ambient 
temperature.81, 89, 96, 98, 100, 101 However, the ‘grafting-from’ and ‘grafting-through’ 
approaches are more often used when combined with CRP techniques.101, 103, 110 This 
is as the conjugation between the biological agent and a small molecule is usually 
much more efficient than between the biological agent and a polymer. In general, the 
‘grafting-from’ polymerisation through CRP is with high yield and high end-group 
fidelity and the final polymer is easy to purify and characterise.109, 110 
Although the covalently linked polymer modification can normally provide a 
good stability to the conjugate both in vitro and in vivo, a significant (or sometimes 
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complete) loss of the activity of the biomolecules has often been reported for many 
polymer-biomolecule conjugates following such modifications.98, 111 This has mainly 
been attributed to blockage of the active site(s) or changes to the structure of the 
biological agent caused by the polymer. Thus, prodrugs based on traceless and/ or 
reversible conjugations have attracted significant attention.112-116 These types of 
prodrugs usually stay as an inactive or less active derivative under normal (storage) 
conditions, but can be converted back to the active drug at the targeted site/ 
environment in vitro/ in vivo. Several dynamic covalent bonds, including 1,6-
elimination,113 thioester,115 bicine,114 azidomethyl-methylmaleic anhydride,117 and 
disulphide bonds115, 118-120 have been explored as releasable linkers. 
1.2.2 Micellar delivery system of poorly soluble antimicrobial 
agents  
Despite the benefits obtained from the polymeric prodrug formulation, some 
antimicrobial agents are very poorly soluble in water/buffer systems and sometimes 
even in organic media, making them difficult to be fabricated into prodrugs. Due to 
the low solubility, these drugs will also cause other clinic problems such as low 
bioavailability and unreliable absorption behaviour.62, 63, 121 To disperse and stabilise 
these drugs in aqueous media on a nanometer scale, one approach is the formation of 
high-order self-assembled structure such as micelles as nano-carriers.85, 122-124 Micelles 
are formed from the self-assembly of amphiphiles and have a spherical structure with 
a hydrophobic core and a hydrophilic shell. The core of the micelle can encapsulate 
hydrophobic antimicrobial drugs while the hydrophilic shell can stabilise the micelles, 
preventing the micelle-micelle/environment interactions.124-126 Although it showed 
some potential in the research, the small molecule based micelles are rarely used in 
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clinic as the critical micelle concentration (CMC) of micelles is relatively high and is 
not stable in the human body.127  
With the development of controlled polymerisation techniques, polymer 
micelles have received more attention.124, 127 Self-assembled micelles with a narrow 
polydispersity can be prepared from well-defined and well-designed amphiphilic 
block copolymers.128, 129 Compared to low molecular weight surfactant, the CMC of 
polymer micelles are normally several orders of magnitude lower, therefore, they are 
more stable when administered. There is a wide choices of polymers that are non-toxic 
and will not trigger the immune response or other adverse effect through the delivery. 
Through the design of the polymers, it is feasible to introduce functionality (i.e., 
pH/chemo-/thermo- response and (bio)degradability) onto the micelles.79, 126, 129 
Furthermore, the tunable hydrophobic/hydrophilic ratio and length of the polymer 
provide a precise control of the size of polymer micelles, which is important for cell 
uptake and the passive targeting delivery through the enhanced permeability and 
retention (EPR) effect.130 
The major approach to load hydrophobic antimicrobial drugs into polymer 
micelles is to dissolve the drugs the same time with the polymers and co-assemble via 
solvent switch.126 However, other methods including the incorporation of the drugs 
after the self-assembled micelle or the conjugation of the drugs onto the polymers side 
chains/end group(s) in advance of self-assembly are also possible to achieve a 
successful drug loading.  
1.2.2.1 Cross-linked polymer micelle formulation  
Unfortunately, most of the drug-loaded polymer micelles developed so far have 
not provided significant improvements compared to the original drug in vivo.131, 132 
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Through dilution from body fluid when administered, the micelles are no longer stable 
and thus disassembly into unimers can occur, which is unable to disperse and stablise 
the poorly soluble antimicrobial agents.  
To avoid this, core or shell ‘cross-linking’ can be applied, preventing micelle 
disassembly in vivo.131-134  By covalently cross-linking the hydrophobic part (‘core 
cross-linking’) or the hydrophilic part (‘shell cross-linking’) of the self-assembly of 
the amphiphilic polymer, the dynamic feature of the micelles is fixed. The cross-linker 
is normally a bi/multi-functional compound that can react with the micelle effectively. 
Other methods for cross-linking include polyelectrolyte complexation,135 
reduction/oxidation,136 metal chelation137 and photo-radiation.138  
As drugs normally stay in the core (the hydrophobic domain) of the polymer 
micelles due to the strong hydrophobic interactions, one concern for the drug-loaded 
cross-linked polymer micelle is whether it is too stable for the release of the drugs. 
Thus, a trigger within the cross-linked polymer micelle system (i.e., cleavable polymer 
side chains or degradable cross-linkers) is normally required to achieve an efficient 
release.80, 136  
1.2.3 Hydrogel formulation for water-soluble antimicrobial 
agents 
Although systemic administration is a powerful method to deliver antimicrobial 
agents and it is necessary for severe or systemic infections, it is also costly and not 
always effective against some local infections (like surface infections). Thus, some 
localised drug delivery systems have been appraised and applied clinically.139, 140 As 
these formulations are only applied topically, the local drug concentration can be high 
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enough against the microorganisms but not high enough to cause systemic toxicity to 
the human body.  
Hydrogel formulation, as one of these topical formulations, is well accepted by 
the market and has been used as contact lenses, wound dressings, tissue engineering 
materials and superabsorbent hygiene products over the last few decades.141 Hydrogels 
are cross-linked polymeric materials that are capable of capture water within the 
porous network.142 The ones cross-linked chemically, also known as permanent 
hydrogels, are normally stable and have strong mechanical properties whilst the one 
cross-linked by physical interaction such as hydrogen bonding, electrostatic 
interaction and Van der Waals forces can sometimes be dissolved or reversible in 
response to the change of the surrounding environment.141 Recent research area 
regarding hydrogels is the development of a covalent cross-linked hydrogel that can 
be responsive to some specific stimuli by introducing some photo-/chemo-cleavable 
linkers.143  
Polymeric materials used to formulate hydrogels can be both synthetic polymers 
and natural biomacromolecules depends on application. Synthetic polymers such as 
PEG, PNIPAM, poly(vinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP), poly(2-
hydroxyethyl methacrylate) (PHEMA), poly(acrylic acid) (PAA), poly(methacrylic 
acid) (PMAA), poly(2-(acrylamido)-2-methylpropanesulfonic acid) (PAMPS) and 
polyacrylamide (PAM) are favoured as they are normally with low cost and easy to 
fabricate and characterise.142-144 The chemo-/bio-stability of synthetic polymers allows 
them to have a longer shelf life and stable performance. However, biomacromolecules 
also have their advantages such as good biocompatibility and biodegradability.145, 146 
As the solid content in hydrogels is normally quite low (< 10% w/w), the cost of using 
biomaterials is also acceptable.  
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1.2.3.1 Water-soluble antimicrobial agents in hydrogel 
formulations used in wound care 
Thanks to the wide choices of hydrogels, this high-water-content, porous and 
soft material is particularly favoured in wound care.142, 147-149 Generally, the high water 
content of the hydrogels ensures this three-dimensional material a good biocompatible 
and non-irritant property.142 The incorporation of therapeutics in hydrogel 
formulations has been widely employed to facilitate and manage many wound-healing 
processes, particularly burn wounds.147-151 In advance to other treatments, the 
application of hydrogels can prevent the loss of the body fluid, keep the wound surface 
hydrated, promote the healing process, and also act as a barrier against further 
infections.152, 153 Furthermore, properties such as degradability,154, 155 environmental 
responsiveness,156, 157and self-healing158, 159 can be fine-tuned to support the curing 
process of specific wound types. 
Chitosan, as a nature biomacromolecules, is of particular interests.145 Chitosan 
is a linear polysaccharide generated by the deacetylation of chitin, a component 
obtained from the exoskeleton of crustaceans and insects. It is consisted of two 
monomer units, the deacetylated unit β-D-glucosamine (commercial product normally 
contains > 60%) and the acetylated unit N-acetyl-D-glucosamine. This unique 
structure allows it to form a hydrogel with other molecules through ionic interaction, 
hydrogen bonding, or/and Van de Waal interaction, providing various types of 
hydrogels for different applications. The sugar units make chitosan a stable 
hydrophilic backbone but also a responsive material to some enzymes. In addition to 
its biocompatibility and biodegradability, chitosan has the potential to induce faster 
wound healing and smoother scarring.145, 160 
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The combination of hydrogel and antimicrobial agents can protect the wound 
site and inhibit the growth of microorganisms at the same time.150 There are three drug 
loading methods: 1) direct addition of the drug during the hydrogel formation; 2) Drug 
loading after the hydrogel formation; 3) Covalent attachment of the drug on the 
hydrogel.145, 161 Amongst all these methods, the former two methods are more 
commonly used for water-soluble antimicrobial agents.145, 161 Due to the high water 
content and the porous structure of hydrogels, a large capacity and high loading 
efficiency can be achieved. The release of these drugs can be promoted by the 
concentration exchange of the solution in the hydrogels and the environment, which 
could provide a high local initial concentration of the antimicrobial agents. 
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 Approaches for the Development of 
Mono PEGylation on Polymyxins    
 
Two approaches for irreversibly PEGylated polymyxins have been developed 
using imine reduction and thiol-acrylate addition reactions. Both small molecule 
models and polymer modification were investigated in both approaches. Through the 
imine reduction reaction, the compositions of products from the modification of 
colistin can be tuned by varing the pH of the reaction while acrylate monomer or 
polymer can be selectively attached onto the Cys residue of an engineered polymyxin 
analogue (Pol-SH) in an atom-economic and efficient way under basic aqueous media 
without catalyst through the thiol-acrylate addition. Although both mono PEGylated 
conjugates failed to demonstrate an antimicrobial activity against the selected MDR 
Gram-negative bacteria, the chemistry developed in this work can still be applied in 
other polymer peptide conjugation that required a stable linker. 
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2.1 Introduction 
As mentioned previously, the PEGylation of biomolecules may sometimes 
improve or hinder its biological performances.1-3 Since the molecular weight of 
colistin is relatively low and the Dab residues on colistin are essential to its 
antibacterial activity, it remained unknown whether the activity of colistin would be 
retained when PEG, especially a single PEG chain, is irreversibly attached on Dab or 
other residue(s). Despite their antibiotic activity, the unique cyclic peptide structure of 
colistin is also attractive. As found in other cyclic peptides, this type of ring structures 
can be a potential unit for self-assembly and have some applications in gas separation,4 
drug delivery or other fields,5, 6 of which normally require a more stable and defined 
modification. Furthermore, although there are many functional groups on colistin, the 
chemistry of the colistin modification, especially the attachment of PEG, has not been 
well studied in general. Because of the poor chemoselectivity among the five amine 
groups on colistin, it is not easy to achieve a selective modification or mono-
modification through traditional chemistry. Thus, two approaches of the irreversible 
mono PEGylation of polymyxins were developed and discussed in this chapter.  
To improve the selectivity on amines and reduce the potential multiple 
modification, a common approach to selectively modify peptide/protein terminal 
amine group presented by the five Dab residues present, was developed. The reductive 
amination has proven to have a good selectivity to amines, especially to terminal 
amines, at a suitable pH in aqueous solution. Through the adjustment of the reagent 
stoichiometry and reaction conditions, the multiple modification of colistin was 
greatly suppressed thanks to the pH-tunable activity of the imine reduction reaction 
and the steric hindrance caused by the addition of PEG. Although the side reactions 
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cannot be avoided and the yield of desired product is not very high, the ‘pure’ mono 
PEGylated products (at one of five undetermined Dab residues) can be obtained via 
the developed high performance liquid chromatography (HPLC) method. 
As an alternative approach to mono PEGylation at undetermined reaction sites, 
PEGylation at a single site of a peptide can minimise the diversity of the products, 
providing a more precise modification. However, it is not practical for native colistin 
due to the similar activity of its functional groups. Thanks to the well-developed solid-
phase peptide synthesis, an engineered peptide with a single site mutation can now be 
achieved in a relative easy way. Recently, a cysteine containing polymyxin analogue, 
Thr10 → Cys polymyxin B (Pol-SH) was successfully synthesised by our collaborator 
from Monash University. Through the ‘thiol-acrylate’ reaction with its thiol group, 
PEG with different size can be site-specifically modified onto this polymyxin 
analogue at ambient temperature without a catalyst in an aqueous solution.   
2.2   Results and Discussion 
2.2.1 Modification of colistin on Dab residues via reductive 
amination approach 
Although the reductive amination has been widely applied for amine 
modification of peptides/proteins,1, 7 it has not been used to modify colistin, which 
does not have a reactive N-terminal amine but does have five amines that are very 
similar in chemical structure, environment and reactivity. Taking into account the fact 
that the Dab amine has a larger base dissociation constant (Kb) than the terminal 
amine,8, 9 it is more likely to be protonated in aqueous media, leading to a less stable 
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imine bond formation. Thus, it is uncertain whether this approach can modify colistin 
under the same conditions as that used for the terminal amine modification on other 
peptides/proteins. Thus, a better understanding of imine reduction reaction and the 
optimisation on the reaction condition are required for the polymer modification of the 
colistin. 
2.2.1.1 Aqueous selectivity and stability analysis of imine bond via 
a small molecule model  
Before using the imine reduction approach for colistin conjugation, the stability 
of imines in aqueous media was first tested through a small molecule model. 2-(2-
aminoethoxy) ethanol (AEE) as a simplified model for colistin and 2-formylpyridine 
(FPy) as the water soluble aldehyde model were selected to investigate the stability of 
the formed imine under different pH conditions through nuclear magnetic resonance 
(NMR) (Figure 2.1). The heterocyclic aromatic ring on FPy was expected to increase 
the stability of the formed Schiff base so that it can be used as a motif to link the 
polymers with the colistin under physiological condition. 
As shown in Figure 2.1, the aldehyde signal (δ = 9.89 ppm) belonged to FPy 
decreased while a new peak belonged to the imine bond (δ = 8.35 ppm) appeared and 
increased when the pH of the reaction mixture increased, indicating FPy can react with 
AEE smoothly in a neutral or basic condition. Although the yield of imine formation 
varies at different pH (Figure 2.2), in general, the higher pH helped the formation and 
the stability of the imine bond, which may be mainly attributed to the chemical 
equilibrium shift caused by the protonation of the amine at a lower pH.  
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Figure 2.1 1H-NMR spectra of the FPy/AEE reaction mixture at different pH. The peaks belonged to 
aldehyde, imine and hydrate product are labled with , ▲, and ♦, repectively. 
 
Figure 2.2 The stability test of the model Schiff base in different pH condition. a) Synthesis of the 
model Schiff base. b) The percentage of Schiff base and other product at different pH in the reaction 
mixture from 1H-NMR spectra. c) Proposed structures of products at different pH for the corresponding 
signals from 1H-NMR. 
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Notably, a side reaction forming FPy hydrate was also observed in the reaction 
mixture over the pH range tested due to the strong electron-withdrawing effect from 
the pyridine ring. Although suppressed at elevated pH, a significant amount of adduct 
(~ 20%) was formed at near physiological conditions. Thus, even though both of the 
amount of the FPy and FPy hydrate decreased dramatically from pH = 6 to pH = 8, 
there was only around 60% imine present in the reaction mixture under physiological 
condition (pH = 7.5). 
2.2.1.2 Colistin modification using small molecule aldehyde model 
via the schiff base reaction 
Although the imine bond is not so stable at physiological pH, the majority of the 
FPy was converted into imine at pH = 10 (Figure 2.2). Thus, an attempt to modify 
colistin linked through the imine formation using FPy directly without reduction was 
conducted. Interestingly, a precipitate formed immediately when FPy was added into 
the colistin solution at pH =10 (Figure 2.16), indicating a chemical reaction between 
FPy and colistin had taken place. Through the imine bond formation, FPy was attached 
onto the amine groups present in colistin, reducing the overall hydrophilicity, resulting 
in the precipitation of the formed FPy-colistin conjugates. To confirm this, the 
precipitate was collected and analysed by matrix-assisted laser desorption/ionisation-
time of flight mass spectrometry (MALDI-ToF MS) (Figure 2.3). 
As the native peptide is water-soluble and should remain in the solution rather 
than in precipitate, it was surprising to see the typical double-peak pattern of native 
colistin A and B at a mass of 1177.7 and 1191.8 Da from the MALDI-ToF MS. 
Although no further solid data can be obtained so far, this might be due to the breakage 
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of the relatively unstable imine bond during the ionisation process of the MALDI-ToF 
MS.  
 
Figure 2.3 MALDI-ToF MS analysis of the colistin-FPy Schiff base from the mixture. a) Synthesis of 
the colistin-FPy Schiff base. b) MALDI-ToF MS analysis of the reaction mixture. c) The set of peaks 
for colistin and the Schiff base conjugate. 
Apart from the colistin double-peak pattern, the similar double-peak patterns of 
the mono-adduct and double-adduct on both colistin A and B were also clearly 
observed from the MALDI-ToF MS spectrum at a distance of 89 Da (Figure 2.3). 
Other signals that may be contributed to colistin with more FPy modification is also 
observable even though the quality of signal is too poor to be confirmed as suppressed 
by the unexpected high signals of the unmodified colistin A and B. Although it is not 
clear that the precipitate was composed of a complete modification of FPy on all five 
amines of colistin, all the data suggested FPy could be successfully attached onto 
colistin amines through the formation of the dynamic imine bond. 
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Given the fact that the imine bond is relatively unstable towards hydrolysis 
under physiological conditions, FPy has been shown the potential to conjugate onto 
colistin without the reducing agent. However, the direct polymer conjugation to 
colistin via the imine formation will be troublesome and difficult to characterise due 
to the dynamic nature of the linkage coupled to the dispersity present in the polymer. 
Thus, the imine reduction approach was tested, initially using a small molecule model. 
With the help of the reducing agents, i.e., sodium cyanoborohydride (NaBH3CN), the 
formed imine bond can be converted into a secondary amine in situ which is stable 
under physiological condition to the hydrolysis.  
 
Figure 2.4 MALDI-ToF MS analysis of the colistin-FBA conjugate from the mixture. a) Synthesis of 
colistin-FBA conjugate. b) MALDI-ToF MS analysis of the reaction mixture. c) The set of peaks for 
colistin and the conjugate. 
In place of FPy, 4-formylbenzoic acid (FBA) was chosen as the aldehyde model 
to modify the colistin. The carboxyl group on FBA can help the solubility of the 
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colistin after modification under basic conditions, preventing the precipitation of the 
product. Instead of using the excess of the aldehyde, FBA and colistin at 1:1 ratio was 
mixed in the reaction solution to examine the selectivity of FBA for the colistin 
amines. This reaction was again carried out in a pH = 10 buffer to promote the 
formation of the colistin-FBA imine conjugates. With NaBH3CN as the reducing 
agent, the unstable colistin-FBA imine conjugates were fixed as the stable reduced 
form. When a 1:1 ratio of FBA and colistin was used, clear patterns corresponding to 
the mono-adduct and di-adduct on both colistin A and B, along with the unmodified 
colistin were identified by MALDI-ToF MS of the dialysed reaction mixture due to 
the similarity of colistin five amines (Figure 2.4). The distance between each double-
peaks pattern is 134 Da, suggesting the addition of FBA onto the colistin with a C-N 
bond instead of C=N bond. 
2.2.1.3 Synthesis and characterisation of the aldehyde-
terminated mPEG (mPEG-FBA) modification of colistin 
Based on the studies of small molecule models described above, a FBA modified 
mPEG (mPEG-FBA) was synthesised for the PEGylation of colistin (Figure 2.5). The 
FBA unit was introduced onto mPEG through the Steglich esterification. Although the 
attachment of FBA onto mPEG through the esterification would cause a mass increase 
of 132 Da, the peak overlapped with the mPEG with the extra three –CH2CH2O- units 
(44 Da for each unit). Thus, it showed an exact mass pattern as the original mPEG 
although the average mass increased slightly from the MALDI-ToF MS analysis. 
Therefore, other characterisation including 1H-NMR, 13C-NMR and Fourier transform 
infrared spectrometry (FTIR) were used to test the purity of the product. As shown in 
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Figure 2.5, all these characterisation suggested the formation of an ester bond and the 
successful introduction of FBA unit onto mPEG.  
 
Figure 2.5 a) Synthesis of mPEG-FBA and its characterisations including b) 1H-NMR, c) 13C-NMR, 
d) MALDI-ToF MS, e) tetrahydrofuran (THF) GPC and f) FTIR. 
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Gel permeation chromatography (GPC) analysis was also performed to check if 
any cross-linking reaction had happened during the modification. Although a small 
high molecular weight peak was observed due to the double PEG modification from 
the potential impurity (terephthalic acid), the high molecular weight impurty cannot 
react with amine and the dispersity index of the product remained low (Đ ~ 1.08). 
Thus, it was then used for the PEGylation of colistin. 
 
Figure 2.6 MALDI-ToF MS analysis (partial) of the colistin-mPEG-FBA conjugate from the reaction 
mixture. a) Synthesis of the colistin polymer conjugate. b) MALDI-ToF MS analysis of the colistin 
polymer conjugate. c) The zoom-in MALDI-ToF MS data of the colistin-mPEG-FBA conjugate. 
Due to the presence of a labile ester bond in mPEG-FBA, the reaction to achieve 
the reduced colistin mPEG-FBA conjugate was conducted at pH = 8.5 rather than pH 
= 10. Through the MALDI-ToF MS analysis of the reaction mixture, a distribution of 
PEGylated species was observed around 3200 Da from the reaction mixture, indicating 
the successful addition of mono mPEG-FBA (Mn ~ 2000 Da) onto colistin (Figure 
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2.6b). The double-peak pattern along with the repeating unit of 44 Da implied the 
mPEG-FBA conjugated to both colistin A and B (Figure 2.6c). No higher degree of 
modification were observed from MALDI-ToF MS due to signal suppression by the 
mono-modification peaks. 
To quantify and separate the obtained amount of mono-PEGylated colistin, 
HPLC was then applied to identify the composition in the reaction mixture (Figure 
2.7). Apart from the original double peaks that belong to the unreacted native colistin, 
multiple broad new peaks between 16 min to 23 min were observed through the HPLC 
analysis of the reaction mixture, indicating the formation of the reduced conjugates 
with mPEG-FBA (Figure 2.7 top trace).  
 
Figure 2.7 HPLC traces of the colistin-mPEG-FBA conjugate (obtained from pH = 8.5 buffer) and the 
starting materials.  
To get a better understanding of the composition of the conjugation product, 
these multiple broad new peaks from the reaction mixture (pH = 8.5 buffer) were then 
isolated by HPLC under optimized conditions, collected with a fraction collector and 
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identified by MALDI-ToF MS (Figure 2.8). The peaks in 11-13 min that eluted at the 
same time of the pure colistin from HPLC (Figure 2.7 top trace and Figure 2.8a) 
showed the same mass from MALDI-ToF MS (Figure 2.8c1), suggested they belonged 
to the unreacted colistin A and B. The peaks between 16 to 22 min (peak ② to ⑤) 
from HPLC all showed a double-peak pattern and a distribution with the repeating unit 
of 44 Da although with different molecular weight ranges, indicating they belonged to 
the colistin-mPEG-FBA conjugates attached with different numbers of mPEG-FBA 
(Figure 2.8c2-c5). Thus, peak ② was the mono PEGylation product and the accurate 
molecular weight further confirmed the generation of the conjugate was linked via C-
N single bond derived from the parent imine formed in situ. 
As shown in the middle trace of Figure 2.7, the HPLC of the reaction showed 
that the peak of the original mPEG-FBA completely disappeared after one-day 
reaction, suggesting the reaction proceeded to completion. However, in addition to 
being involved in the formation of conjugates with colistin, several side reactions 
including reduction and hydrolysis processes, were also found to be responsible for 
the consumption of mPEG-FBA. The MALDI-ToF MS analysis of the peak ⑥ at 22.5 
min showed a polymer pattern of a molecular weight distribution around 2000 Da with 
a repeating unit of 44 Da, suggested it was the reduction product of mPEG-FBA by 
NaBH3CN (Figure 2.8c6). The hydrolysis of the mPEG-FBA at this pH was also 
observed in both MALDI-ToF MS (Figure 2.17a-b) and HPLC as a new peak at 9.8 
min that belongs to the reduction product from FBA (Figure 2.8 top trace).  
Ion-exchange fast protein liquid chromatography (IE-FPLC) was also 
introduced to isolate the species with different numbers of amine groups in the reaction 
mixtures using a cationic exchange column and a fraction collector system. Each 
fraction was then identified by MALDI-ToF MS. (Figure 2.8c1-c3).  
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Figure 2.8 The identification of each peak from HPLC and FPLC. A typical RP-HPLC (a) and ion 
exchange (IE)-FPLC (b) curve of the reduced conjugation mixtures (at pH = 8.5) were shown. c) 
MALDI-ToF MS of each peak from FPLC (①-③) and HPLC (②-⑥).  
The species in the first peak from FPLC were uncharged. The analysis by 
MALDI-ToF MS showed it was the unmodified mPEG polymers generated from the 
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hydrolysis (Figure 2.17c-d). The reduced mPEG-FBA should also be present in this 
peak as it was uncharged. However, it was not observed in this case due to the in situ 
hydrolysis through the purification or the suppression by the strong signal of mPEG. 
The elution time from FPLC suggested greater positive charge was present in 
the compound in peak ② than peak ③ at pH = 4, meaning more amine groups 
remained on the conjugates in peak ②. The MALDI-ToF MS of the peak ② and peak 
③ in FPLC gave similar results as in HPLC, indicating that peak ② contained mainly 
mono-mPEG-FBA colistin conjugate with four free amine groups whilst the double 
mPEG-FBA modified colistin conjugate with three amine groups was in peak ③. 
These data agreed with the result observed from FPLC. 
 
Figure 2.9 HPLC traces (partial) of the colistin-mPEG-FBA conjugates at different pH. 
Knowing the compositions of the reaction mixture, the conjugation reaction was 
then conducted at different pH values for comparison, expecting to find an optimal 
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condition for the synthesis of mono PEGylated colistin. All of the reaction mixtures 
were analysed by HPLC as it showed a better separation of the products. As expected, 
the ratio of each conjugate in the reaction mixture varied with changing the pH. As 
shown in Figure 2.9, the maximum yield was achieved at pH 8.5-9 when reacting the 
same mPEG-FBA and colistin. Although the formation and stability of imine bond 
were favoured at high pH, NaCNBH3 showed less reduction activity at basic condition 
and the labile ester bond in mPEG-FBA would hydrolyse at this pH, leading to an 
overall lower yield of the mono PEGylation product. On the other hand, both imine 
bond and NaCNBH3 are unstable at low pH, mPEG-FBA would be reduced prior to 
the attachment onto colistin, resulting in the unwanted reducing products. 
2.2.2 Antibiotic activity of Dab-modified colistin conjugates 
 
Figure 2.10 The antibiotic activity of the colistin conjugates against P. aeruginosa ATCC 27853. Both 
pH = 8 and 10 buffers were used for the conjugation. CFU: colony-forming unit. 
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As mentioned previously, the amines on colistin are essential to its antimicrobial 
activity. However, it was suspected whether the mono PEGylated colistin conjugate 
still had antimicrobial activity since it retained four unreacted amines. Thus, prior to 
obtaining the purified mono-conjugate, the antibiotic activity of both small molecule 
(FBA) and polymer (mPEG-FBA) colistin conjugation reaction mixtures were tested 
against a MDR Gram-negative strain, P. aeruginosa ATCC 27853 (Figure 2.10). 
Unfortunately, no visible activity was found for the ‘time-kill’ experiments of all the 
samples at the concentration of 1 mg/L while the native colistin showed significant 
suppression of bacterial growth at the same concentration. The number of the colony-
forming unit (CFU) decreased dramatically within an hour in the presence of colistin 
while it increased slightly in all the conjugates samples. Although the ratio of colistin 
content by weight is less than 50% in the mPEG-FBA colistin conjugation mixture, 
the activity data obtained from the FBA implied suggesting the modification of colistin 
on even one of its amine groups with either FBA or mPEG-FBA inhibited the activity 
of the colistin. 
2.2.3 Thiol-acrylate approach for polymyxin analogue (Pol-SH) 
modification 
Although the site-specific modification of native polymyxin is difficult, Pol-SH, 
a synthetic polymyxin analogue that has a cysteine on position 10, provides an 
opportunity for the site-specific modification. Several motifs including maleimide and 
orthopyridyl disulphide, have been widely used for polymer peptide/protein 
conjugates targeting the cysteine residue.1, 10-12  However, the synthesis of these 
functional end-group polymers can be rather complicated. A simple reaction, the thio-
michael addition to acrylates (thiol-acrylate reaction) seems to be underestimated in 
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that field.13 Unlike other motifs, there is a library of acrylates, most of which are easily 
synthesized or commercial available. Thus, using small molecule and polymer 
acryaltes, conjugation at the thiol group on Pol-SH was demonstrated in this section. 
2.2.3.1 Pol-SH modification using small molecule acrylate model 
Although the thiol-acrylate reaction usually requires a catalyst such as tris(2-
carboxyethyl)phosphine (TCEP), triethylamine (TEA) or hexylamine,14 no additional 
catalyst in this case was needed since the five primary amines on the peptide will be 
deprotonated in a basic condition and act as catalyst for this reaction. In order to prove 
that, small molecule acrylates; 2-hydroxyethyl acrylate (HEA), a glucose acrylate 
monomer, and poly(ethylene glycol) methyl ether acrylate (Mn ~ 480, PEGA480) were 
tested as models with Pol-SH at both pH = 8 and pH = 9. Slight stoichiometric excess 
of the acrylates were used to promote the reaction and to minimise the thiol oxidation 
side reaction. 
For glucose acrylate monomers and PEGA480, new peaks were observed 
between the acrylate and Pol-SH at both pH values through the HPLC analysis, while 
the peaks of starting materials were significantly consumed within 3 h (Figure 2.11b-
c), indicating the high efficiency of this thiol-acrylate reaction. Although no new peak 
was observed for the HEA conjugates due to the similar polarity of the conjugate and 
Pol-SH, the decrease of the acrylate peak on the HPLC traces implied the successful 
conjugation was achieved as well (Figure 2.11a). Interestingly, a negligible but 
observable peak around 10 min was also found in the HPLC of the conjugation 
mixture. It is thought to be the oxidation product of the Pol-SH into the disulphide 
form. Although slow, the oxidation of the Pol-SH into the disulphide form can also 
occur in a basic condition. However, the side reaction can be suppressed at a higher 
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pH due to the faster thiol-acrylate reaction catalysed by colistin amines in higher pH, 
thus, it is less visible at pH = 9 than pH = 8. 
 
Figure 2.11 The modification of Pol-SH using small molecules. HPLC traces from top to bottom in 
each graph is 1) small molecular acrylates (red traces): a) HEA, b) glucose acrylate monomer, c-d) 
PEGA480; 2) reaction mixture in pH = 9 after 3 h (blue traces); 3) reaction mixture in pH = 8 after 3 h 
(green traces); and 4) Pol-SH (a-c) or colistin (d) (black traces). The thiol-addition products and the 
oxidized side products were labeled with red arrows and triangles, respectively. 
Although the addition of the acrylate onto the thiol group is expected to be much 
faster than onto the amine (or aza-michael addition), a control experiment was 
conducted to investigate this phenomenon. PEGA480 was again used to conjugate with 
the native colistin which has no thiol group. After 3 h, no decrease of the starting 
material peaks or new product peak was observed (Figure 2.11d), impling that the 
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conjugation between Pol-SH and acrylates occured only at the thiol group, and not at 
the amine groups on the same time scale. 
 
Figure 2.12 HPLC traces of the attempt addition of PEGMA480 (red trace) on Pol-SH (black trace) with 
TCEP (blue trace) or without (green trace) at pH = 8 buffer. The starting material PEGMA480, the thiol-
addition products and the oxidized side products were labeled with yellow arrows, red arrows and 
triangles, respectively. 
To explore the applicability of this reaction, a poly(ethylene glycol) methyl ether 
methacrylate (Mn ~ 480, PEGMA480) was also tested under the similar condition 
(Figure 2.12). However, only a small peak was observed at around 10.5 min from 
HPLC was found while all the starting material peaks remained high, indicating the 
reaction was much slower and was greatly hindered by the extra methyl group of the 
methacrylate group, which fitted the observation of this reaction in organic solvents 
from previous reports.14 An attempt to accelerated this procoss was then conducted by 
adding a water-soluble catalyst as well as a reducing agent, TCEP. As shown in Figure 
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2.12, although more PEGMA480 was reacted during the same reaction time and the 
oxidation side product of Pol-SH disappeared completely in this case, both starting 
materials were still not consumed completely due to the hindered structure of the 
PEGMA480. 
2.2.3.2 Pol-SH modification using acrylate modified mPEG 
derivatives (PEGA) 
 
Figure 2.13 HPLC results of the PEGA Pol-SH conjugates and the starting materials. The conponents 
in each reaction mixture was labled as followed: the formed conjugates (red arrows); the starting 
polymers (yellow arrows); the oxidised side product (pink triangles) and the potential amine-addition 
side product (purple stars). The high UV absorbent peak (labelled as Imp.) in the starting material of 
PEGA2000 and PEGA5000 was considered to be the inhibitor added commercially although more 
characterisations were required to confirm this. 
Given a better understanding of the thiol-acrylate addition through the small 
molecule model, the polymer conjugation was then tested using two commercial 
available polymer acrylates, PEGA2000 and PEGA5000. TCEP was not added in both 
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cases to simplify the system. Although a longer reaction time was required in both 
systems due to the larger size of polymers, similar results were obtained as the small 
molecule models after 18 h (Figure 2.13). The decrease of the starting polymers and 
the new peak eluting between the starting polymers and peptide from the HPLC 
indicated the formation of the PEGylated Pol-SH conjugates. However, the longer 
reaction time, because of the slower reaction rate of the thiol-acrylate addition to larger 
polymers, also led to more side reactions. A second polymer containing peak around 
12.5 min from HPLC was also observed from the reaction mixture of Pol-SH with 
PEGA2000, which was likely to be due to the amine addition of the acrylate. The 
oxidation product of Pol-SH was also more significant especially in the case of 
PEGA5000.  
 
Figure 2.14 The monitoring of the conjugation between APPEGA and Pol-SH using HPLC. The thiol-
addition product and APPEGA polymer were labeled with red and yellow arrows, respectively. 
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Although side reactions were observed using larger PEGA, it may be partially 
attributed to the lack of acrylate material caused by the impurities in the commercial 
PEGA (only half or less of the functionalised end group was found in commercial 
PEGA2000 and PEGA5000 through 
1H-NMR analysis, Figure 2.18). Thus, instead of 
using the commercial PEGA, an acrylate modified poly(PEGA480) polymer 
(APPEGA) was also synthesized via aqueous SET-LRP to conjugate with Pol-SH. The 
reaction was again monitored by HPLC (Figure 2.14). It turned out that the conjugate 
was formed within 30 min (Figure 2.14, the peak appeared around 15 min), with the 
reaction reaching completion within 4 h. Negligible amounts of oxidation product 
were observed, indicating that the thiol-acrylate addition was the dominant reaction 
even with high molecular weight species, at least with the comb-like polyPEG 
structure.  
2.2.4 Antibiotic activity of Pol-SH polymer conjugates and their 
native form 
Table 2.1 MIC experiments of the peptides, polymers and peptide-polymer conjugates against three 
bacterial strains (P. aeruginosa ATCC 27853, A. baumannii ATCC 19606, K. pneumoniae ATCC 
13883). 
 
To verify whether the Pol-SH retained its antibiotic activity when a polymer was 
attached on its Cys residue, the PEGA5000 and APPEGA polymyxin conjugates were 
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purified by preparative HPLC and then assessed for antibiotic activity (Table 2.1). 
Through the minimum inhibitory concentration (MIC) assay, all the polymers and 
their conjugates showed no activity at a concentration of 32 mg/L while the native 
polymyxin B and the engineered poly-SH showed activity below that concentration 
against all three bacterial strains. Notably, although poly-SH showed an antibacterial 
activity, the MIC of it is much higher than the native polymyxin B, indicating the 
change, even a small one, on native polymyxins can dramatically reduce their 
antibacterial activity. Thus, it implied the permanent attachment of a polymer onto 
polymyxin is not suitable for a potential drug candidate as it hindered polymyxin 
antimicrobial activity. 
2.3 Conclusions 
Two PEGylation approaches, imine reduction and thiol-acrylate addition 
reactions, have been developed to achieve the mono PEGylation of colistin and Pol-
SH, respectively. Through the small molecule models, it was found the imine bond is 
unstable in aqueous media although it can be enforced by a basic environment. 
Therefore, it is not practical to form colistin conjugates directly through imine 
formation, but it was interesting to find that the small molecule 2-formylpyridine 
(FPy) can modify colistin forming a precipitate without the reduction process at pH = 
10. With the help of NaCNBH3, both small molecules and polymer aldehyde can be 
successfully attached onto colistin although it ended up with a mixture of products 
with different degrees of modification. Through the fine tuning of the reaction pH, the 
highest yield of the mono PEGylation product can be obtained at pH around 8.5-9.  
The thiol-acrylate addition, on the other hand, can achieve a targeted 
modification on the Cys residue onto the engineered peptide (Pol-SH) with an easily 
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acquired or commercially available acrylate monomer or polymer. As colistin amines 
can act as a catalyst for the efficient addition reaction, the modification of Pol-SH by 
the acrylates can be achieved under basic aqueous media without additional catalysts, 
although TCEP was suggested that can reduce the side reactions and accelerate the 
addition process. 
Both mono PEGylated conjugates showed no antimicrobial activity against the 
selected MDR Gram-negative bacteria even though most or all of the amines were 
retained through the modification. It was probably due to the steric hindrance caused 
by the bulky polymer on its reactive site(s). Although the polymer conjugates have 
proven not to be the good candidates for antimicrobial application, they have potential 
in other applications that required a stable linker. Also, the chemistry developed in this 
work can still be applied in other polymer peptide/protein conjugation that targeting 
primary amines with high Kb or thiol residue.  
2.4 Experimental 
2.4.1 Materials 
2.4.1.1 Chemicals 
All reagents were purchased from Aldrich or VWR international and used 
without further purification unless otherwise stated. All solvents were purchased from 
Fisher Chemicals. The dialysis membranes were purchased from Spectrum® 
Laboratories, Inc. Colistin (A&B mixture) and Pol-SH were kindly provided by 
Monash Institute of Pharmaceutical Sciences and stored at 4 oC. PEGA480 was passed 
through the basic aluminium column to remove the inhibitor before being used in the 
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polymerisation. Tris[2-(dimethylamino)ethyl]amine (Me6TREN),
15 2-(2-
hydroxyethoxy)ethyl 2-bromo-2-methylpropanoate,17 and the glucose acrylate 
monomer18 were synthesised as described in the literature. 
2.4.1.2 Bacterial strains 
Bacterial strains of P. aeruginosa ATCC 27853, A. baumannii ATCC 19606 and 
K. pneumoniae ATCC 13883 (American Type Culture Collection, Manassas, VA) 
were used in this study. The strains were stored at -80 °C in a cryovial storage 
container (Simport Plastics, Quebec, Canada). Fresh isolates were sub cultured on 
nutrient agar (Media Preparation Unit, The University of Melbourne, Parkville, 
Australia) and incubated at 37 °C for 24 h prior to each experiment. Cation-adjusted 
Mueller-Hinton broth (CAMHB; Oxoid, Hampshire, England) was used as culture 
medium. 
2.4.2 Instruments 
2.4.2.1 Nuclear magnetic resonance (NMR) spectroscopy 
1H-NMR and 13C-NMR spectra were recorded on Bruker DPX-250, HD 300, 
HD 400 and HD 500 spectrometers using deuterated solvents obtained from Aldrich.  
2.4.2.2 Fourier transform infrared (FTIR) spectrometry 
FTIR spectra were recorder on a Bruker VECTOR-22 FTIR spectrometer using 
a Golden Gate diamond attenuated total reflection (ATR) cell. 
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2.4.2.3 Gel permeation chromatography (GPC) 
GPC was performed on a Varian 390-LC MDS system equipped with a PL-AS 
RT/MT autosampler, a PL-gel 3 μm (50 x 7.5 mm) guard column, two PL-gel 5 μm 
(300 x 7.5 mm) mixed-D columns equipped with a differential refractive index using 
THF (+ 2% triethylamine (TEA) + 0.01% butylated hydroxytoluene (BHT)) as the 
eluent with a flow rate of 1.0 mL min-1 at 30 oC. The calibration was fitted with a 3rd 
order polynomial using narrow molecular weight standards of both poly(methyl 
methacrylate) (PMMA, between 200 and 467,400 g mol-1). 
2.4.2.4 Matrix-assisted laser desorption/ionisation-time of flight 
mass spectrometry (MALDI-ToF MS) 
MALDI-ToF MS was acquired from a Bruker Daltonics Autoflex MALDI-ToF 
mass spectrometer or Bruker Daltonics Ultraflex MALDI-ToF mass spectrometer. The 
MALDI-ToF samples were prepared by mixing a solution of α-cyano-4-
hydroxycinnamic acid (CHCA) or trans-2-[3-(4-tert-Butylphenyl)-2-methyl-2-
propenylidene] malononitrile (DCTB) as a matrix (20 mg/mL in THF) and sample (1-
2 mg/mL in THF) at 1:1 ratio. 0.5 μL of this mixture was spotted to the target plate. 
Spectra were recorded in reflector mode calibrating with PEG or mPEG at a similar 
average molecular weight of each sample. 
2.4.2.5 Reversed phase HPLC (RP-HPLC) 
2.4.2.5.1 Analytical HPLC 
The analytical HPLC system used was an Agilent 1260 infinity series stack 
equipped with an Agilent 1260 binary pump and a degasser. 50 μL of samples were 
injected using Agilent 1260 autosampler. The HPLC was fitted with a phenomenex 
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Lunar C18 column (250 x 4.6 mm) 5 micron packing (100Ǻ).  Detection was achieved 
using an Agilent 1260 variable wavelength detector connected in series with UV 
detection monitored at 225 nm. The method to separate each conjugate varies for 
different conjugates (typically 5%-70% B) while the total flow rate was set to 1.0 
mL/min. 
The mobile phases were as followed. 
Mobile phase A: 100% water, 0.04% trifluoroacetic acid (TFA);  
Mobile phase B: 100% acetonitrile (ACN), 0.04% TFA. 
HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TFA 
was used as additive.  
2.4.2.5.2 Preparative HPLC (PREP HPLC) 
The PREP HPLC system used was an Agilent 1260 infinity series stack 
equipped with a 1260 Quat Pump VL, a degasser and a fraction collector (FC-AS). 
Samples were injected using Agilent 1260 autosampler with a 100 μl injection volume. 
The HPLC was fitted with a Jupiter C18 column (250 x 21.2 mm) 5 micron packing 
(300Ǻ).  Detection was achieved using an Agilent 1260 TCC detector with UV 
detection monitored at 225 nm. The method to separate each conjugate varies for 
different conjugates (typically 30%-45% B) while the total flow rate was set to 8.0 
mL/min. 
The mobile phases were as followed. 
Mobile phase A: 100% water, 0.04% TFA;  
Mobile phase B: 100% ACN, 0.04% TFA. 
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HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TFA 
was used as additive.  
2.4.2.6 Ion exchange-fast protein liquid chromatography (IE-
FPLC) 
IE-FPLC (Pharmacia Äkta Purifier) was performed using a cation exchange 
column, HiTrap SP FF column and eluted in sodium acetate-acetic acid (NaAc-AcOH) 
buffer at 1 mL/min as the flow rate. The elution of protein fractions was monitored at 
both 220 nm and 280 nm and the fractions were collected each 0.5 mL.  
The details of the mobile phases and the gradient method are showed below: 
Mobile phase A: NaAc-AcOH buffer (pH = 4, 20 mM); 
Mobile phase B: NaAc-AcOH buffer (pH = 4, 20 mM) + 0.5 M NaCl; 
The method for elution started with 100% A, equilibrated with 5 CV, delayed 
the gradient for 2 mL and gradient eluted for 30 CV to reach 100% B, and washed 
with 100% B for 5 CV. 
The column need to be washed with HPLC water before and after use, and stored 
in 0.1% sodium azide solution.  
2.4.3 Synthesis 
2.4.3.1 Synthesis of mPEG-FBA 
The synthesis of mPEG-FBA was based on the previous report.16 Briefly, 
mPEG2000 (4.0 g, 2 mmol, 1 equiv.) was first dissolved with toluene in a 200 mL round 
bottom flask and the solvent was then evaporated under the vacuum to remove the 
remaining water in the starting material. FBA (0.60 g, 4 mmol, 2 equiv.), and DMAP 
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(24.4 mg, 0.2 mmol, 0.1 equiv.) were then added and fully dissolved with 100 mL dry 
THF under N2. DCC (0.824 g, 4 mmol, 2 equiv.) was then added into the solution and 
the reaction mixture was kept stirring overnight. After the removal of the formed 
precipitation from the reaction mixture, the polymer was obtained after repeated 
dissolution in THF and precipitation in diethyl ether for three times. The total yield is 
around 80% with end-group functionality above 95%.  
1H-NMR (400 MHz, CDCl3, 298 K) δ (ppm) = 10.08 (-CHO), 8.20 (d, J = 8.3 
Hz, -CHCCHO), 7.94 (d, J = 8.3 Hz, -CHCHCCHO), 4.48 (-COOCH2), 3.85-3.40 (-
OCH2CH2-), 3.35 (-OCH3). 
13C-NMR (126 MHz, CDCl3, 298 K) δ (ppm) = 191.45 (-CHO), 165.27 (-COO-
), 138.97 (-CCHO), 134.84 (-COOC-), 130.08 (-COOCCH-), 129.27 (-CHCCHO), 
74.00-66.00 (-OCH2CH2-), 64.44 (-OCH3). 
Other characterisations including MALDI-ToF, GPC and FTIR were shown in 
Figure 2.5. MnMALDI = 2125.2 (DP =44, [M+Na]
+) 
2.4.3.2 Synthesis of acrylate modified poly(PEGA480) (APPEGA) 
2.4.3.2.1 Synthesis of poly(PEGA480) with a hydroxyl end group 
(poly(PEGA480)-OH) 
The synthesis of poly(PEGA480)-OH was carried out using the copper-mediated 
photoinduced living radical polymerisation (CP-LRP) technique.19 Filtered PEGA480 
(2 g, 4.16 mmol, 12 equiv.), the initiator, 2-(2-hydroxyethoxy)ethyl 2-bromo-2-
methylpropanoate (88.1 mg, 0.345 mmol, 1 equiv.), CuBr2 (1.5 mg, 6.9 µmol, 0.02 
equiv.), Me6TREN (8.9 mg, 0.0414 mmol, 0.12 equiv.) and DMSO (2 mL) were added 
to a sealed vial and degassed by purging with nitrogen for 15 min. Polymerisation was 
conducted under the UV lamp and left overnight. The product was dialysed against 
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water for 2 days using the dialysis membrane (1000 MWCO) and freeze-dried to 
obtain the product as an oil with a degree of polymerisation (DP) of 14.  
1H-NMR (700 MHz, CDCl3, 298 K)  (ppm) = 1.08-1.17 (-OC(O)C(CH3)2-), 
1.30-2.80 (polymer backbone, br, -CH2CH-), 3.35 (br, CH3O-), 3.40-3.85 (-
OCH2CH2O-), 4.05-4.40 (-OCH2CH2OC(O)C(CH3)2- and -CHC(O)OCH2CH2O-) , 
5.80-6.00 (br, HOCH2CH2) 
13C-NMR (176 MHz, CDCl3, 298 K)  (ppm) = 24.50-26.00 (multiple peaks), 
32.00-38.00 (br), 39.90-40.20 (br), 40.70-41.50 (br), 59.00, 61.56, 63.20-
63.80(multiple peaks), 64.99, 68.55-69.15 (multiple peaks), 70.25-70.75 (multiple 
peaks), 71.89, 72.50, 169.18, 169.30, 169.37, 173.5-174.5 (multiple peaks), 175.45, 
177.05 
IR (neat) /cm-1: 2865 (CH2, CH3), 1731(C=O), 1091 (C-O-C). 
MnNMR ~ 6720 g mol
-1. MnGPC ~ 7200 g mol
-1. Đ ~ 1.14 (Figure 2.15 black line). 
2.4.3.2.2 Synthesis of APPEGA 
Poly(PEGA480)-OH (0.5 g, 0.744 mmol, 1 equiv.) and TEA (70 µL, 5.03 mmol 
7 equiv.) were dissolved in 2 mL dry DCM. Acryloyl chloride (40 µL, 4.92 mmol, 6.5 
equiv.) was then added in to the reaction mixture and the system was stirred for 1 day 
at ambient temperature. The product was dialysed against water for 2 days using the 
dialysis membrane (1000 MWCO) and freeze-dried to obtain the product. The yield 
of the end-group modification (~87%) is calculated using the vinyl peaks (δ = 5.7 - 
6.6 ppm) and the methyl peaks on the initiator (δ = 1.0 - 1.2 ppm).  
1H-NMR (700 MHz, CDCl3, 298 K)  (ppm) = 1.08 - 1.17 (-OC(O)C(CH3)2-), 
1.30 - 2.80 (polymer backbone, br, -CH2CH-), 3.35 (br, CH3O-), 3.40 - 3.85 (-
OCH2CH2O-), 4.05 - 4.40 (CH2=CHC(O)OCH2-, -OCH2CH2OC(O)C(CH3)2- and -
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CHC(O)OCH2CH2O-), 5.83 (CHcisHtrans=CHC(O)OCH2-, dd, J1 = 10.54, J2 = 1.25 Hz) 
6.13 (CH2=CHC(O)OCH2-, dd, J1 = 17.32, J2 = 10.04 Hz) 6.40 
(CHcisHtrans=CHC(O)OCH2-, J1  = 17.32, J2  =  1.25 Hz) 
13C-NMR (176 MHz, CDCl3, 298 K)  (ppm) = 24.50 - 26.00 (multiple peaks), 
32.00 - 38.00 (br), 39.90 - 40.20 (br), 40.70 - 41.50 (br), 58.99, 61.56, 63.20 - 
63.80(multiple peaks), 64.98, 68.55 - 69.15 (multiple peaks), 70.25 - 70.75 (multiple 
peaks), 71.88, 128.21, 131.13, 166.05, 169.17, 169.29, 169.39, 173.5 - 174.5 (multiple 
peaks), 175.34, 176.95 
IR (neat) /cm-1: 2865 (CH2, CH3), 1731(C=O), 1091 (C-O-C). 
MnGPC ~ 7400 g mol
-1. Đ ~ 1.15. (Figure 2.15 red line) 
 
Figure 2.15 THF GPC traces for poly(PEGA480)-OH and APPEGA. 
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2.4.3.3 Synthesis of the colistin-FPy schiff base  
 
Figure 2.16 Image of the FPy modification within 30 s.  
5 mg of colistin (4.7 µmol, 1 equiv.) and 2.5 mg of FPy (23.4 µmol, 5 equiv.) 
were separately dissolved in 800 µL water and 200 µL pH = 10 Na2CO3-NaHCO3 
buffers (500 mM). 500 µL of both solution were then mixed together. A precipitate 
formed within 30 s (Figure 2.16) and was collected for MALDI-ToF MS (Figure 2.3). 
2.4.3.4 Synthesis of colistin conjugates using the imine reduction 
approach 
Colistin FBA conjugates: 10 mg of colistin (9.5 µmol, 1 equiv.) and 1.4 mg of 
FBA (9.3 µmol, 1 equiv.) were dissolved in 900 µL pH = 10 Na2CO3-NaHCO3 buffers 
(500 mM). The reaction mixture was stirring for 1 day and 100 µL 200 mg/mL 
NaBH3CN solution (31.7 mmol, 33 equiv.) was added. The sample for MALDI-ToF 
MS test was dialysed against water to remove salts and small molecules using the 
dialysis membrane (500 MWCO) (Figure 2.4). The time-kill tests for the obtained 
products were shown in Figure 2.10. 
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Colistin mPEG-FBA conjugates: 2 mg of colistin (1.9 µmol, 1 equiv.) and 4 
mg of mPEG-FBA (2 µmol, 1 equiv.) were dissolved in 900 µL different pH buffers 
(100 mM). The reaction mixture was stirring for 1 day and 6.3 mg NaBH3CN (0.1 
mmol, 50 equiv.) in 100 µL buffer was added. The reaction mixture was then stirring 
for a further day and samples were taken out for HPLC analysis. The sample for FPLC 
and MALDI-ToF MS was dialysed against water to remove the salt and small 
molecules using the dialysis membrane (500 MWCO) before the test. The HPLC, 
FPLC, and MALDI-ToF MS characterisations for the mixtures were shown in Figure 
2.7-2.9. The time-kill tests for the obtained products were shown in Figure 2.10. 
2.4.3.5 Synthesis of Pol-SH conjugates using thiol-acrylate 
addition approach 
1 mg of Pol-SH TFA salt (5.68 µmol, 1 equiv.) and 1 equiv. of small molecules 
were dissolved in HPLC vials with 1 mL buffer (pH = 8 or 9). The reaction mixtures 
were directly sampled after 3 h for HPLC. The polymer modification was carried out 
under the similar condition while 4 equiv. of PEGA2000 or PEGA5000 were used instead 
since 1H-NMR showed only half of the commercial PEGA2000 and PEGA5000 have the 
vinyl groups (Figure 2.18). For antibiotic tests, the synthesis is scaled up to 10 mg of 
peptide. 1.1 equiv. of APPEGA and 2.2 equiv. of PEGA5000 were used to minimize the 
side reactions. The HPLC characterisations of the conjugates were shown in Figure 
2.13-2.14. 
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2.4.4 Methods 
2.4.4.1 The stability test of the imine bond  
Dissolved 44 µL (47.2 mg, 0.448 mmol) 2-(2-aminoethoxy)ethanol (AEE) in 3 
mL D2O (solution A). Dissolved 40 µL (46.8 mg, 0.437 mmol) 2-
pyridinecarboxaldehyde (FPy) into another 3mL D2O (solution B). Mixed 2 mL of 
solution A and solution B to get the schiff base solution (solution C). Add 200 µL of 
solution C into 300 µL different buffers (pH = 4.0, 5.0, 6.5, 7.0, 7.5, 8.5, 9.0, 9.5, 10.0, 
100 mM prepared from either acetate, phosphate or carbonate buffers) for 1H-NMR 
spectrum. Starting materials were sampled in the similar method. Add 100 µL of 
solution A or B, 100 µL D2O into 300 µL different buffers (pH = 4.0 or 10.0, 100 
mM). 
2.4.4.2 Minimum inhibitory concentration (MIC) test 
MICs were determined in accordance to the recommendations of the Clinical 
and Laboratory Standards Institute.20 P. aeruginosa ATCC 27853, A. baumannii 
ATCC 19606 and K. pneumoniae ATCC 13883 were used for the tests. Experiments 
were performed with CAMHB in 96-well polystyrene microtiter plates. Wells were 
inoculated with 100 μL of bacterial suspension prepared in CAMHB (containing ∼ 
106 CFU/mL) and 100 μL of CAMHB containing increasing concentrations of colistin 
polymer conjugates (0 − 32 mg/L). The MIC measurements were carried out in 
duplicates with the MIC being defined as the lowest concentration at which visible 
growth was inhibited following 18 − 20 h of incubation at 37 °C. 
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2.4.4.3 Time-kill test 
The time-kill kinetics of the colistin samples were examined against P. 
aeruginosa ATCC 27853 at 1 mg/mL. Briefly, 20 mg of each test sample was added 
into a 50 mL Eppendorf tube loaded with 20 mL of a logarithmic-phase bacteria 
containing broth culture of approximately 106 CFU/mL. The tubes were incubated in 
a shaking water bath at 37 oC. The samples were taken at 0, 1 and 4 h. Subcultures for 
viable counts were performed on nutrient agar (Oxoid) using WASP2 Spiral Plater 
(Don Whitley Scientific) and incubated at 37 °C for 24 h. Viable counts were 
determined by either manual counting or using ProtoCol3 Colony Counter (Don 
Whitley Scientific). 
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2.4.5 Others 
2.4.5.1 MALDI-ToF MS analysis of the hydrolysis product of mPEG-
FBA found in reaction mixture 
 
Figure 2.17 MALDI-ToF MS data (partial) of the reaction mixture and FPLC fraction. a) The reaction 
mixture. b) Partial enlargement in the region around 1945-2005 Da. c) Peak ⑥ in FPLC. d) Partial 
enlargement in the region around 1900-1960 Da.    
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2.4.5.2 1H-NMR spectra of the commerial PEGA2000 and PEGA5000 
 
Figure 2.18 1H-NMR spectra of commercial PEGA2000 (a) and PEGA5000 (b) in CDCl3. The DP and the 
functionalised end group was calculated by the integration of each peak. The integration (I) of the 
methyl group on the ω-end of PEGA was set for 3. 
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 A Traceless Reversible Polymeric 
Colistin Prodrug to Combat Multidrug-resistant (MDR) 
Gram-negative Bacteria 
 
A PEGylated colistin prodrug with a cleavable linker (col-aaPEG) has been 
developed as a potential alternative for the current colistin prodrug (CMS). This 
PEGylated prodrug was linked by a labile ester introduced through an acetic acid 
terminated poly (ethylene glycol) methyl ether (aaPEG) onto the Thr residue of 
colistin. Due to the labile ester linker, this prodrug can be converted back into active 
colistin in vitro within 24 h. Compared to CMS, it showed a similar or better 
antimicrobial performance against two MDR Gram-negative bacteria through in vitro 
disk diffusion, broth dilution and time-kill studies. In a mouse infection model, col-
aaPEG displayed acceptable bacterial killing against P. aeruginosa ATCC 27853 and 
no nephrotoxicity was found after systemic administration. 
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3.1 Introduction 
The major issue of colistin systematic administration is its high incidence of 
nephrotoxicity. Although the irreversible PEGylation of colistin has been proven to 
hinder it antibacterial activity in the previous chapter, formulating colistin into a 
prodrug form using a releasable linker can potentially improve the in vitro and in vivo 
performance of colistin while remaining its activity against the MDR Gram-negative 
bacteria. A successful example using releasable modification is the current colistin 
prodrug, colistimethate sodium (CMS). It has become the only colistin treatment for 
systemic administration. Although CMS is approved by FDA, the slow and variable 
colistin release rates from CMS complicate its pharmacokinetics, resulting in variable 
treatment outcomes for patients.1-3 A further concerning feature of the prodrug is the 
heterogeneity of the methanesulfonate modification which leads to supplier to supplier 
and batch to batch structural variation in the prodrug form.4 Therefore, an alternative 
prodrug to CMS is highly desirable.  
In order to address this, we designed a PEGylated colistin prodrug with a site-
specific, traceless, releasable linker. Instead of modifying the five Dab residues of 
colistin as in case of CMS, the two threonine (Thr) residues were targeted here as it 
can greatly reduce the site-diversity of the modification products. A relatively labile 
ester linkage was chosen to build up the colistin prodrug using an acetic acid 
terminated mPEG (aaPEG) considering the ester is base and enzyme (i.e. lipase) 
hydrolysable bond that can be cleaved easily in the human body. A commercial mPEG 
acid with a succinic acid (saPEG) was also applied to achieve colistin conjugation for 
comparison. In vitro degradation studies were performed to investigate colistin release 
rate. The effect upon the number of mPEG attachments and different linkages on 
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colistin were also evaluated through the degradation studies. Moreover, the 
antibacterial activity of the PEGylated colistin prodrug was systematically studied 
through disk diffusion, broth dilution and time-kill experiments. It turned out to exhibit 
a similar or better antibacterial activity to the commercial CMS prodrug in all these 
tests. In addition, a mouse thigh infection model was used to compare the activity 
performance and toxicity of the PEGylated colistin prodrug with colistin in vivo, 
suggesting the PEGylated colistin demonstrated both low systematic and 
nephrotoxicity.  
3.2 Results and Discussion  
3.2.1 Synthesis of reversibly PEGylated colistin  
 
Figure 3.1 a) Synthesis of the Boc5-colistin. Both HPLC (b) and MALDI-ToF MS (c) of the native 
colistin and the Boc-modified one showed a fully modified Boc5-colistin was achieved. 
For the site-specific modification of polymyxin we targeted the Thr residues. 
However, since the amines of the Dab residues in colistin are more chemically reactive 
than the hydroxyl groups of Thr residues, it was necessary to first protect each of the 
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amine groups prior to the conjugation of the polymer. A well-developed amine-
protection approach using tert-butyloxycarbonyl (Boc) protecting groups was 
therefore applied (Figure 3.1a). In order to ensure that all the five amines were fully 
protected, an excess of di-tert-butyl dicarbonate (Boc2O) was used with the addition 
of potassium carbonate (K2CO3) during the modification. The reaction was carried out 
in a water/ tetrahydrofuran (THF) mixed solvent system so as to prevent further 
reaction of Boc2O with the Thr residues. As commercial colistin has two major 
components (colistin A and colistin B), a double-peak pattern was observed during 
HPLC analysis of the native lipopeptide (Figure 3.1b, black trace). An identical 
pattern, but at a higher retention time, was found following reaction with Boc2O, 
indicating the protecting groups were successfully introduced onto the amines, 
rendering the colistin more hydrophobic (Figure 3.1b, red trace). Furthermore, a 
careful comparison by MALDI-ToF MS of the modified polymyxin to the native 
colistin measurements (Figure 3.1c), revealed a 500 Da molecular weight increase 
confirming that all five amines were modified whilst both hydroxyl groups of the Thr 
residues remained intact. 
As hydrolysis was to be used as the mechanism to release the native polymyxin 
from the prodrug form, aaPEG was chosen since the electron-withdrawing nature of 
the oxygen bonded to the α-carbon of the carboxyl group makes it a better leaving 
group thus rendering the ester bond formed less stable and more hydrolytically labile. 
The synthesis of aaPEG was following a developed method via Williamson ether 
synthesis.5 mPEG was first deprotonated by a strong base (potassium tert-butoxide, 
tBuOK) in anhydrous tert-butanol (tBuOH). The formed reactive oxygen anion on 
mPEG then attacked a primary alkyl halide, replacing the halide to form an ether bond. 
As the carboxylic acid group can also react with oxygen anion, an ethyl protected 
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halide, ethyl bromoacetate, was used in this reaction. After the formation of ether 
bond, the ethyl protecting group was then hydrolysed under a basic condition and 
protonated to recover the acid group of aaPEG (Figure 3.2a).  
 
Figure 3.2 a) Synthesis procedure of the aaPEG. b) 1H-NMR and c) 13C-NMR of aaPEG using D2O as 
solvent. d) MALDI-ToF MS and e) THF GPC analysis of aaPEG. f) The zoom-in data of (d). 
The product was then characterised by NMR, MALDI-ToF MS, and GPC 
(Figure 3.2b-f). The integration of the original methyl end group (δ = 3.35 ppm) on 
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mPEG and the formed methylene group next to the carboxyl group (δ = 4.20 ppm) 
from 1H-NMR while no signal of the ethyl group was found in the both 1H-NMR and 
13C-NMR, indicating a successful cleavage of the protecting ethyl group and a 
complete modification of the acetic acid on the hydroxyl group of mPEG was achieved 
(Figure 3.2b,c). Although the GPC trace was less symmetrical and had a low molecular 
weight tailing due to the potential interaction between the acid group of aaPEG and 
the GPC column, only one molecular weight distribution of around 2000 Da was found 
in both MALDI-ToF and GPC analyses, suggesting the modification occurred on the 
end group of mPEG and did not cause the cross-linking of mPEG or the damage to the 
polymer chain. 
Although two main distributions that both have a repeating unit of 44 Da were 
found through the MALDI-ToF MS (Figure 3.2f), they were considered to be the 
H+/Na+ ion substitution during the sample analysis rather than incomplete protonation 
through the aaPEG synthesis as only one signal of the formed carboxyl group (δ = 
174.3 ppm) can be clearly seen from the 13C-NMR (Figure 3.2c). 
 
Scheme 3.1 Synthesis of the Boc protected PEGylated colistin conjugates (Boc5-col-aaPEGx, x = 1, 2) 
via Steglich esterification. 
After the pure aaPEG was obtained and well characterised, it was then used to 
PEGylate the Thr residues on Boc-protected colistin via Steglich esterification 
(Scheme 3.1). With the help of dehydrating agent, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC·HCl), and the catalyst, 4-
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dimethylaminopyridine (DMAP), aaPEG was attached onto Boc-protected colistin at 
ambient temperature. 
 
Figure 3.3 MALDI-ToF MS results (a-b) and the related zoom-in data (c-d) of the purified Boc 
protected conjugation products, Boc5-col-aaPEG (a, c)  and Boc5-col-aaPEG2 (b, d). 
 Since there are two hydroxyl groups on the Boc5-colistin, two products with 
different molecular weight distributions, a mono-mPEG adduct (Boc5-col-aaPEG, Mn 
Theory ~ 3.7 kDa, Mn MALDI ~ 3.6 kDa, Figure 3.3a) and a bis-mPEG adduct (Boc5-col-
aaPEG2, Mn Theory ~ 5.7 kDa, Mn MALDI ~ 5.5 kDa, Figure 3.3b), were obtained and 
isolated by HPLC from the reaction mixture at 20-22 min (Figure 3.4b, black trace) 
and 18-20 min (Figure 3.4b, green trace), respectively. A polymeric distribution with 
a typical PEG repeating unit of 44 Da and the double-peak pattern of colistin A and B 
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can be observed from the MALDI-ToF MS data of both adducts (Figure 3.3c-d), 
suggesting the successful attachment of aaPEG onto colistin. 
 
Figure 3.4 The dimethylformamide (DMF) GPC (a) and HPLC (b) traces of the four aaPEG colistin 
conjugates (Boc5-col-aaPEG, col-aaPEG, Boc5-col-aaPEG2 and col-aaPEG2). c) A summary of the 
theoretical mass, the mass analysed from MALDI-ToF MS and DMF GPC analysis, and the dispersities 
of these conjugates. 
 
Scheme 3.2 The deprotection of the Boc groups from the Boc5-col-aaPEGx (x = 1, 2) conjugates to 
recover the colistin amines. 
The regeneration of the free amines on colistin was conducted under routine 
conditions for the cleavage of the Boc-protecting groups (Scheme 3.2). After the 
treatment with 33% trifluoroacetic acid (TFA) in dichloromethane (DCM), the more 
hydrophilic deprotected products (col-aaPEG and col-aaPEG2) were obtained. A 
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successful deprotection was indicated by the shift to a shorter retention time during 
HPLC characterisation when comparing the protected form (Figure 3.4b). Moreover, 
only a slight decrease in the molecular weight was observed upon GPC 
characterisation (Figure 3.4a), suggesting the ester bond between colistin and aaPEG 
remained unaffected during deprotection of both conjugates. Both col-aaPEG (Mn 
Theory ~ 3.2 kDa, Mn MALDI ~ 3.2 kDa, Figure 3.5a) and col-aaPEG2 (Mn Theory ~ 5.2 kDa, 
Mn MALDI ~ 5.2 kDa, Figure 3.5b) retained the PEG polymeric distribution along with 
the colistin double-peak pattern through the MALDI-ToF MS data. A molecular 
weight decrease of 500 Da was observed for the deprotected products, further 
confirming a full recovery of all the amines on the colistin conjugates.  
 
Figure 3.5 MALDI-ToF MS results (a-b) and the related zoom-in data (c-d) of the purified deprocted 
conjugation products, Boc5-col-aaPEG (a, c)  and Boc5-col-aaPEG2 (b, d). 
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3.2.2 Stability and degradation of the PEGylated colistin 
conjugates 
 
Figure 3.6 a) The proposed mechanism of the colistin release from the col-aaPEG2 conjugate. The 
ability to release the col-aaPEG (b) and col-aaPEG2 (c) conjugate at 37 oC in PBS (1X) buffer was 
monitored by HPLC. MALDI-ToF MS data of the commercial colistin (d) and the isolated colistin 
peaks (e and f) from the col-aaPEG prodrug solution after the incubation for 2 days.  
In order to study the cleavable nature of the ester bond, the degradation of both 
PEGylated conjugates was performed in vitro and monitored by HPLC (Figure 3.6). 
To mimic physiological condition, the test was conducted at 37 oC in phosphate 
buffered saline (PBS, pH = 7.4). For the col-aaPEG form, the signal of the conjugate 
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decreased continuously with a concomitant appearance and increase in the typical 
colistin double-peaks up to 48 h (Figure 3.6b). Noticeably, we found that more than 
75% colistin can be released from col-aaPEG within 6 h whilst it normally required > 
24 h for CMS to achieve a similar extent of colistin release under similar conditions.4 
The two colistin peaks were then collected and analysed via MALDI-ToF MS 
confirming their identity as native colistin A and B (Figure 3.6d-f). This suggested 
that the released colistin was chemically unchanged and therefore potentially still 
active. As for col-aaPEG2, although the hydrolysis rate is almost twice as slow 
compared to col-aaPEG in the first 6 h, a similar pattern was observed when following 
the reaction by HPLC with the colistin peaks appearing and increasing as a function 
of time, leading to full release of colistin within 48 h (Figure 3.6c). Interestingly, 
during degradation a broad peak appeared at 12-13.5 min, which coincided with the 
col-aaPEG conjugate. The intensity of this peak initially increased during the first 4 h 
and then decreased along with the full consumption of col-aaPEG2 to furnish the native 
lipopeptides. This indicates that the release of colistin from col-aaPEG2 undergoes a 
stepwise degradation process, proceeding via a col-aaPEG as an intermediate product 
(Figure 3.6a). Regardless, this also confirmed that the two aaPEGs which are attached 
onto the different Thr residues can both be hydrolysed during the degradation process 
to fully liberate native polymyxins. 
To investigate the effect of the traceless linker between mPEG and colistin, a 
second PEGylated colistin with a different ester bond was synthesized by the same 
protocol using a commercial available succinic acid terminated mPEG (saPEG) 
(Figure 3.7a). Lacking an electron-withdrawing oxygen bonded to the α-carbon, 
saPEG was expected to form a more stable conjugate. It was observed that colistin is 
still released from both mono- and bis-saPEG modified products through the same 
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hydrolysis protocol although the amount of the released colistin is nearly twice slower 
than from the corresponding colistin aaPEG conjugates in the first 6 h (Figure 3.7b-
c).  
 
Figure 3.7 a) The chemical structures of the aaPEG modified colistin prodrugs (left) and saPEG 
modified ones (right). The colistin release profiles of the mono PEGylated prodrugs (b) and double 
modified prodrugs (c) from PBS solution. Red lines: aaPEG modified produrgs (left: col-aaPEG and 
right: col-aaPEG2); blue lines: saPEG modified produrgs (left: col-saPEG and right: col-saPEG2); solid 
lines: 37 oC and dotted lines: ambient temperature. 
A similar degradation study was conducted at ambient temperature to evaluate 
the influence of temperature on the conjugate release (Figure 3.7b-c). As expected, the 
rate of hydrolysis for all the colistin conjugates was retarded compared to those at 
body temperature. In particular, the double-modified conjugates showed much slower 
release compared to the mono-adducts due to the stepwise nature of the hydrolysis 
process. All of the results implied that both ester linkers were temperature sensitive 
with regards to stability. 
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3.2.3 In vitro antimicrobial activity test of the PEGylated colistin 
conjugates 
The antibiotic activity of the PEGylated conjugates was subsequently tested 
against two different MDR Gram-negative bacterial strains (P. aeruginosa ATCC 
27853 and A. baumannii ATCC 19606). A disk diffusion assay was first conducted 
using colistin and CMS as positive controls. 20 µg of each conjugates was applied 
onto a blank disc (Ø = 0.6 cm) before placed on a bacterial inoculated agar plate. The 
potency of each conjugates was estimated through the measurement of their diameter 
of zone of inhibition (ZoI) (Table 3.1). 
Table 3.1 The diameter of zone of inhibition (ZOI) results of the conjugates against two different Gram-
negative bacterial through disk diffusion assay (20 µg, 24 h). 
 
Overall, aaPEG alone showed no antibiotic activity whereas both aaPEG 
modified colistin conjugates showed a clear ZoI. This indicated that the colistin 
conjugates exhibited antimicrobial activity and crucially that the activity did not occur 
as a result of the cleaved polymer but rather, from the released native colistin. Owing 
to the larger molecular weight and a slower colistin release rate, col-aaPEG2 showed 
a smaller ZOI compared to col-aaPEG at the same loading amount (20 µg). 
Conversely, both saPEG modified colistin conjugates showed a smaller ZOI compared 
to the corresponding aaPEG modified colistin conjugates which is in agreement with 
the observed colistin release profiles. Notably, col-saPEG2 revealed no activity 
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through the disk diffusion assay, indicating the attachment of PEG inhibited the 
activity of colistin and highlighting the need for a more labile, cleavable linker for the 
desired prodrug to maintain its activity over a time scale relevant to microbial 
proliferation.  
Table 3.2 The minimum inhibitory concentration of the conjugates against two different Gram-
negative bacteria on a weight and molar basis. 
 
To obtain a more accurate comparison of the relative activities of the prepared 
conjugates, minimum inhibitory concentration (MIC) assays were performed using P. 
aeruginosa ATCC 27853 and A. baumannii ATCC 19606 (Table 3.2). In general, each 
sample was dissolved and serial diluted to the test concentration with a bacteria 
containing broth. The dilutions were then examined for the visible growth of the 
bacteria after overnight incubation. The potency of each sample can be determined by 
the lowest concentration, or MIC, that inhibiting the bacterial growth. 
The results revealed that the col-aaPEG conjugate behaved similarly to the 
native colistin in terms of the molar activity. This suggests that nearly full cleavage 
can be achieved from this colistin conjugate. Furthermore, the released colistin was 
chemically identical to native colistin, as confirmed during chemical characterisation 
(Figure 3.6d-f), and crucially that activity of the released polymyxin was retained. 
More interestingly, even though the molecular weight of the col-aaPEG are nearly 
twice that of the commercial prodrug CMS (Mn CMS ~ 1743 g mol
-1), less material was 
required to inhibit the bacteria, indicating that the colistin release profile of the col-
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aaPEG prodrug is more efficient than of CMS in the selected bacterial growth media. 
In agreement with the colistin release profiles (Figure 3.7b) and disk diffusion assay 
(Table 3.1), the col-saPEG conjugate showed a lower activity (2-4 times) than the 
aaPEG conjugate, highlighting the need for faster colistin release to inhibit the growth 
of bacteria. Conversely, both double PEGylated prodrugs exhibited less activity 
against both bacterial strains on both mass and molar basis due to the molecular weight 
of the prodrugs as well as the slower degradation process. Especially col-saPEG2 
showed no activity in the selected concentration range, confirming the inhibition of 
the bacterial growth results from the release of colistin rather than from the prodrug 
itself. 
As the antimicrobial activity of colistin is concentration dependent, different 
‘killing’ rates will be obtained from different concentrations. The amount of active 
colistin of the PEGylated conjugates released at each time point can be obtained 
through a comparison of their ‘killing’ kinetics. In order to determine a better 
understanding of the “killing” kinetics of the prodrug conjugates, time-kill studies 
were subsequently conducted by incubating A. baumannii ATCC 19606 bacterial 
strain as a model with colistin, CMS and colistin-aaPEG conjugates. The time-kill 
curves for selected dosage regimen are shown in Figure 3.8. Three different doses (0.5 
x MIC, 1 x MIC, and 2 x MIC, referring to mass based MICs of each compound) were 
initially tested. At the lower dose (0.5 x MIC), neither CMS nor aaPEG prodrugs 
exhibited inhibition with the killing curves essentially indistinguishable from those of 
the control, whereas colistin showed antibacterial killing in the first 6 h (Figure 3.8a). 
By increasing the dose to 1 x MIC and 2 x MIC of both CMS and col-aaPEG, 
antimicrobial activity was observed with col-aaPEG performing better at both doses 
than CMS (Figure 3.8b-c). Particularly, col-aaPEG could inhibit the growth of bacteria 
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to below the detection limit within 30 min at 2 x MIC, whilst it takes 4 h for CMS to 
control the bacterial growth close to the detection limit. At all three dosage regimens, 
col-aaPEG2 did not show any inhibition against the bacteria which is possibly due to 
the slower degradation rate compared to the bacterial growth rate. However, it still 
showed an antibacterial killing at 30 min up to 4 h with regrowth occurring at 24 h 
when using a higher dose (8 x MIC) (Figure 3.8d, purple trace).  
 
Figure 3.8 In vitro time-kill studies of colistin (a), col-aaPEG (b), CMS (c), col-aaPEG2 (d). The dashed 
line indicates the lower limit of detection of bacterial growth. 
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3.2.4 In vivo antimicrobial activity and toxicity evaluation of the 
PEGylated colistin conjugates 
 
Figure 3.9 In vivo activity of colistin and prodrugs (col-aaPEG and col-aaPEG2) against P. aeruginosa 
ATCC 27853 using a mouse thigh infection model. (n = 4) 
Due to the encouraging in vitro performance from the col-aaPEG prodrugs, the 
in vivo efficacy of these two labile ester based conjugates (col-aaPEG and col-aaPEG2) 
was investigated in comparison to native colistin treatment against P. aeruginosa 
ATCC 27853 in a neutropenic mouse thigh infection model. Colistin was employed 
as the comparator as the highly variable release and inter-batch heterogeneity of CMS 
yields large data fluctuations. After 18 h administration of colistin and the aaPEG 
prodrugs (40 mg colistin base/kg), a significant reduction in the bacterial burden was 
observed for both colistin (mean log10 CFU/thigh 0.73±1.46) and col-aaPEG (mean 
log10 CFU/thigh 4.77±0.89) compared to the 0 h (mean log10 CFU/thigh 5.85±0.06, > 
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91.6% bacteria kill). However, col-aaPEG2 failed to produce sufficient bacterial 
killing in vivo (mean log10 CFU/thigh 8.75±0.12) (Figure 3.9).  
 
Figure 3.10 a) Summary of histology kidney scoring from each sample. b)-e) Microscopic image of 
the cortex section of the kidneys of mice treated with saline control, colistin, prodrugs col-aaPEG and 
col-aaPEG2 (accumulated dose 40 mg colistin base/kg). b) Control (0 h) (SQR score 0); c) colistin (SQR 
score 1); d) col-aaPEG (SQR score 0), e) col-aaPEG2 (SQR score 1). 
Nephrotoxicity remains a dose-limiting issue with the broader application of 
polymyxin therapy as it impacts the ability of clinicians to increase the dose.6-12 
Therefore, in the present study, the in vivo apoptotic effect of col-aaPEG and col-
aaPEG2 was examined through the histological examination of the kidneys from mice 
subcutaneously administered either colistin or PEGylated colistin prodrugs at an 
accumulated dose of 40 mg colistin base/kg (Figure 3.10a). The kidneys of mice 
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administered with the saline control had no observable histological damage (semi 
quantitative SQR score of 0, Figure 3.10b). In comparison, the histological 
examination of the kidneys from the mice treated with colistin, col-aaPEG2 showed 
comparable mild histological damage with tubule damage, i.e. tubular dilation and 
degeneration (semi quantitative SQR score of 1, Figure 3.10c, e). Encouragingly, the 
kidneys of mice treated with col-aaPEG had no significant histological damage and 
were essentially comparable to the saline control (grade 0 histology kidney scoring; 
Figure 3.10d). These results demonstrate that colistin and col-aaPEG2 (both grade 1 
histology kidney scoring) appears to be more nephrotoxic than col-aaPEG. 
3.3 Conclusions  
In this chapter, fully characterised mono- and bis-mPEG modified colistin 
conjugates with two different ester linkages on the Thr residue(s) of colistin were 
synthesised via Boc-protection/deprotection and Steglich esterification. All of the 
prodrug candidates were tested through the in vitro degradation studies and revealed 
native colistin can be released smoothly from all the colistin conjugates and that the 
colistin release rate from the PEGylated conjugates can be altered by the number of 
mPEG attachment and the lability of the linker. Studies also showed the degradation 
process is temperature sensitive and the prodrugs are relatively stable at ambient 
temperature. Among them, the col-aaPEG showed the fastest colistin release rate, 
achieving near full colistin release within 24 h, which makes it a viable prodrug 
candidate. All in vitro antimicrobial activity tests suggested col-aaPEG performs with 
a similar or better activity relative to the commercial prodrug CMS or colistin on both 
molar and mass basis. In comparison to colistin, col-aaPEG showed acceptable 
bacterial killing in an in vivo mouse model against P. aeruginosa ATCC 27853 and 
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displayed no nephrotoxicity through the histological examination of the kidneys. 
Although further evaluation is needed to determine whether this activity profile of col-
aaPEG in vivo extends to other Gram-negative species, we believe that due to the 
enhanced specificity confirmed by targeting Thr residues without loss of antibacterial 
activity, col-aaPEG has the potential candidate to become a potent alternative prodrug 
to CMS.  
3.4 Experimental  
3.4.1 Materials 
3.4.1.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich and used directly unless 
otherwise stated. HPLC solvents are obtained from VWR international, LLC. The 
acetic acid functional mPEG (aaPEG, Mn ~ 2kDa) was synthesised based on the 
previous report.5 The succinic acid functional mPEG (saPEG, Mn ~ 2kDa; commercial 
name: CH₃O-PEG-NHCO-C₂H₄-COOH; reference number: 122000-3) was 
purchased from Rapp Polymere GmbH. 
3.4.1.2 Bacterial strains 
Bacterial strains of P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606 
(American Type Culture Collection, Manassas, VA) were used in this study. The 
strains were stored at -80 °C in a cryovial storage container (Simport Plastics, Quebec, 
Canada). Fresh isolates were sub cultured on Nutrient agar (Media Preparation Unit, 
The University of Melbourne, Parkville, Australia) and incubated at 37 °C for 24 h 
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prior to each experiment. CAMHB (Oxoid, Hampshire, England) was used as culture 
medium. 
3.4.2 Instruments 
3.4.2.1 MALDI-ToF MS 
MALDI-ToF MS was acquired from a Bruker Daltonics Autoflex MALDI-ToF 
mass spectrometer. The MALDI-ToF samples were prepared by mixing a solution of 
CHCA or DCTB as a matrix (20 mg/mL in THF) and sample (1-2 mg/mL in THF) at 
1:1 ratio. 0.5 μL of this mixture was spotted to the target plate. Spectra were recorded 
in reflector mode calibrating with PEG or mPEG at a similar average molecular weight 
of each sample. 
3.4.2.2 GPC 
DMF GPC was performed on an Agilent PL50 equipped with 2 Agilent Polargel 
M Columns and a differential refractive index detector eluting with DMF (0.1 M LiBr) 
with a flow rate of 1.0 mL min-1 at 50 oC. THF GPC was performed on a Varian 390-
LC MDS system equipped with a PL-AS RT/MT autosampler, a PL-gel 3 μm (50 x 
7.5 mm) guard column, two PL-gel 5 μm (300 x 7.5 mm) mixed-D columns equipped 
with a differential refractive index using THF (+ 2% triethylamine (TEA) + 0.01% 
butylated hydroxytoluene (BHT)) as the eluent with a flow rate of 1.0 mL min-1 at 30 
oC. The calibration was fitted with a 3rd order polynomial using narrow molecular 
weight standards of PMMA (between 200 and 467,400 g mol-1). 
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3.4.2.3 HPLC 
3.4.2.3.1 Analytical HPLC 
The HPLC system used was an Agilent 1260 infinity series stack equipped with 
an Agilent 1260 binary pump and a degasser. Samples (10 – 70 µL) were injected 
using Agilent 1260 autosampler. The HPLC was fitted with a Phenomenex Lunar C18 
column (250 x 4.6 mm) 5 micron packing (100Ǻ).  Detection was achieved using an 
Agilent 1260 variable wavelength detector connected in series with UV detection 
monitored at 214 nm.  
The mobile phase condition is as follows. 
Mobile phase A: 100% water, 0.04% TFA; 
Mobile phase B: 100% ACN, 0.04% TFA. 
HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TFA 
was used as additive. 
The standard analysis method is as followed: 0-24 min 10%-80% B; 24-25 min 
80-10%B; 25-40 min 10% B. The total flow rate was set to 1.0 mL/min and the 
temperature for the column is set to 40 oC. 
3.4.2.3.2 PREP HPLC 
The PREP HPLC system used was an Agilent 1260 infinity series stack 
equipped with a 1260 Quat Pump VL, a degasser and a fraction collector (FC-AS). 
Samples were injected using Agilent 1260 auto-sampler with a 100 μL injection 
volume. The HPLC was fitted with a phenomenex Lunar C18 column (250 x 4.6 mm) 
5 micron packing (100Ǻ) for more precise separation.  Detection was achieved using 
an Agilent 1260 TCC detector with UV detection monitored at 214 nm.  
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The mobile phase condition is as follows. 
Mobile phase A: 100% water, 0.04% TFA; 
Mobile phase B: 100% ACN, 0.04% TFA. 
HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TFA 
was used as additive. 
The standard preparative method is as followed: 0-20 min 5%-100% B; 20-25 
min 100% B; 25-30 min 100%-5% B; 30-40 min 5% B. The total flow rate was set to 
1.0 mL/min and the temperature for the column is set to 40 oC. 
3.4.3 Synthesis 
3.4.3.1 Synthesis of Boc5-colistin 
The synthesis of Boc5-colistin was as follows. Colistin sulphate (0.56 g, 0.4 
mmol, 1 equiv.) was dissolved with 20 mL water in a 100 mL round bottom flask. 
Boc2O (2.18 g, 10 mmol, 25 equiv.) was dissolved with 25 mL THF in a 50 mL 
Eppendorf tube before adding into the 100 mL round bottom flask. The reaction 
mixture was stirred vigorously at ambient temperature for 5 min. Sequentially, K2CO3 
(1.38 g, 10 mmol, 25 equiv.) were dissolved in 5 mL of water and the solution was 
added slowly into the reaction mixture. The reaction mixture would become creamy 
once the base was added. The mixture was then kept stirring overnight. After that, the 
mixture was transferred into a separating funnel along with 30 mL saturated sodium 
chloride solution and 30 mL THF. The mixture was then let stand for around 30 min 
until two layers was observed. The upper layer was collected and the bottom layer was 
extracted with 30 mL THF twice. The combined organic solution was dried with 
MgSO4 and concentrated under the vacuum. The further purification can be done by 
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the flash column (0% -10% MeOH in DCM).The final product is a fine pale yellow 
powder with a total yield of 78%. The MALDI-ToF MS and HPLC analyses were 
shown in Figure 3.1. MnMALDI = 1678.1 (colA), 1692.1 (colB) ([M+Na]
+). 
3.4.3.2 Synthesis of Boc5-col-aaPEGx (x = 1,2) 
The synthesis of the Boc5-col-aaPEGx was modified from the standard Steglich 
esterification.  aaPEG (Mn ~ 2kDa, 120 mg, 60 µmol, 1.5 equiv.), Boc5-colistin (66.0 
mg, 40 µmol, 1 equiv.), and DMAP (24.4 mg, 0.2 mmol, 5 equiv.) were fully dissolved 
in 6 mL of dry DCM. EDC·HCl (76.7 mg, 0.4 mmol, 10 equiv.) was added afterwards 
and the reaction mixture was kept stirring overnight. The crude product was obtained 
after the removal of DCM and used directly for the next step. The further separation 
of Boc5-col-aaPEG and Boc5-col-aaPEG2 can be done by diluting the crude product 
using ACN and purifying by RP-HPLC. The ratio between Boc5-col-aaPEG and Boc5-
col-aaPEG2 is around 1:1. The standard preparative method was used. Boc5-col-
aaPEG2 appears around 18-20 min and Boc5-col-aaPEG appeared around 20-22 min. 
The detailed MALDI-ToF MS, GPC and HPLC characterisations of the products were 
shown in Figure 3.3-3.4. 
3.4.3.3 Synthesis of col-aaPEGx (x = 1,2) 
The deprotection of the Boc groups was followed the typical Boc cleavage 
procedure. 6 mL 33% TFA in DCM was added slowly into the crude Boc5-col-aaPEGx 
(x = 1,2). [Be caution of the release of gas!] After most gas was released, the reaction 
mixture was sealed and kept stirring at ambient temperature overnight. After the 
removal of solvents, the crude product was diluted by ACN and separated by RP-
HPLC. The standard preparative method was used. Col-aaPEG appears around 11.4 - 
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12.2 min and col-aaPEG2 appeared around 12.2 - 13 min. The detailed MALDI-ToF 
MS, GPC and HPLC characterisations of the products were shown in Figure 3.4-3.5. 
3.4.4 Methods 
3.4.4.1 Protocol for in vitro release of PEGylated colistin prodrugs 
The degradation of the PEGylated colistin prodrugs were conducted in 7 mL 
vials using 2 mL PBS (1X). 1 mg of the mono PEGylated prodrugs and 2 mg of the 
double PEGylated prodrugs were used for the test. 500 µL of each prodrug solution 
was taken into another vial and stirred at ambient temperature. The rest of each 
prodrug solution was stirred and incubated in an oil bath at 37 oC. Samples (100 μL 
each time) were taken periodically and frozen by liquid nitrogen before the analysis. 
The analysis was conducted by RP-HPLC using the standard analysis conditions. The 
colistin release percentage was calculated through the following method.  
The integration (I𝑡) of colistin double-peak of the sample at each time point (T 
= t) was recorded. As the absorbance and concentration of colistin at 214 nm in the 
measuring concentration range follows the Beer-Lambert law, the concentration of 
colistin in the solution at each time point (𝑐𝑡) is proportional to its integration (I𝑡) from 
the HPLC chromatograph at 214 nm, meaning 𝑐𝑡 =  A × I𝑡 where A is constant. The 
total amount of colistin released at T = t (𝑚𝑡 ) from the prodrug, which is 𝑚𝑡 =
 𝑚𝑠𝑎𝑚𝑝𝑙𝑒 + 𝑚𝑟𝑒𝑚𝑎𝑖𝑛 = 𝑚𝑠𝑎𝑚𝑝𝑙𝑒 + 𝑉𝑟𝑒𝑚𝑎𝑖𝑛 × 𝑐𝑡 = 𝑚𝑠𝑎𝑚𝑝𝑙𝑒 + 𝑉𝑟𝑒𝑚𝑎𝑖𝑛 × A ×
I𝑡 where;  𝑚𝑠𝑎𝑚𝑝𝑙𝑒 means the amount of colistin taken for analysis before T = t; 
 𝑚𝑟𝑒𝑚𝑖𝑎𝑛  the remaining colistin amount in the solution; 𝑉𝑟𝑒𝑚𝑎𝑖𝑛means the remaining 
volume at T = t.  As the volume taken for each sample at each time is the same 
( 𝑉𝑠𝑎𝑚𝑝𝑙𝑒 = 100 μL ), 𝑚𝑠𝑎𝑚𝑝𝑙𝑒 = ∑ (𝑐𝑉)𝑇
𝑇=𝑡−1
𝑇=0 = 𝑉𝑠𝑎𝑚𝑝𝑙𝑒 × ∑ 𝑐𝑇
𝑇=𝑡−1
𝑇=0 = 100μL ×
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A × ∑ I𝑇
𝑇=𝑡−1
𝑇=0 ,where t-1 means the last time point before T = t. Therefore, 𝑚𝑡 =
𝑉𝑟𝑒𝑚𝑎𝑖𝑛 × A × I𝑡 + 100μL × A × ∑ I𝑇
𝑇=𝑡−1
𝑇=0 =  A × (𝑉𝑟𝑒𝑚𝑎𝑖𝑛 × I𝑡 + 100μL ×
∑ I𝑇
𝑇=𝑡−1
𝑇=0 ) . 
Thus, the colistin release percentage at T = t can be calculated as follows:  
Percentage (%) = 100 ×
𝑚𝑡
𝑚𝐹𝑖𝑛𝑎𝑙
= 100 ×
𝑉𝑟𝑒𝑚𝑎𝑖𝑛 × I𝑡 + 100μL × ∑ I𝑇
𝑇=𝑡−1
𝑇=0
𝑉𝐹𝑖𝑛𝑎𝑙 × I𝐹𝑖𝑛𝑎𝑙 + 100μL × ∑ I𝑇
𝑇=48ℎ
𝑇=0
 
where 𝑚𝐹𝑖𝑛𝑎𝑙 ,  𝑉𝐹𝑖𝑛𝑎𝑙  and I𝐹𝑖𝑛𝑎𝑙 are the mass, volume, and integration of the final 
sample. The final sample was taken from each sample incubated at 37 oC for 5 days. 
 
Figure 3.11 HPLC traces of the release profile from the prodrugs. a) col-saPEG, 37 oC; b) col-saPEG2, 
37 oC; c) col- aaPEG, ambient temperature; d) col- aaPEG2, ambient temperature; e) col- saPEG, 
ambient temperature; f) col- saPEG2, ambient temperature. The release polymer from col-saPEG and 
col-saPEG2 (labeled with blue arrow) can be seen from the HPLC traces as it absorbed at 214 nm. 
3.4.4.2 Disk diffusion assay 
According to the EUCAST guidelines,13 inoculum was standardised in saline to 
the density of a McFarland 0.50±0.02 standard, corresponding to ~108 CFU/mL of 
each isolate. A freshly prepared suspension was evenly inoculated onto plates and 
disks were applied within 15 min and incubated for 18 h at 37 °C. Plates were 
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examined for satisfactory streaked suspension and evenly distributed growth to 
achieve uniformly circular inhibition zones within the quality control limits. 
3.4.4.3 MIC test 
MICs were determined in accordance to the recommendations of the Clinical 
and Laboratory Standards Institute.14 P. aeruginosa ATCC 27853 and A. baumannii 
ATCC 19606 were used for the tests. Experiments were performed with CAMHB in 
96-well polystyrene microtiter plates. Wells were inoculated with 100 μL of bacterial 
suspension prepared in CAMHB (containing ∼ 106 CFU/mL) and 100 μL of CAMHB 
containing increasing concentrations of colistin, CMS and PEGylated colistin 
prodrugs (0 − 128 mg/L). The MIC measurements were carried out in duplicates with 
the MIC being defined as the lowest concentration at which visible growth was 
inhibited following 18 − 20 h of incubation at 37 °C. 
3.4.4.4 Time-kill test 
The time-kill kinetics of the PEGylated colistin prodrugs at 0.5, 1, and 2 x MIC 
were examined against A. baumannii ATCC 19606. Briefly, each test sample was 
added into a 50 mL Eppendorf tube loaded with 20 mL of a logarithmic-phase broth 
culture of approximately 106 CFU/mL to yield concentrations of 0, 0.5, 1, and 2 x MIC 
(8 x MIC was also tested for col-aaPEG2) of the isolate. The tubes were incubated in 
a shaking water bath at 37 oC. The samples were taken at 0 min, 30 min and 1, 2, 4, 6 
and 24 h. Subcultures for viable counts were performed on nutrient agar (Oxoid) using 
WASP2 Spiral Plater (Don Whitley Scientific) and incubated at 37 °C for 24 h (48 h 
for plates with small colonies). Viable counts were determined by either manual 
counting or using ProtoCol3 Colony Counter (Don Whitley Scientific). 
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3.4.4.5 In vivo efficacy study using a neutropenic mouse thigh 
infection model 
All animal experiments were approved by the Monash Institute of 
Pharmaceutical Sciences Animal Ethics Committee (ID: MIPS.2010.35) and were in 
conductance with the Australian Code for Care and Use of Animals for Scientific 
Purposes (8th Edition 2013).  
The polymyxin-susceptible strain P. aeruginosa ATCC 27853 was cultured on 
nutrient agar plates. One colony was randomly selected and incubated overnight at 37 
°C. An aliquot of 0.2 mL of the overnight culture was dispersed in 20 mL CAMHB 
and incubated for the production of an early log-phase culture. Bacteria suspension 
was concentrated via centrifugation (3220 × g for 10 min) and the resuspended in 0.9% 
sterile saline for inoculation onto mice. The bacterial concentration of 2x105 CFU/50 
μL per mouse was estimated by determining the optical density (OD) at 600 nm and 
confirmed via plating onto agar. 
Swiss mice were rendered neutropenic via two intraperitoneally i.p. doses of 
cyclophosphamide, 4 days (150 mg/kg) and 1 day (100 mg/kg) prior to infection. 
Thigh infection was established by injecting i.v. bolus of 50 µL of the bacterial 
suspension (2x105 CFU/50 µL per mouse). Solutions for colistin, col-aaPEG and col-
aaPEG2 were prepared at 1 mg/mL in sterile saline solution (0.9%). At 2 h after 
inoculation, the mice were treated with 40 mg colistin base/kg of each compound or 
the same volume of saline, respectively, for the control group. At 0 h and 18 h after 
administration of either the compound or the control, the animals were sacrificed by 
an inhalation of isoflurane. The skin was disinfected with 70% ethanol and blood was 
collected via cardia puncture using a 1 mL syringe rinsed with 5,000 IU/mL heparin, 
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diluted serially in sterile 0.9% saline and plated on nutrient agar plates using WASP2 
Spiral Plater (Don Whitley Scientific) and incubated at 37 °C for 24 h (48 h for plates 
with small colonies). Viable counts were determined by either manual counting or 
using ProtoCol3 Colony Counter (Don Whitley Scientific). The bacterial load (log10 
CFU/mL) was calculated for each mouse. Experiments were conducted in duplicates 
and a mean and standard deviation (SD) was calculated.  
3.4.4.6 Measurement of nephrotoxicity in mice 
All animal experiments were approved by the Monash Institute of 
Pharmaceutical Sciences Animal Ethics Committee. Mice were subcutaneously 
administered with either colistin or PEGylated colistin prodrugs at an accumulated 
dose of 40 mg colistin base/kg was achieved. At 20 h after the last dose, mice were 
euthanized by inhalation of an overdose of isoflurane. Immediately after sampling the 
blood by cardiac puncture (above) the right kidney of each mouse was collected and 
placed into 10% buffered formalin at pH 7.4 (Sigma, Australia) and stored in a 5 mL 
plastic tube. The formalin-fixed kidneys were subjected to histological examination at 
the Australian Phenomics Network, Histopathology and Organ Pathology (The 
University of Melbourne, Parkville, Australia). Samples were examined by a 
pathologist who was blind to the treatment groups. The nature and severity of the 
histological changes was graded as follows: (i) grade 1, mild acute tubular damage 
with tubular dilation, prominent nuclei and a few pale tubular casts; (ii) grade 2, severe 
acute tubular damage with necrosis; (iii) grade 3, acute necrosis/infarction.  
The overall kidney histology score was calculated as a product of percentage 
score and grade score.15 The SQR score (range: 0-5) was assigned as follows: (0): no 
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significant change; (1): mild damage; (2): mild to moderate damage; (3): moderate 
damage; (4): moderate to severe damage; (5): severe damage.  
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 A Poly(PEGA480) Colistin Prodrug for 
Antimicrobial Treatment 
 
Novel polymeric colistin prodrugs with three different lengths of polymer have 
been developed. Through the modification of a cleavable initiator linker, 2-(2-bromo-
2-methylpropanoyloxy) acetic acid (BMPAA), on both Thr residues of colistin, the 
polymer-colistin conjugates (col-PPEGA) with two cleavable poly(PEGA480) chains 
were achieved by the polymerisation of PEGA480 monomer via the recent developed 
copper-mediated photoinduced living radical polymerisation (CP-LRP). Thanks to the 
nature of the linker, most of the active colistin can be recovered from the conjugates 
in vitro within 2 days. Further in vitro biological analyses including disk diffusion, 
broth dilution and time-kill studies suggested all the conjugates have the ability to 
inhibit the growth of MDR Gram-negative bacteria, of which col-PPEGA DP5 and 
DP10 showed similar antibacterial performance as CMS, indicating their potential as 
an alternative treatment for CMS. 
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4.1 Introduction 
As demonstrated in chapter 3, the PEGylated colistin conjugate showed an 
encouraging in vitro and in vivo performance compared to CMS and revealed no 
systematic toxicity nor nephrotoxicity. However, this modification approach still has 
its limitation despite PEGylation being an established method to improve the 
biological drug performance. In order to obtain better pharmaceutical properties for 
the conjugate, a high molecular weight PEG modification is sometimes necessary. As 
a ‘grafting-to’ approach, the conjugation efficiency of PEGylation can vary depending 
on the molecular weight of the PEG and normally reduces dramatically when a high 
molecular weight PEG is used.1 The purification of the conjugate from the PEG 
starting material is also sometimes problematic. In addition, the attachment of a high 
molecular weight PEG increases the overall viscosity of the PEGylated conjugate, 
making it not suitable for intravenous administration.2 Furthermore, the high 
molecular weight PEG is a crystalline polymer that can also accumulate in the human 
body, causing damage to human kidney and/or liver, which is not ideal for drug 
delivery system.3 Moreover, due to the structure configuration, PEG normally acts like 
a random coil in the aqueous solution, which can hinder the hydrolysis of the linker 
between the polymer and peptide. Thus, the bis-PEG modification colistin conjugate 
described in chapter 3 (col-aaPEG2), which is modified on both Thr residues, showed 
a much slower hydrolysis profile, resulting a less active product compared to col-
aaPEG. 
Alternatively, polyPEG is a comb-like PEG-based biocompatible polymer that 
has similar properties to PEG.3 Synthesized from the PEG (meth)acrylate monomer, 
polyPEG is a non-crystalline material and the comb-like structure makes it act as a 
Chapter 4 
Chongyu Zhu  103 
rigid rod in aqueous solution, therefore, it normally has a lower viscosity compared to 
linear PEG at the same molecular weight. With the recent development of new 
polymerisation techniques, such as living/controlled radical polymerisation,  polyPEG 
can now be attached to biological drugs through the ‘grafting from’ approach of PEG 
(meth)acrylate monomer with a controlled molecular weight range and a narrow 
dispersity (Ɖ) under a mild conditions, leading to an efficient conjugation and easy 
purification.4, 5  
In present work, the possibility of introducing poly(PEGA480) onto both Thr 
residues of colistin, transferring it into a polymeric prodrug has been demonstrated 
and discussed. With the attachment of a hydrolysable initiator precursor, the PEGA480 
monomer can be grown evenly from both Thr residues of colistin via copper-mediated 
photoinduced controlled radical polymerisation. The colistin conjugates were 
prepared with various degrees of polymerisation with low dispersities. In vitro 
hydrolysis studies were conducted to investigate the effect of increasing the degree of 
polymerisation and therefore the molecular weight on the colistin release rate. Further 
biological evaluation including disk diffusion, broth dilution and time-kill experiments 
were also performed to analyse the effect of polymer length on colistin antimicrobial 
activity. 
4.2 Results and Discussion  
4.2.1 Design of the initiator linker for colistin conjugation 
As the colistin release rate from the polymeric prodrug will greatly affect the 
final antimicrobial activity, the design of linker between the colistin and the initiating 
group is imperative to the proposed ‘grafting from’ approach for formation of a 
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suitable prodrug candidate. To obtain a better performance and a faster colistin release 
rate, a labile linker comparable to that present in aaPEG (chapter 3) would be required 
in order to afford a suitable hydrolysis rate whilst counteracting the two-step 
hydrolysis effect.  
 
Scheme 4.1 The acid dissociation constant at logarithmic scale (pKa) of the acids with different side 
group and their relative initiator linker. 
The stability of an ester is influenced by the different side groups attached on 
the carboxyl group. A more acidic group (quantified by the acid dissociation constant 
Ka) which normally has a stronger electron withdrawing group, can act as a better 
leaving group, leads to a faster ester hydrolysis rate. Due to the same reason, col-
saPEG hydrolysed slower than col-aaPEG as demonstrated in chapter 3. Thus, 2-(2-
bromo-2-methylpropanoyloxy) acetic acid (BMPAA) was synthesised and chosen as 
the initiator linker (Scheme 4.1). 
Prior to the attachment of this initiator linker to colistin, a Boc5-colistin was 
synthesized using tert-butyloxycarbonyl (Boc) amine protecting group following the 
procedure developed in chapter 3 to protect all the amine residues on colistin. The 
initiator linker was then introduced onto both colistin Thr residues using standard 
Steglich esterification (Figure 4.1a). A clear molecular weight increase (414 Da) was 
observed from the modified product (Boc5-colistin-ini2) compared to Boc5-colistin 
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through MALDI-ToF MS analysis, indicating two initiator linkers were attached 
(Figure 4.1b). The isotope pattern from the Boc protected colistin initiator also 
suggested this product contains two bromine atoms (Figure 4.1c), further confirming 
the successful attachment of two initiators on Boc5-colistin and both bromines of the 
initiators were stable under the reaction conditions. 
 
Figure 4.1 a) The Boc-protection reaction on colistin Dab amines and the subsequent modification of 
the labile BMPAA initiator on colistin Thr groups. b) MALDI-ToF MS data of native colistin (black), 
Boc5-colistin (red), Boc5-colistin-ini2 (blue). c) The zoom-in data of Boc5-colistin-ini2. 
4.2.2 Polymerisation of PEGA480 from colistin intiator 
Due to the hydrolytic and heat sensitive features of both colistin and the labile 
initiator linker, a compatible polymerisation system with a non-aqueous solvent and a 
low temperature was required. The recent developed copper-mediated photoinduced 
living radical polymerisation (CP-LRP) was subsequently explored to achieve 
polymerisation from the colistin initiator.  
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Figure 4.2 a) Scheme of the polymerisation of MA using the colistin initiator via CP-LRP. b) 1H-NMR 
spectrum of the reaction mixture. The spectrum was acquired using d6-DMSO as solvent. 
Although this technique has shown to be a versatile and robust platform, a 
peptide-based initiator has not been investigated and it was not certain whether the UV 
would damage the peptide itself. Methyl acrylate (MA) was first used as a model 
monomer to study the feasibility of the polymerisation (Figure 4.2). Degrees of 
polymerisation (DP) was set to 20 for each initiator (e.g., DP = 40 for each Boc5-
colistin-ini2) to achieve a better resolution from both NMR and MALDI-ToF MS 
analyses. The reaction was conducted under the UV light (λmax ~ 360 nm) with 
copper(II) bromide (CuBr2) and the ligand (Me6TREN) at a ratio of 0.02:0.12:1 to the 
colistin initiator. Anhydrous DMSO was used to prevent the initiator hydrolysis during 
the polymerisation. A cooling plate was also applied to maintain the reaction 
temperature (~ 15 oC), further minimising any side reactions. The conversion of MA 
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was measured through 1H-NMR analysis of the reaction mixture, comparing the vinyl 
groups (δ = 5.70 - 6.35 ppm, Figure 4.2b, peak b-d) against the signal of methyl group 
on both the unreacted monomer and the formed polymer (δ = 3.48 -3.68 ppm, Figure 
4.2b, peak a and a’). This revealed that around 96% of the methyl acrylate was 
converted into polymer after 4 h polymerisation. A monomodal peak with narrow 
dispersity (Ɖ ~ 1.12) was observed through GPC analysis (Figure 4.3b, black trace), 
suggesting that the MA monomer polymerised successfully from the colistin initiator 
and that the polymerisation was controlled. This also indicated the colistin peptide 
structure did not disrupt the polymerisation process. 
 
Figure 4.3 a) Scheme of the cleavage of PMA colistin conjugate using NaOMe (3% in MeOH). b) 
DMF GPC and c) MALDI-ToF MS of the Boc5-colistin-PMA conjugate before (black traces) and after 
(red traces) treating with NaOMe. 
 As there were two initiating sites in the colistin initiator, a further cleavage 
experiment was performed on the PMA colistin conjugate (Boc5-colistin-PMA) under 
a basic condition (3 wt% sodium methoxide, NaOMe) in order to investigate whether 
the polymerisation had occurred from both sites (Figure 4.3a). The cleaved product 
was found to be monomodal with approximately half the molecular weight of the 
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initial polymer colistin conjugate through both the GPC and MALDI-ToF MS 
analysis, confirming the polymer was grown evenly from both sides of the colistin 
initiator. Moreover, the peaks that belonging to Boc5-colistin were also observed via 
MALDI-ToF MS (Figure 4.3c, red trace), indicating the colistin structure was 
undamaged through the polymerisation. 
The PEGA480 monomer was then polymerised at three different DPs (DP = 5, 10 
and 20 of each initiator) under the similar condition (Scheme 4.2). As expected, most 
of the PEGA480 was consumed after 2-4 h and all the final products retained narrow 
dispersities (Figure 4.4a-c and Table 4.3), suggesting the successful synthesis of all 
the polymers in a controlled manner.  
 
Scheme 4.2 Polymerisation of PEGA480 using CP-LRP and the cleavage of the Boc groups on the 
polymer. 
After the purification, the polymers were then treated with trifluoroacetic acid 
(TFA, 20% in dichloromethane, DCM), removing all the Boc groups on colistin to 
recover the amine residues. A clear shift to a shorter retention time was observed in 
all three polymers through HPLC analysis, suggesting a full removal of all the Boc 
groups (Figure 4.4d). The GPC analysis revealed that a similar molecular weight and 
dispersity were obtained from the polymers before and after the TFA cleavage process 
(Figure 4.4a-c), indicating the successful synthesis of the conjugates between colistin 
and PPEGA polymer with three different DPs (col-PPEGA DP5, DP10 and DP20) 
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with both ester bonds from the initiator linker being stable to the deprotection 
conditions.  
 
Figure 4.4 DMF GPC (a-c) traces of the col-PPEGA conjugates with different DPs in reaction mixture, 
after purification and after TFA cleavage. a) DP = 5, b) DP = 10, and c) DP = 20. d) HPLC traces of 
the col-PPEGA conjugates before and after the Boc groups cleavage. 
4.2.3 Hydrolysis test of col-PPEGA conjugates 
After obtaining the pure col-PPEGA conjugates, the hydrolytic nature of the 
linkers was investigated at both body and ambient temperature through the developed 
hydrolysis method described in chapter 3 (Figure 4.5a). Phosphate-buffered saline 
(PBS, 1X, pH = 7.4) was again used to mimic physiological conditions. The 
degradation of the col-PPEGA conjugates can be monitored by HPLC. A similar two-
step degradation process was observed in all three conjugates. Typically, the col-
PPEGA conjugate peak (varied from 14 - 16 min depending on the DP of polymers) 
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reduced gradually over the time and two peaks (9.8 - 10.6 min) that belonged to 
colistin A and B appeared and increased accordingly. An intermediate peak, with a 
retention time approximately 1.5 min earlier than that of the conjugate peak, was 
attributed to the mono-cleaved col-PPEGA conjugate. These peaks appeared and 
increased over the first 6 h and then decreased accordingly as a result of further 
cleavage. The cleaved PPEGA was also observed through the HPLC but the signal 
was relatively low owing to the weak absorbance of PPEGA at 214 nm (Figure 4.5b). 
The released colistin peaks were then collected and analysed from MALDI-ToF 
MS. It revealed the released colistin had a same molecular weight as the native colistin, 
suggesting the chemical structure of the released colistin was unchanged through both 
the polymerisation and the TFA cleavage process. Moreover, it confirmed that the 
initiator linkers were cleaved completely from colistin and that the hydrolysis occurred 
at the ester bond to the colistin rather than the ester bond to the PPEGA polymer. 
In general, the colistin release rates of each conjugate were similar, suggesting 
the hydrolysis of the cleavable linker was not hindered greatly by the large polymers, 
owing to the comb-like structure of the attached polymers. However, a slow-down of 
the colistin release rate (5-10%) can still be observed when the DP and the molecular 
weight of the attached polymers increased, which could have an effect on their 
antimicrobial activity.  
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Figure 4.5 a) Scheme of the hydrolysis process of the col-PPEGA conjugates. b) The degradation of 
col-PPEGA conjugates (DP = 5) at 37 oC in PBS (1X) monitoring by HPLC. c) Different colistin release 
profiles obtained from col-PPEGA conjugates with different DPs at 37 oC or ambient temperature. 
MALDI-ToF MS of the commercial colistin (d) and the released colistin from the degradation of col-
PPEGA conjugates (e). 
4.2.4 Disk diffusion assay for in vitro antimicrobial activity 
evalutaion of the col-PPEGA conjugates with various DPs  
In order to evaluate the antibiotic activity of each col-PPEGA conjugates, two 
MDR Gram-negative bacterial strains, P. aeruginosa ATCC 27853 and A. baumannii 
ATCC 19606, were first tested through disk diffusion assay. Thus, 20 µg of each 
conjugate was applied onto a blank disc (Ø = 0.6 cm) before being placed on a bacteria 
inoculated agar plate. Colistin and CMS was also tested as positive controls and saline 
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as a negative control. The potency of each conjugate was estimated through the 
measurement of their diameter of zone of inhibition (ZoI) (Table 4.1).  
Table 4.1 The diameter of zone of inhibition (ZOI) results of the colistin-PPEGA conjugates against 
two different Gram-negative bacteria through disk diffusion assay (24 h). 
 
As the PEG has been proven to have no antibiotic activity and the molecular 
weight of each col-PPEGA conjugate (Table 4.3) is at least 5 times larger than colistin 
and CMS, it is expected that they would show much less activity with the same mass. 
For this reason, col-PPEGA DP20 did not show a significant activity during the test. 
Surprisingly, the other two col-PPEGA conjugates still showed a clear ZoI, indicating 
the potency of these colistin conjugates resulted from the released colistin. Although 
the ZoIs are smaller than the ones obtained from colistin and CMS, the observant 
antimicrobial activity obtained from col-PPEGA DP5 and DP10 suggested the 
cleavable linker can be effectively hydrolysed under physiological conditions and this 
‘grafting-from’ approach for colistin conjugation did not alter the biological activity 
of the released colistin.  
4.2.5 Quantitative in vitro antimicrobial activity evaluation of 
the col-PPEGA conjugates with various DPs via broth 
microdilution method 
A further examination for the minimum inhibitory concentration (MIC) of each 
conjugate was performed through a broth microdilution method to achieve a more 
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accurate quantitative comparison. Although all the obtained polymer colistin 
conjugates have a narrow dispersity, an accurate comparison through the molar basis 
is not possible. Thus, the MIC test was conducted on a mass basis. 
As shown in Table 4.2, all the col-PPEGA conjugates have shown antibacterial 
activity against Ab ATCC 19606, indicating active colistin can be released from these 
colistin conjugates via the successful linker cleavage. Particularly, all these conjugates 
have comparable or better antimicrobial activity than col-aaPEG2 (from chapter 3) 
even though the molecular weight of these conjugates are all larger than col-aaPEG2. 
This suggests that the PPEGA polymer with the BMPAA linker released colistin faster 
than aaPEG and that the molecule weight of the comb-like PPEGA did not greatly 
hinder the linker hydrolysis which is in agreement to the colistin release profile from 
previous studies. Furthermore, col-PPEGA DP5 has a similar activity to the 
commercial prodrug CMS although the average molecular weight is around five times 
larger, highlighting its potential as a more efficacious alternative to CMS.  
Table 4.2 The minimum inhibitory concentration (MIC) of the conjugates against two different Gram-
negative bacteria on a mass basis. (Data with* was acquired from chapter 3.) 
 
4.2.6 Kinetics of in vitro antimicrobial activity of the col-PPEGA 
conjugates with various DPs 
To study the effects of the colistin release rate and the DP of the polymer 
employed in the col-PPEGA conjugates upon their antibacterial kinetics, time-kill 
studies of these conjugates were performed against A. baumannii ATCC 19606 
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bacterial strain at three different doses (0.5 x MIC, 1 x MIC, and 4 x MIC, referring 
to mass based MICs of each compound). 
 
Figure 4.6 The ‘time-kill’ kinetics with different amount for a) colistin b) CMS and c-e) the col-PPEGA 
conjugates with DP 5 (c), 10 (d), and 20 (e). 
All of the conjugates showed no significant inhibition towards the bacteria at a 
dose of 0.5 x MIC or 1 x MIC. When applying a higher dose (4 x MIC), both the DP5 
and DP10 polymer-colistin conjugates were found to have a similar antibacterial 
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performance compared to the commercial prodrug CMS, causing a significant 
decrease of the amount of live bacteria in the broth. Although the DP20 polymer 
conjugate did not produce a similar effect found from the DP5 and DP10 conjugates, 
an inhibition of bacterial growth was still observed through the experiment, suggesting 
antibacterial activity caused by the successful release of colistin.  
4.3 Conclusions  
In conclusion, col-PPEGA conjugates with different DPs have been successfully 
achieved through the attachment of a cleavable linker/initiator (BMPAA) on to both 
Thr residues, followed by the polymerisation of PEGA480 monomer using through the 
CP-LRP technique. All the conjugates were obtained with narrow dispersities. A 
model PMA polymer synthesis, confirmed that the structure of colistin remained intact 
during the polymerisation process. The in vitro degradation studies suggested most of 
the native colistin can be recovered from all three conjugates under a mimic 
physiological condition within 48 hours. The colistin release rate from the three 
PEGylated conjugates were similar though it slightly decreased with increasing the 
DP of the attached polymers. It revealed all three conjugates remained active against 
the tested MDR Gram-negative bacteria through the in vitro antimicrobial activity 
tests. In particular, col-PPEGA DP5 and DP10 showed a similar antibacterial activity 
to CMS, implying their potential as CMS alternatives. Although these col-PPEGA 
conjugates required a higher inhibitory concentration and exhibited less active 
antibacterial performance than the linear PEGylated colistin conjugate (col-aaPEG) 
described in Chapter 3 on mass basis, they still have some advantages, i.e., the 
modification sites of these conjugates are well-defined, which are important as 
prodrug candidates. 
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4.4 Experimental  
4.4.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich and used directly unless 
otherwise stated. HPLC solvents are obtained from VWR international, LLC.  
4.4.2 Bacterial strains 
Bacterial strains of P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606 
(American Type Culture Collection, Manassas, VA) were used in this study. The 
strains were stored at -80 °C in a cryovial storage container (Simport Plastics, Quebec, 
Canada). Fresh isolates were subcultured on nutrient agar (Media Preparation Unit, 
The University of Melbourne, Parkville, Australia) and incubated at 37 °C for 24 h 
prior to each experiment. . CAMHB (Oxoid, Hampshire, England) was used as culture 
medium. 
4.4.3 Instruments 
4.4.3.1 NMR 
1H-NMR and 13C-NMR spectra were recorded on Bruker HD 300 spectrometers 
and referenced relative to deuterated solvent (Sigma Aldrich) shifts. 
4.4.3.2 MALDI-ToF MS 
MALDI-ToF MS was performed on a Bruker Daltonics Autoflex MALDI-ToF 
mass spectrometer. The MALDI-ToF MS samples were prepared by mixing a matrix 
solution (20 mg/mL DCTB in THF) and a sample solution (1-2 mg/mL in THF) at the 
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same volume. 0.5 μL of this mixture was spotted to the target plate. Spectra were 
required from either reflector mode or linear mode calibrating with PEG or mPEG at 
a similar average molecular weight of each sample. 
4.4.3.3 GPC 
GPC was performed on an Agilent PL50 equipped with 2 Agilent Polargel M 
Columns and a differential refractive index detector eluting with DMF (0.1 M LiBr) 
with a flow rate of 1.0 mL min-1 at 50 oC. The calibration was fitted with a 3rd order 
polynomial using narrow molecular weight standards of PMMA (between 200 and 
467,400 g mol-1). 
4.4.3.4 HPLC 
Both sample analysis and collection were conducted from a PREP HPLC system 
(Agilent 1260 infinity series stack) equipped with a 1260 Quat Pump VL, a degasser 
and a fraction collector (FC-AS). Samples (10-70 µL) were injected using Agilent 
1260 auto-sampler. The HPLC was fitted with a Phenomenex Lunar C18 column (250 
x 4.6 mm) 5 micron packing (100Ǻ).  Detection was achieved using an Agilent 1260 
variable wavelength detector connected in series with UV detection monitored at 214 
nm.  
The mobile phase condition is as follows.  
Mobile phase A: 100% water with 0.04% TFA; 
Mobile phase B: 100% ACN with 0.04% TFA. 
The gradient of the mobile phase varied in each analysis. The standard analysis 
method is as followed: 0-20 min 5%-100% B; 20-25 min 100% B; 25-26 min 100%-
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5% B; 26-35 min 5% B. The total flow rate was set to 1.0 mL/min and the temperature 
for the column is set to 40 oC. 
HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TFA 
was used as additive. 
4.4.3.5 FTIR 
FTIR spectra were recorder on a Bruker VECTOR-22 FTIR spectrometer using 
a Golden Gate diamond attenuated total reflection (ATR) cell. 
4.4.3.6 Electrospray ionisation-mass spectroscopy (ESI-MS)  
ESI-MS was done on the Bruker MaXis II instrument (equipped with ESI 
source) through direct infusion at 1 µL/min. The sample was dissolved and diluted in 
50% ACN/water with 0.1% formic acid and run in the positive ion mode. 
4.4.4 Methods 
4.4.4.1 Disk diffusion assay 
According to the EUCAST guidelines,6 inoculum was standardised in saline to 
the density of a McFarland 0.50±0.02 standard, corresponding to ~108 CFU/mL of 
each isolate. A freshly prepared suspension was evenly inoculated onto plates and 
disks were applied within 15 min and incubated for 18 h at 37 °C. Plates were 
examined for satisfactory streaked suspension and evenly distributed growth to 
achieve uniformly circular inhibition zones within the quality control limits. 
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4.4.4.2 MIC test 
MICs were determined in accordance to the recommendations of the Clinical 
and Laboratory Standards Institute.7 A. baumannii ATCC 19606 was used for the tests. 
Experiments were performed with CAMHB in 96-well polystyrene microtiter plates. 
Wells were inoculated with 100 μL of bacterial suspension prepared in CAMHB 
(containing ∼ 106 CFU/mL) and 100 μL of CAMHB containing increasing 
concentrations of colistin, CMS and col-PPEGA conjugates (0 − 128 mg/L). The MIC 
measurements were carried out in duplicates with the MIC being defined as the lowest 
concentration at which visible growth was inhibited following 18 − 20 h of incubation 
at 37 °C. 
4.4.4.3 Time-kill test 
The time-kill kinetics of the col-PPEGA conjugates at 0.5, 1, and 4 x MIC were 
examined against A. baumannii ATCC 19606. Briefly, each test sample was added 
into a 50 mL Eppendorf tube loaded with 20 mL of a logarithmic-phase broth culture 
of approximately 106 CFU/mL to yield concentrations of 0, 0.5, 1, and 4 x MIC  of the 
isolate. The tubes were incubated in a shaking water bath at 37 oC. The samples were 
taken at 0 min, 30 min and 1, 3, 6 and 24 h. Subcultures for viable counts were 
performed on nutrient agar (Oxoid) using WASP2 Spiral Plater (Don Whitley 
Scientific) and incubated at 37 °C for 24 h (48 h for plates with small colonies). Viable 
counts were determined by either manual counting or using ProtoCol3 Colony Counter 
(Don Whitley Scientific). 
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4.4.5 Synthesis 
4.4.5.1 Synthesis of initiator precursor, 2-((2-bromo-2-
methylpropanoyl)oxy)acetic acid (BMPAA) 
Glycolic acid (3.00 g, 40 mmol, 1.0 equiv.) was dissolved with DCM (60 mL) 
and N,N-diisopropylethylamine (DIPEA, 8 mL, 45 mmol, 1.125 equiv.) in a 250 mL 
3-neck round bottom flask under N2. The reaction mixture was kept stirring in an ice 
bath for 30 min before the dropwise addition of α-bromoisobutyryl bromide (6 mL, 50 
mmol, 1.25 equiv.) along with DCM (30 mL) through a dropping funnel. After the 
addition of all the chemicals, the system was gradually warmed up to ambient 
temperature and left overnight. The solvent was then removed under vacuum and the 
crude product was extracted by diethyl ether/0.2 M hydrochloric acid (HCl) solution 
to remove the remaining DIPEA. After the removal of solvent, the product was then 
purified by Kugelrohr Distillation. The product is normally obtained as a white solid 
with a slight amount of an acid impurity (which we suspected it to be α-
bromoisobutyric acid) at 50 oC to 100 oC under 2.2x10-2 mbar. The purity of the 
product can be analysed by TLC plate (diethyl ether: AcOH = 400: 1 v/v). A further 
purification was performed by the recrystallisation from hot hexane. The final product 
is a white flaky crystal with a yield of 3.6 g (16 mmol, 40%).  
1H-NMR (300 MHz, CDCl3, 298 K) δ (ppm) = 1.99 (-C(CH3)2Br), 4.76 (-
OCH2CO-) and 7.83 (br, -COOH). 
13C-NMR (75.5 MHz, CDCl3, 298 K) δ (ppm) = 30.73 (-C(CH3)2Br), 54.56 (-
C(CH3)2Br), 61.12 (-OCH2CO-), 171.21 (-COOCH2CO-), 172.74 (-OCH2CO-). 
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IR (neat) /cm-1: 3300-2300 (O-H), 2975, 2865 (CH2, CH3), 1724, 1706 (C=O), 
1421, 1248, 1147. 
ESI-MS (negative mode): m/z (found) 222.9607 (M-H), m/z (calculated) 
222.9611 (M-H). 
4.4.5.2 Synthesis of Boc5-colistin-ini2 
The synthesis of Boc5-colistin-ini2 was modified from the standard Steglich 
esterification.  1.00 g of colistin sulphate (0.789 mmol, 1 equiv.) was converted into 
Boc5-colistin based on the previous chapter. The crude Boc5-colistin product (~ 1.10 
g) was then dissolved in anhydrous THF (50 mL), following the addition of 2-((2-
bromo-2-methylpropanoyl)oxy)acetic acid (885.0 mg, 3.95 mmol, 5 equiv.) and 
DMAP (48.0 mg, 0.393 mmol, 0.5 equiv.). After the chemicals completely dissolved, 
N,N'-dicyclohexylcarbodiimide (DCC, 977.0 mg, 4.74 mmol, 6 equiv.) was added 
afterwards and the reaction mixture was kept stirring overnight. The reaction mixture 
was then centrifuged to remove most of insoluble compounds. The solvent was then 
removed under vacuum and a further purification was performed by the flash column 
(0% -10% MeOH in DCM).The final product is a fine pale yellow powder with a total 
yield around 0.96 g (0.463 mmol, 59%). 
4.4.5.3 Procedure for the polymerisation of MA using colistin 
initiator Boc5-colistin-ini2 
The polymerisation condition of MA was modified from the standard CP-LRP. 
MA was passed through a short basic aluminium column to remove the inhibitor prior 
to use. A stock solution of CuBr2 (1 mg/mL in DMSO) and the ligand Me6TREN (6.5 
μL/mL in DMSO) was freshly prepared before the reaction. MA (73 μL, 0.80 mmol, 
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40 equiv., 20 equiv. per arm), Boc5-colistin-ini2 (42 mg, 20 μmol, 1 equiv.), CuBr2 
stock solution (90 μL, 0.4 μmol, 0.02 equiv.), Me6TREN stock solution (100 μL, 2.4 
μmol, 0.12 equiv.) were added to a 2 mL vial. 102 μL DMSO was then added to make 
the monomer/solvent ratio to around 1: 4. The reaction mixture was then stirred until 
all the compounds were dissolved. The system was then sealed and carefully degassed 
by purging with N2 for 15 min (make sure the monomer is not blown off by the N2). 
The polymerisation was performed under UV with a cooling plate (CAMLAB, 
KP283)  to maintain the reaction temperature. The reaction was stopped at 4h and the 
conversion were measured using 1H-NMR. MALDI-ToF MS and GPC analyses were 
also conducted to evaluate the molecular weight and dispersity of the polymer. 
The cleavage of the linker from PMA-Boc5-colistin conjugate was conducted 
directly using the crude polymer obtained from previous procedure. 100 μL of the 
crude polymer was diluted by 1mL 3% NaOMe in MeOH and the reaction mixture 
was kept stirring at ambient temperature for 1 day. The solvent was then blown off by 
N2 and the product were analysis by MALDI-ToF MS and GPC. 
4.4.5.4 Polymerisation of PEGA480 of different DPs  using colistin 
initiator Boc5-colistin-ini2 
The polymerisation procedure of PEGA480 was similar to MA. The ratio of 
initiator: CuBr2: ligand was kept the same as the one used in the polymerisation of 
MA(1: 0.02: 0.12). The PEGA480 monomer to initiator ratio was set to 10:1, 20:1, 40:1 
for the synthesis of DP5, DP10, and DP20 polymer, respectively. For the synthesis of 
DP10 and DP20 polymer, 21 mg colistin initiator was used and the monomer/DMSO 
ratio was changed to 1: 2 so that the reaction time was shorten to 2 h instead of the 
standard 4h to reach high monomer conversion (> 90%) which can be analysed by 1H-
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NMR. To minimise the hydrolysis during the purification steps, the further separation 
of the polymer and the trace PEGA480 monomer was done by diluting the crude using 
ACN and purifying by RP-HPLC (0-12 min 50%-100% B; 12-20 min 100% B, 20-21 
min 100%-50% B; 21-30 min 50% B). The polymer peak would be found from 8-15 
min depending on the DP.  Once collected from RP-HPLC, the product was frozen by 
liquid N2 and the solvents were directly removed under high vacuum. The products 
before and after the purification were performed by GPC and HPLC analysis to 
observe whether any change was occurred during the purification step. 
 
4.4.5.5 Deprotection of Boc groups from Boc5-col-PPEGA 
conjugates 
Table 4.3 1H-NMR and DMF GPC analysis of the product from the reaction mixture, after purification 
and after deprotection of the Boc groups. 
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The deprotection of the Boc groups was modified from the typical Boc cleavage 
procedure. 5 mL 20 % TFA in DCM was added slowly into the purified polymer 
conjugates. [Be cautious of the release of gas!] After most gas was released, the 
reaction mixture was sealed and kept stirring at ambient temperature overnight. After 
the removal of solvents, the product was frozen by liquid N2 and all the solvents were 
directly removed under high vacuum. The products were performed by GPC and 
HPLC analysis for comparison. 
4.4.5.6 Protocol for in vitro releasability of col-PPEGA prodrugs 
The degradation of the col-PPEGA conjugates was based on the previous 
chapter. Each conjugate was weighed into a 2 mL vial, followed by the addition of a 
certain amount of PBS (1X) to make the final concention of 0.4 μmol/mL. 900 µL of 
each prodrug solution was taken into another vial and incubated in an oil bath with 
stirring at 37 oC. The rest of each prodrug solution (> 500 µL) was stirred at ambient 
temperature. Samples (85 μL each time) were taken periodically and frozen by liquid 
nitrogen before the analysis. The analysis was conducted by RP-HPLC (injection 
volume = 70 µL) using the standard analysis condition. The colistin release percentage 
was calculated based on the reported method.  
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 A Hydrogel Based Localised Release of 
Colistin for Antimicrobial Treatment of Burn Wound 
Infection 
 
In this chapter, a localised hydrogel-based delivery system for colistin has been 
developed for a topical delivery regime to demonstrate the possibility to reduce the 
systemic toxicity caused by colistin treatment. Colistin was incorporated into a self-
healable hydrogel (formed via dynamic imine bonds between the amine groups present 
in glycol chitosan and an aldehyde modified PEG). The storage modulus (G’) of the 
colistin-loaded hydrogel ranged from 1.3 kPa to 5.3 kPa by varying the amount of the 
cross-linker and colistin loading, providing different options for topical wound care. 
Most of the colistin is released from the hydrogel within 24 h and remains active as 
demonstrated by both antibacterial in vitro disk diffusion and time-kill assays. 
Moreover and pleasingly, the colistin-loaded hydrogel performed almost equally as 
well as native colistin against both the colistin-sensitive and also colistin-resistant P. 
aeruginosa strain in the in vivo animal 'burn' infection model despite exhibiting a 
slower killing profile in vitro. 
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5.1 Introduction  
In the previous two chapters, the possibility of using colistin polymeric prodrugs 
synthesised through two approaches to reduce colistin toxicity while maintaining its 
antimicrobial activity during systemic administration has been demonstrated. 
However, in some cases, such as for treating localised infections like open wounds or 
burn wound infections, systemic administration of colistin is not necessary and not 
efficient to achieve a high local concentration to inhibit the growth of bacteria, not to 
mention that the delicate synthesis and purification steps involved in the synthesis of 
prodrug would increase the cost of the colistin treatment. It has been demonstrated that 
the localised application of colistin to the infection site can also reduce its systemic 
toxicity while maintain its activity.1 Thus, instead of making any chemical 
transformations to colistin, focus was switched to colistin formulation in a hydrogel 
network for localised delivery. 
As colistin is a small lipopeptide antibiotic that is sensitive to many thermal, 
enzymatic and chemical conditions, a hydrogel based delivery platform with facile 
preparation, easy operation, mild gel formation environment, and high drug loading 
capacity could be a suitable candidate to deliver colistin in a local and effective manner 
to wounds. Recently, Wei and co-workers developed an injectable chitosan-based 
hydrogel through the utilisation of dynamic imine bond chemistry, which exhibits high 
biocompatibility and allows for the controlled storage and release of proteins, and even 
cells.2-4 An inexpensive hydrogel can be formed using commercially available glycol 
chitosan and an easily prepared low-toxicity aldehyde-modified poly(ethylene glycol) 
derivative (DF-PEG, the chemical structure of DF-PEG was shown in Scheme 5.1c).2-
4 The resulting hydrogel is a transparent material with self-healing properties; which 
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can provide better monitoring of the wound through direct observation, and improved 
adhesion to the wound. The quick and efficient chemistry used allows this hydrogel to 
be formed either at ambient or body temperatures, which is convenient for topical 
delivery. More importantly, the starting materials of this hydrogel, as well as colistin, 
are highly water soluble, suggesting that colistin could be loaded and distributed into 
the system evenly during the gel formation.  
In this chapter, a patch candidate using the dynamic glycol chitosan/DF-PEG 
hydrogels loaded with colistin was presented. The effects of DF-PEG and colistin 
concentration on the gel material properties were investigated. The release profile of 
colistin was determined both in PBS and bacterial growth media by HPLC analysis. 
Furthermore, the antibacterial activity of the released colistin was evaluated in vitro 
via disk diffusion and time kill experiments. Proof-of-concept in vivo experiments 
were performed using a mouse ‘burn’ infection model. 
5.2 Results and Discussion  
5.2.1 Initial attempts to form a colistin/DF-PEG hydrogel 
As colistin itself contains five primary amines that are capable of imine 
formation as demonstrated in chapter 2, initial attempts to prepare a hydrogel were 
focused on direct mixing of colistin and DF-PEG (20 mg colistin with 500 μL 20% 
w/w DF-PEG PBS solution, Figure 5.1). However, there was no hydrogel or visible 
precipitation formed during this process, indicating no effective cross-linking reaction 
happened between the two materials. This may be attributed to the dynamic 
reversibility of the imine bonds under these conditions. In order to act as a stable cross-
linking point, at least three amines on each colistin need to form imine bonds with DF-
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PEG at all times, which is not necessarily easy as the individual imine bond is weak 
and hydrolytically labile. However, it is more likely to happen with a multi-functional 
amine-rich material such as glycol chitosan. The viscosity produced by glycol chitosan 
may hinder the reversibility of the imine bond, which could also promote hydrogel 
formation. Thus, glycol chitosan is necessary in this system to obtain a stable hydrogel 
network.  
 
Figure 5.1 The visualisation of the hydrogels using different components. All the hydrogels (vial 3-6) 
were prepared through the standard condition. Colistin loading amount for each hydrogel sample is 5 
mg. GCh: 475 μL 3% glycol chitosan in PBS; DF-PEG: 475 μL 20% w/w DF-PEG PBS solution; 
colistin+PEG-DF: 20 mg colistin with 500 μL 20% w/w DF-PEG PBS solution. 
5.2.2 The formation and characterisation of colistin-loaded 
hydrogels with different cross-linker ratios 
The synthesis of a colistin-loaded hydrogel was achieved by integrating colistin 
into the glycol chitosan/DF-PEG hydrogel formulation (Scheme 5.1). The original 
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hydrogel was prepared by mixing an aqueous glycol chitosan solution with an aqueous 
DF-PEG solution at a volume ratio of 2.8:1. Instead of the established protocol, PBS 
buffer was used as the solvent in an attempt to more closely mimic the wound 
environment. To obtain a stronger but not brittle material for patch application, a 
preliminary study on tuning the concentration of glycol chitosan/DF-PEG was 
performed. After the optimisation, two types of hydrogels (HG-5 and HG-10) formed 
from 3% w/w glycol chitosan solution and either 5% or 10% w/w DF-PEG solution 
were chosen for comparison.  
 
Scheme 5.1 a) Cartoon illustration of the synthesis of colistin-loaded hydrogels. The chemical structure 
of b) glycol chitosan, c) DF-PEG and d) colistin A and B. 
The incorporation of colistin was conducted by the addition of colistin either to 
the glycol chitosan solution or to the DF-PEG solution, and after mixing the two 
solutions a transparent hydrogel was formed instantly (typically < 1.6 min) as shown 
in Figure 5.1. To investigate the effect of colistin upon the hydrogel formation, the gel 
formation process was then monitoring by the rheological analysis. Both HG-5 and 
HG-10 were tested. It turned out that the gel formation process of the colistin-loaded 
hydrogels was not affected by the addition of colistin in both cases, and in fact, the 
presence of colistin in the formulation accelerated the gelation process compared to 
the original hydrogels. This effect may be explained by the increased number of 
amines that can act as catalysts/gelation points in the system (Figure 5.2). 
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Figure 5.2 Storage modulus G’ and loss modulus G’’ analyses during gelation process for different 
hydrogels. (Black: storage modulus; white: loss modulus; blue: phase angle; 37 °C; frequency: 1.0 Hz; 
strain: 5.0 %). 
 
Figure 5.3 Rheology analyses of the hydrogel deformation and recovery with different loading amount 
of colistin. Black: storage modulus; red: loss modulus. Amplitude oscillatory forces were changed from 
γ = 250% (last for 2 min) to 1% (last for 5 min) under the same frequency (1.0 Hz) at 37 oC. 
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Since the hydrogel network is mainly dominated by glycol chitosan and DF-
PEG, it is expected that the mechanical properties of the hydrogel can still be tuned 
by adjusting the amount of the DF-PEG cross-linker in the presence of colistin. Even 
through a slight decrease of the storage modulus (G’) was observed by increasing the 
loading amount of  colistin, the HG-10 hydrogels prepared from a higher concentration 
DF-PEG solution (10% w/w) all exhibited a larger storage modulus compared to the 
corresponding HG-5 hydrogels with the same amount of colistin loaded. The G’ range 
of the HG-5 is suitable for application as a topical gel, while the higher G’ of HG-10 
makes it a suitable candidate for patch processing.  
The self-healing property provided by the dynamic imine bond of the original 
hydrogel has proven to be helpful to tissue repair.4 To observe whether the self-
healable gel would be affected by the addition of colistin, the rheology of the colistin-
loaded hydrogels was examined (Figure 5.3). As colistin does not interrupt the 
formation of the main dynamic cross-linked network of the hydrogels, both hydrogels 
demonstrated self-healing properties in the presence of colistin whilst the G’ of the 
hydrogels only reduced slightly after three cycles, implying the colistin-loaded 
hydrogels can still provide similar protection on the wound after suffering some small 
damage. 
5.2.3 Colistin release from the hydrogels 
Since the integration of colistin into the hydrogels was successful, the potential 
for tuning the colistin release was investigated. The release rate of colistin was first 
tested in PBS (1X) using both HG-5 and HG-10 formulations for comparison. Due to 
the potency of colistin, the release experiment was then carried out at relatively low 
concentrations. A high (5 mg colistin per hydrogel; final colistin concentration in 
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solution, 250 mg/L) and a low dose (0.5 mg colistin per hydrogel; final colistin 
concentration in solution, 25 mg/L) colistin were loaded into both hydrogels for the 
test. In order to confirm colistin is incorporated within the hydrogel as opposed to 
being located at the surface, a washing step was conducted prior to the release study. 
The recovered wash solutions were systematically analysed by HPLC and revealed no 
detectable signals, suggesting near quantitative encapsulation of colistin. 
Interestingly, although adjusting the amount of the DF-PEG cross-linker is used 
to tune the physical properties of the hydrogels, it has little impact upon the colistin 
release rate under the formulation conditions used herein (Figure 5.4). The colistin 
concentration difference at each sampling time is sufficiently insignificant not to have 
any biological implication for both hydrogels loaded with the same amount of colistin. 
We attribute this observation to the dynamic properties of the hydrogel cross-linked 
network and the weak interactions between colistin and the hydrogel scaffold. The low 
colistin loading may also be one of the reasons for the little difference of the release 
rate between the HG-5 and HG-10 formulations. 
Similarly, the release of colistin was tested in cation-adjusted Mueller-Hinton 
(CAMHB) bacterial growth media to evaluate the effect of a complex biological media 
on the colistin release rate. Even though the CAMHB contains amino acids, proteins 
and various ions, which is very different to PBS, the release profiles of both colistin-
loaded hydrogels were found to be very similar (Figure 5.4). Again, under these 
conditions the amount of the cross-linker in the hydrogel did not have a great influence 
on the release of colistin due to similar reasons described above. All of these results 
suggest that the antibiotic activity between these two colistin-loaded hydrogels should 
be similar. 
 
Chapter 5 
Chongyu Zhu  134 
 
Figure 5.4 The release study in PBS and cation-adjusted Mueller-Hinton broth. The data of HG-5 is 
described in dash lines and HG-10 in solid lines. (The release traces of the blank hydrogels overlap with 
the x axis). 
5.2.4 In vitro bio-activity evaluation of colistin-loaded hydrogels 
The activity of the colistin-loaded gels was investigated in vitro against two P. 
aeruginosa strains, a colistin-sensitive strain (ATCC 27853, minimum inhibitory 
concentration (MIC) = 1 mg/L) and a colistin-resistant strain cystic fibrosis isolate 
(19147 n/m, MIC > 128 mg/L). Firstly, a disk diffusion assay was used to evaluate the 
release of colistin from the hydrogel through the interface (Figure 5.5). Briefly, the 
colistin-loaded hydrogels were placed on an agar plate surface that was swabbed with 
a bacterial isolate solution and the plate was then incubated for 24 h. A clear bacteria-
free zone, also known as zone of inhibition (ZoI), would be found from the samples 
that have antibiotic activity and the larger size of ZoI indicates a higher potency of the 
sample. 
Although the hydrogel per se did not show any inhibition against the bacteria, 
clear ZoIs were found from the colistin-sensitve P. aeruginosa strain when colistin-
loaded hydrogels were applied (Figure 5.5a, left lane), suggesting that colistin is 
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effectively released from the colistin-loaded hydrogels to the bacterial interface and 
more importantly, that the released colistin remains active.  
 
Figure 5.5 a) Disk diffusion assay for the colistin-loaded hydrogels against the colistin-sensitive (left) 
and colistin-resistant (right) P. aeruginosa strains. b) Zone of inhibition (ZoI) results of the colistin-
loaded hydrogels. Blank: commercial blank disc; Col: commercial colistin disk (contains 10 μg 
colistin); HG-10/5: blank hydrogels; HG-10/5-L: hydrogels loaded with 10 μg colistin; HG-10/5-H: 
hydrogels loaded with 100 μg colistin. 
ZoIs of similar size were found between both colistin-loaded hydrogels (HG-5 
and HG-10) against the P. aeruginosa strain, in accordance with the extent of colistin 
release after 24 h from the release profile (Figure 5.4), proposing the two colistin-
loaded hydrogels have similar antibacterial properties despite the difference in their 
physical properties. More importantly, the colistin-loaded hydrogels showed similar 
activity to commercial colistin disks containing the same amount of colistin (10 μg), 
indicating the released colistin has similiar activity against the P. aeruginosa bacteria 
as the native one and that the hydrogel does not severely hinder or alter the activity of 
the colistin during loading and whilst encapsulated. Similar results were also found 
from the colistin-resistant P. aeruginosa strain (Figure 5.5a, right lane). Owing to the 
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high loading capacity of the hydrogel, it was possible to increase the loading of colistin 
into the hydrogel of the same size. With the higher loading of the colistin (100 μg 
colistin per hydrogel), the hydrogels showed the expected enhanced antibiotic 
performance against the bacteria when compared to the commercial disks.  
 
Figure 5.6 Time-kill test of the colistin-loaded hydrogels. Black lines: blank control and blank 
hydrogels; red lines: samples loaded with 0.5 mg colistin (final concentration: 25 mg/L); blue lines: 
samples loaded 5 mg colistin (final concentration: 250 mg/L). The detection limit is shown in dash line. 
In order to obtain a better understanding of the killing kinetics of the colistin-
loaded hydrogels, time-dependent bacterial inhibition experiments (time-kill 
experiments) were conducted (Figure 5.6). Briefly, the colistin-loaded hydrogels were 
introduced into the broth containing bacteria at the logarithmic phase of growth and 
the broth samples were taken periodically for viable counts. As the growth of the 
colistin-sensitive P. aeruginosa strain can be easily inhibited at a very low colistin 
concentration, only the colistin-resistant strain was investigated in these time-kill 
studies. Although the MIC of the colistin-resistant strain is greater than 128 mg/L, 
colistin solution at a final concentration of 25 mg/L inhibited the growth of the bacteria 
from 0.5-6 h. On the contrary, the lower colistin dose hydrogels (0.5 mg colistin per 
hydrogel; final colistin concentration in solution, 25 mg/L), showed a lower level of 
activity. This is mainly due to the different diffusion profiles obtained from the two 
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solutions and the hydrogel-solution interface. The slower colistin release provided by 
colistin-loaded hydrogel in the first few hours resulted in a lower local concentration 
of released colistin, compared with the colistin solution, thus inhibition of the growth 
of bacteria at that dose is not observed. To increase the initial local colistin 
concentration, a higher concentration of colistin was loaded into the hydrogels (5 mg 
colistin per hydrogel; final colistin concentration in solution, 250 mg/L). At this 
loading, colistin-loaded hydrogels showed a much better performance against the 
resistant P. aeruginosa strain. Akin to the previous colistin release curve (Figure 5.4), 
the difference of the killing profiles between HG-5 and HG-10 were again very subtle, 
indicating similar concentrations of colistin with similar antibiotic ability were 
released from both colistin-loaded hydrogels. Although a slightly slower killing 
profile was still observed compared to a solution containing the same amount colistin 
due to the reduced initial local concentration provided from the hydrogels, the survival 
bacteria number was significantly decreased (Figure 5.6). 
5.2.5 In vivo animal ‘burn’ infection model test of colistin-loaded 
hydrogels 
An animal 'burn' infection model was also developed to evaluate the gel 
performance in vivo (see section 4.4 Experimental for the details). Both the colistin-
sensitive strain and the resistant strain were tested. Although colistin-loaded hydrogels 
were quite stable in vitro, a visible weight loss was found in both blank and colistin-
loaded hydrogels during the test due to the biodegradability of the hydrogels (Figure 
5.7). Notably, no matter if colistin was loaded, HG-5 degraded much faster compared 
to HG-10, leading to a complete degradation after being applied onto the wound for 
24 h. Since the HG-5 hydrogel required a longer gelation time and it exhibited a faster 
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degradation rate in vivo, only the HG-10 formulation was examined in the following 
in vivo test.  
 
Figure 5.7 The weight loss of the colistin-loaded hydrogels in vivo over the time. ColHG-10 and 
ColHG-5 were the corresponding hydrogels loaded with 0.3 mg colistin. 
100 µL 109 CFU/mL of bacteria at the early logarithmic growth phase was 
inoculated onto the wound (1 cm2) of each mouse, two hours in advance of the test. 
Then patches made from colistin solution, colistin-loaded hydrogel or blank hydrogels 
were applied onto the wound at time = 0 h. Colistin (0.3 mg) was loaded into the 
hydrogel to kill the colistin-sensitive strain. Surprisingly, in spite of the slower colistin 
release in vitro, the colistin-loaded hydrogel performed as efficiently as the colistin 
solution in vivo (Figure 5.8).  
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Figure 5.8 The ‘burn’ infection model test of the colistin-loaded hydrogel against colistin-sensitive P. 
aeruginosa strain. Black line: blank infection control; red line: blank HG-10 hydrogel; blue line: HG-
10 with colistin (0.3 mg/wound); pink line: colistin solution (0.3 mg/wound). The detection limit is 
shown in dash line. 
 
Figure 5.9 The ‘burn’ infection model test of the colistin-loaded hydrogel against colistin-resistant P. 
aeruginosa strain. Black line: blank infection control; red line: blank HG-10 hydrogel; blue line: HG-
10 with colistin (a: 0.3 mg/wound and b: 1.5 mg/wound); pink line: colistin solution (a: 0.3 mg/wound 
and b: 1.5 mg/wound). The detection limit is shown in dash line. 
In the case of the resistant strain, the colistin concentration was not sufficient to 
kill the bacteria whether it was applied in the hydrogel or as a solution (Figure 5.9a). 
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Therefore, a higher dose (1.5 mg colistin) was used instead to kill the resistant strain. 
Although the killing profile is slower due to the nature of the resistant strain, the 
colistin-loaded hydrogel again showed a similar activity as the colistin solution, 
leading to approximately 2 logarithm reductions of the bacteria population (i.e. ~99% 
bacteria population was killed) (Figure 5.9b). This implies that the hydrogel 
formulation did not inhibit the activity of the colistin in vivo even though it has a 
slower release rate than that observed in the time-kill study. This may partially be 
attributed to the similar diffusion profile occurring at the wound interface but also 
through the enhanced degradation of the hydrogel in the biologically complex local 
wound environment. Moreover, since the colistin-loaded hydrogels were applied 
directly onto the burn wound, it appears that the local concentration on the wound was 
high enough to kill the bacteria whilst all the tested mice survived suggesting the 
overall systemic concentration and toxicity remained low. 
5.3 Conclusions  
In summary, self-healing colistin-loaded hydrogels by incorporating colistin 
into an inexpensive, biocompatible and biodegradable chitosan hydrogel has been 
successfully prepared. The hydrogel structure was not affected by the addition of the 
colistin lipopeptide and the colistin-loaded hydrogels inherited all of the properties 
from the original hydrogel without disrupting their desired physical properties. 
Interestingly, the hydrogel formation process could be accelerated in the presence of 
the colistin. Colistin is released from the hydrogel at a similar rate at body temperature 
in different buffers. The disk diffusion assay showed that the released colistin 
remained active and had comparable antibacterial activity as the colistin solution. 
Although the colistin-loaded hydrogels showed a slower killing profile in vitro 
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compared with the colistin solution, it performed as well as the colistin solution in vivo 
thanks to the biodegradable and dynamic nature of this glycol chitosan hydrogel. 
Furthermore, a wide range of colistin loading was easily achievable, thus allowing the 
tuning of the release of colistin for different applications. Indeed, even the colistin 
resistant P. aeruginosa strains can easily be killed in vivo in a mouse burn infection 
model. Finally, this hydrogel system can achieve the localized release of active colistin 
without causing any toxicity to the mice. This colistin-loaded hydrogel holds 
significant potential for the treatment of chronic wound infections caused by 
problematic Gram-negative ‘superbugs’. 
5.4 Experimental  
5.4.1 Materials  
5.4.1.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich and used directly unless 
otherwise stated. Colistin sulfate salt (≥ 15,000 U/mg) was used as colistin source in 
all the experiments. HPLC solvents are obtained from VWR international, LLC. 
5.4.1.2 Bacterial strains 
Bacterial strains of P. aeruginosa ATCC 27853 (American Type Culture 
Collection, Manassas, VA) and P. aeruginosa 19147 n/m (MIC > 128 μg/L, clinical 
isolate) were used in this study. The strain was stored at -80 °C in a cryovial storage 
container (Simport Plastics, Quebec, Canada). Fresh isolates were subcultured on 
Nutrient agar (Media Preparation Unit, The University of Melbourne, Parkville, 
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Australia) and incubated at 35°C for 24 h prior to each experiment.  CAMHB (Oxoid, 
Hampshire, England) was used as culture medium. 
5.4.2 Instruments  
5.4.2.1 NMR 
1H-NMR spectra were recorded on Bruker HD 500 spectrometers and referenced 
relative to deuterated solvent shifts using deuterated solvents obtained from Aldrich.  
5.4.2.2 HPLC 
HPLC was performed using an Agilent 1260 infinity series stack equipped with 
a binary pump and degasser. The HPLC was fitted with a Phenomenex Lunar C18 
column (250 x 4.6 mm) with 5 micron packing (100Ǻ). Samples were injected using 
Agilent 1260 autosampler. UV detection was monitored at λ = 214 or 225 nm. The 
flow rate was set to 1.0 mL/min. The condition for the detection of colistin release is 
shown below: 
Mobile phase A: 100% water, 0.04% TFA.  
Mobile phase B: 100% ACN, 0.04% TFA.  
Programmed Gradient: 10%-80% B (0-30 min); 80% B (30-35 min); 80%-10% 
B (35-36 min); 10% B (36-50 min). 
5.4.2.3 Rheometer 
Rheology analysis was performed using a Kinexus Rheometer (Kinexus Ultra, 
Malvern Instruments. Inc, MA, USA) with a JULABO heating module (CF-41, 
JULABO USA, Inc.). 
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5.4.3 Synthesis 
5.4.3.1 Synthesis of difunctionalized PEG (DF-PEG) 
The synthesis of DF-PEG was adapted from literature using PEG4000.
2, 3 PEG4000 
(12.0 g, 3 mmol, 1 equiv.), FBA (1.80 g, 12 mmol, 4 equiv.), and DMAP (0.36 g, 3 
mmol, 1 equiv.) were fully dissolved in 200 mL of dry THF under N2. DCC (5.85 g, 
0.28 mmol, 9.5 equiv.) was then added into the solution and the reaction mixture was 
kept stirring overnight. The white precipitation was filtered and the filtrate was 
concentrated under vacuum. The polymer was obtained after repeated dissolution in 
THF and precipitation in diethyl ether for three times. The total yield is around 89% 
with end-group functionality above 93%.  
1H-NMR (400 MHz, CDCl3, 298 K) δ (ppm) = 10.11 (s, 2H, CHO), 8.22 (d, J = 
8.0 Hz, 4H, CHCCHO), 7.96 (d, J = 8.3 Hz, 4H, CHCHCCHO), 4.51 (m, 4H, 
COOCH2), 3.86-3.55 (m, 364H, OCH2CH2O). 
5.4.3.2 Synthesis of colistin-hydrogels 
The synthesis of the colistin-hydrogels was modified from previous report.2, 3 
Briefly, 125 μL freshly prepared solution B was added into 350 μL solution A, mixing 
properly to form a hydrogel. The hydrogel usually can be formed with 2 min (Size 
around 0.5 cm3). The gel size can be scaled-up or down by simply increase or decrease 
the volume of solution A and B. The details of solution A and B are shown below. 
[Solution A] Prepare 3% glycol chitosan in PBS.  
A 3% (w/w) glycol chitosan solution was prepared by dissolving 88 mg glycol-
chitosan in 2.8 mL PBS (1X) solution. The mixture was kept stirring overnight until a 
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clear viscous solution was obtained. Filtration sterilisation was applied to the solution 
before biological tests. 
[Solution B] Prepare 5% or 10% DF-PEG solution with different amount 
of colistin.  
Typically, a 5% or 10% (w/w) DF-PEG solution was obtained by dissolving a 
certain amount of the DF-PEG (26.3 mg for 5% and 52.6 mg for 10%) into 500 μL 
PBS (1X) or PBS (1X) contains colistin. A syringe filter was used to sterilise the 
solution before biological test.  
5.4.4 Methods 
5.4.4.1 Rheology analysis 
A series of hydrogels were prepared with different colistin loading amount to 
test their mechanical properties followed by the protocol described above. As a typical 
operation, glycol chitosan solution (280 μL, 3% in PBS) was spread on a parallel plate 
(diameter: 20 mm). Then, DF-PEG aqueous solution (100 μL, with different amount 
of colistin) was evenly added dropwise onto the glycol chitosan solution surface at 
37°C. The storage moduli G’ and loss moduli G’’ were measured as a function of time 
for 45 min at constant frequency (1 Hz) and strain (5%) as the monitoring of the gel 
formation process (Figure 5.2). For the self-healing property of the colistin gel, the 
profile of G’ and G’’ values to different amplitude were tested subsequently. 
Amplitude oscillatory forces were changed from γ = 250% (last for 2 min) to 1% (last 
for 3 min) under the same frequency (1.0 Hz) at 37 oC. This process was repeated 
twice (Figure 5.3). 
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5.4.4.2 In vitro release 
The release of the colistin-loaded hydrogel was conducted in 50 mL Eppendorf 
tubes using 20 mL buffers (PBS or CAMHB). The hydrogels were prepared according 
to the standard protocol in situ in the tubes. The solution A and B were sequentially 
added into the bottom of each tube and the tube was then immediately centrifuged at 
5000 rpm at 37 oC using a horizontal centrifuge for 10 min to make sure the hydrogel 
can stick to the bottom of the tube. The hydrogels were washed gently with 6 mL PBS 
3 times before the test. 20 mL buffer was then carefully introduced and the tubes were 
incubated in a shaking water bath at 37 oC. Samples (200 μL each time) were taken 
periodically for analysis. The hydrogels should stay at the bottom of the tubes during 
the test otherwise the surface area would change, leading a faster release. The release 
from PBS was analysed by RP-HPLC and the released from CAMHB was analysed 
by LC-MS using the method adapted from literature.5  
To investigate the integration of the hydrogel network during the release, the 
experiment was conducted under a concentrated condition (size of gel is twice as the 
standard one with 10 mg colistin loading). The release was conducted in 5 mL PBS 
and samples were taken from the release solution for HPLC analysis (Figure 
5.10).Even though the hydrogels were cross-linked through the dynamic imine bonds, 
the signal of DF-PEG cross-linker was hardly detectable and stayed low during the 
release. Thus, the main hydrogel structure stayed intact even after 2 days.  
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Figure 5.10 The typical HPLC trace of the released solution from PBS. (UV detector: λ = 225 nm).  
5.4.4.3 Disk diffusion assay 
Test isolates were matched to a 0.5 McFarland standard before being swabbed 
onto nutrient agar. The experimental materials (disks or hydrogels) were applied after 
allowing the surface of the agar to dry at ambient temperature for 20 minutes (agar 
side down). The agar plates were then inverted and incubated at 37 oC for 24h and 
recorded using Plate Counter (ProtoCol3 Colony Counter, Don Whitley Scientific). 
Controls used were: Commercial colistin disk (contains 10 μg colistin) and blank disk 
(contains 10 μL F/S MQ H2O). The hydrogels were prepared at a small scale based on 
the standard procedure described above (2.5 μL for solution B and 7 μL for solution 
A). The low-dosing and high-dosing colistin-loaded hydrogels contain 10 μg and 100 
μg colistin, respectively. 
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5.4.4.4 Time kill test 
The time-kill kinetics of the colistin-loaded hydrogels against P. aeruginosa 
19147 n/m were examined according to the developed method.6 For the hydrogel 
samples, the testing hydrogels were pre-prepared in a similar way as the ones from in 
vitro release. 20 mL of a logarithmic-phase broth culture of approximately 106 
CFU/mL was carefully added into each tube at 37 oC without stirring up the hydrogels. 
The tubes were incubated in a shaking water bath at 37 oC. The samples were taken at 
0 min, 30 min and 1, 2, 4, 6 and 24 h. Subcultures (50 μL sample) for viable counts 
were performed on nutrient agar (Oxoid) using WASP2 Spiral Plater (Don Whitley 
Scientific) and incubated at 37 °C for 24 h (48 h for plates with small colonies). Viable 
counts were determined by either manual counting or using ProtoCol3 Colony Counter 
(Don Whitley Scientific). 
5.4.4.5 Animal ‘burn’ infection model test 
Animal experiments were approved by the institutional animal ethics committee 
and animals were maintained in accordance with the criteria of the Australian code of 
practice for the care and use of animals for scientific purposes.  
Neutropenic mice were rendered and maintained as previous report7 and a burn 
wound with the size of 1.4 cm2 was introduced onto each posterior thigh skin.8, 9 The 
details of creating the burn wound are shown below. The neutropenic mice was then 
placed in an induction chamber for initiation of anesthesia. A mouse mask will be used 
for delivery of isoflurane for maintaining anesthesia afterwards. The hair on the dorsal 
skin of mice will be shaved and residual hair removed using Nair hair removal cream. 
Bupivacaine (Marcaine 0.5%, 0.1 mL, single dose, local anesthetics/analgesia) will be 
injected under the dorsal skin over the shoulder (i.e. the burn area) to prevent pain. 
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While the mouse is still under anesthesia, an iron bolt will be placed in boiling water 
(100 °C) for more than 5 min and then be taken out of the boiling water and quickly 
fixed on a see-saw like device. The touch pressure of the bolt on the skin will be 
controlled by moving the balance weight on the other side of the see-saw like device. 
The height of the bottom end of the heated bolt will be adjusted to touch (within 10 
seconds after out of boiling water) the dorsal skin over the shoulder for 5 seconds to 
deliver a full-thickness skin burn. (Diameter = 1.4 cm, two-degree burn wound) 
Burn infection was produced by swabbing 100 μL of an early-logarithmic-phase 
bacterial suspension (109 CFU/mL) of either P. aeruginosa ATCC 27853 or P. 
aeruginosa 19147 n/m) onto each wound. The colistin-loaded treatment was 
conducted 2 h after inoculation, by which time an infection was reproducibly 
established. 
Single-dose pharmacodynamics studies were performed with neutropenic burn-
infected mice after applying the colistin solution or colistin-loaded hydrogel (HG-10 
was used here. 0.3 mg/wound colistin was used for P. aeruginosa ATCC 27853 and 
1.5 mg/wound colistin for P. aeruginosa 19147 n/m) onto the wound. For the 
appliance of colistin-containing sample, a mouse was anaesthetised by gaseous 
isoflurane. Colistin solution was dropped to the surface of burn wound. The mouse 
was kept under anaesthesia for a while until the applied solution was absorbed by 
wound tissue. The colistin hydrogel samples were applied  
The blank hydrogel was also tested for comparison. The animals were humanely 
killed at different time point (0h, 4h, and 24h), and the hydrogel was re-collected and 
weighed (Figure 5.7). The wound tissue samples were collected at the same time, 
destructed and mixed with 8 mL saline to obtain the homogenate. 50 μL homogenate 
was then plated on nutrient agar (Oxoid) using WASP2 Spiral Plater (Don Whitley 
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Scientific) and incubated at 37 °C for 24 h (48 h for plates with small colonies). Viable 
counts were determined by either manual counting or using ProtoCol3 Colony Counter 
(Don Whitley Scientific).  
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 PEGylation Nystatin Prodrug for 
Antifungal Treatment 
 
A PEGylated Nys conjugate has been prepared using an aldehyde modified 
mPEG (mPEG-FBA) via a labile imine bond. The conjugate can be obtained nearly 
quantitatively in organic media with or without the addition of dehydrating agent, 
Na2SO4. Due to the labile nature of the imine bond, this conjugate was prone to 
hydrolysis in the presence of water, which proved problematic for its purification. 
However, the solubility of Nys in the crude conjugate is much better than the native 
Nys, and more importantly, the conjugate showed an excellent antifungal performance 
against the human pathogen, Candida albicans, through the in vitro antifungal tests 
while the more stable PEGylated Nys obtained through reductive amination showed 
nearly no activity. More importantly, unlike the native Nys, this mPEG-FBA Nys 
conjugate showed no visible acute cytotoxicity towards the model mice cell, 
highlighting its potential as an alternative formulation for delivery of Nys for 
intravenous treatment of antifungal treatments. 
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6.1 Introduction  
Nystatin (Nys) and amphotericin B (AmB) are important polyene antifungal 
agents used to combat many pathogenic fungi. Although potent, their use is limited 
due to concerns regarding their poor aqueous solubility and the potential toxicity to 
humans. Amongst all the fungal infections, systemic fungal infections are one of the 
most obnoxious and normally difficult to treat.1 So far, only AmB has been formulated 
for intravenous treatment while no Nys formulation has been approved by the FDA.2-
4 Compared to AmB, Nys is less toxic and also exhibits activity against some fungi 
that are resistant to AmB.3, 5, 6 Considering the increasing population of the drug-
resistant human pathogens, the development of Nys for systemic application is timely 
and relevant.  
As mentioned previously, prodrug formulations could potentially reduce the 
toxicity of Nys as well to improve its aqueous solubility. Due to the small size of Nys, 
the attachment of PEG via an irreversible linker could potentially hinder its antifungal 
activity. Therefore, a single-site PEGylation of Nys through a labile imine bond was 
developed in this work. With the help of an aldehyde functionalised mPEG (mPEG-
FBA), a PEGylated Nys conjugate (mPEG-FBA Nys) targeting its sugar amine has 
been achieved. Through the formed water-sensitive imine bond, the conjugate can be 
stable in an anhydrous organic medium but is able to release the free native Nys in the 
presence of water. Thanks to the labile linker, this conjugate has been demonstrated to 
have a similar antifungal activity as native Nys against a fungal infection model, 
Aspergillus carbonarius CICC 41254. More importantly, it exhibited a much less 
toxicity to the human cells comparing to the native Nys and the mPEG/Nys mixture, 
suggesting its potential as a Nys formulation for systemic treatments. 
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6.2 Results and Discussion 
6.2.1 Evaluation of the imine bond under physiological 
conditions through a small molecule model 
Although demonstrated in chapter 2, the stability of the imine bond formation in 
aqueous media is unstable and prone to hydrolysis, depending on the aldehyde and 
amine. As the amine on nystatin is a glycosylamine which has a lower Kb
7  than other 
primary amines due to the hydroxyl groups on the neighbouring carbons, it behaves 
similar to the protein terminal amine. Therefore, it is possible to form a relatively 
stable imine bond with aldehydes at a lower pH, i.e., physiological pH. To test the 
feasibility of PEGylating Nys via dynamic imine chemistry, the mPEG-FBA, as 
described in chapter 2 was again used as a model aldehyde. Due to the complexity and 
the poor aqueous/organic solubility of Nys, a small molecule sugar amine model 
(glucosamine) was employed as a Nys model, mimicking the glycosylamine on Nys, 
to investigate the stabililty of the formed imine bond. The formation of a conjugate 
between the polymer and glucosamine were conducted at a 1 : 1 ratio in aqueous 
solution and the stability of the formed imine bond was measured at different pH 
values (pH = 4.2, 6.8, 7.4, 8.2, 10.2), monitored by 1H-NMR (Figure 6.1).  
The formation of the imine bond (δ = 8.45 ppm) was observed when the two 
compounds were mixed at neutral and basic condition through 1H-NMR analysis along 
with the decrease of the aldehyde peaks of the starting material, mPEG-FBA (δ = 10.02 
ppm). The formation of imine bond increased as a function of pH, consistent with the 
observation in chapter 2, suggesting the imine bond is more stable at a basic condition. 
The conversion of the imine bond was approximately 33% at physiological pH (pH = 
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7.4) indicating the imine bond can be formed under physiological condition although 
it is not as stable (Figure 6.1). Apart from the instability of imine bond in aqueous 
system, the low yield was also partially due to the formation of a hydrate peak (around 
δ = 6.07 ppm, < 10% in all the pH range tested), which is mainly the product obtained 
through the reaction of mPEG-FBA with water. Interestingly, the hydrolysis of the 
ester bond linking the mPEG and FBA occurred at a basic pH, confirming by the split 
of the aldehyde and imine peak on the 1H-NMR (Figure 6.11), suggesting 
degradability of mPEG-FBA.   
 
Figure 6.1 The ratio of the main products (unreacted aldehyde, formed imine, and side product acetal) 
obtained through mPEG-FBA and glucosamine in aqueous media under various pH conditions. 
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6.2.2 Conjugation of mPEG-FBA onto Nys through a labile imine 
bond 
 
Figure 6.2 1H-NMR spectra showing the reaction between Nys and mPEG-FBA using d6-DMSO as 
solvent. 
As the imine bond is not very stable in the presence of water, the conjugation 
between Nys and mPEG-FBA was conducted in an organic solvent. Due to the poor 
solubility, Nys can only be dissolved above 1 mg/mL for reaction in a few polar 
solvents such as DMSO, DMF, and DMAc. Therefore, the conjugation of Nys and 
mPEG-FBA was performed in deuterated DMSO (d6-DMSO) by mixing the two 
materials at 1:1 ratio for 1H-NMR analysis (Figure 6.2). Since the imine formation 
generates one equivalent of water, a dehydrating agent, anhydrous Na2SO4, was also 
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added to effectively remove the water by-product as well as any remaining water in 
the solvent, to promote the formation of the imine bond. The imine proton (δ = 8.41 
ppm) and the shifts of the aromatic ring protons affected by the imine bond can be 
observed while the aldehyde peak of mPEG-FBA (δ = 10.12 ppm) decreased, 
suggesting the formation of PEGylated Nys. Through the integration of the formed 
imine bond and the original aldehyde peak, it revealed > 75% of mPEG-FBA was 
conjugated onto Nys. However, due to the complex structure of Nys, more accurate 
calculation of the imine conversion was difficult to be obtained.  
 
Figure 6.3 a) UV-Vis spectra of Nys and mPEG-FBA in a 50:50 water/ACN mixture ranging from 
200-600 nm. The signals are normalised for comparison. The actually UV absorbance of the water/ACN 
solvent is below 0.2 Abs. 
In order to further characterise the conjugate, HPLC analysis was also 
performed. As the imine bond is not as stable in standard HPLC eluents that containing 
TFA, a basic HPLC eluent using triethylamine (TEA) as an additive was selected for 
the detection of the formation of Nys-PEG conjugates. To choose the right wavelength 
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for HPLC detection, the ultraviolet–visible (UV-Vis) spectra of the starting materials 
were recorded in a water-acetonitrile (ACN) mixture (Figure 6.3). Although Nys has 
a strong and unique pattern of UV absorbance from 280 nm to 350 nm, mPEG-FBA 
has nearly no absorbance at that range. Therefore, to detect both starting materials, 
260 nm was then used. As Nys is a fluorescent molecule, a fluorescence detector was 
also set for the detection of Nys and mPEG-FBA Nys conjugates. As shown in Figure 
6.4, both Nys (~ 4.9 min) and mPEG-FBA (~ 7.5 min) peaks decreased and a new 
peak (~ 6.2 min) appeared between the starting materials from the HPLC. This peak 
can was detected in both UV and fluorescence detectors, suggesting the mPEG-FBA 
Nys conjugate was obtained with a high efficiency. 
 
Figure 6.4 HPLC traces of the starting materials and their reaction mixture with or without Na2SO4, 
recorded by UV (a) and fluorescence (b) detector. 
  To observe the necessity of the dehydrating agent, a comparison of the 
reaction with and without Na2SO4 was also conducted. Surprisingly, no visible 
difference was observed over the reaction time scale through HPLC analysis (Figure 
6.4), suggesting the imine bond is stable in an organic medium in the presence of a 
small amounts of water. 
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A small peak between 5-6 min, attributed to Nys was observed in both UV and 
fluorescence traces. To test if the reaction could be promoted to reach higher 
conversions, the stoichiometry of mPEG-FBA was increased (2 or 4 equivalents) 
(Figure 6.5). However, apart from the increased signal generated from the addition of 
more mPEG-FBA starting material, no significant change was observed through both 
UV and fluorescence detectors. This indicated that the conjugation reaction was 
complete by mixing both starting materials at the same ratio and the remained peak 
could be the amine-lacking impurities from the Nys. 
 
Figure 6.5 The a) UV and b) fluorescence traces through the HPLC analysis from the reactions between 
Nys and mPEG-FBA with different ratios.  
To remove the excess of mPEG-FBA and other impurities, PREP HPLC was 
conducted using a multiple wavelength UV detector. Both 260 nm and 300 nm were 
used for the identification of the starting materials and the PEGylated conjugate. After 
the collection of the conjugation product from 10.2-11.4 min of the HPLC trace, the 
product was injected directly into the system to analyse its purity. Unfortunately, 
instead of a single peak of the conjugate, three peaks which were assigned to both 
starting materials and the conjugate were observed and the ratio of the conjugates was 
much lower than the reaction mixture (Figure 6.6). This suggests that the imine bond 
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was hydrolysed gradually in the water/ACN mixture with the TEA as additive during 
the purification process even though a single peak was observed during the analysis. 
Thus, the conjugate cannot be purified through this method. 
 
Figure 6.6 UV traces of the reaction mixture (black) and the collected peak (blue) from the PREP 
HPLC (λ = 260 nm and 300 nm). The collected peak from the reaction mixture is highlighted with a 
red star. 
Instead of further purification, the reaction mixture was then precipitated 
directly and washed with diethyl ether to remove the reaction solvent. However, it was 
found that the product had hydrolysed slightly after the precipitation as an increase in 
the Nys peak (~ 8.0 min from λ = 260 nm) was observed in the HPLC traces (Figure 
6.7). Although no further evidence has been obtained to date, it was considered that 
the trace of water presented in the atmosphere or in the solvent used for precipitation 
was the reason for the hydrolysis.  
Chapter 6 
Chongyu Zhu  159 
 
Figure 6.7 HPLC traces of the reaction mixture (black) and the precipitate (red). 
 
Figure 6.8 The difference between the UV absorbance of Nys and mPEG-Nys in PBS (1X) after 1 day. 
The solubility of the mPEG-Nys conjugate was then tested via a UV-Vis 
analysis as Nys has a unique UV absorbance pattern at a range of 280 - 350 nm. 
Although the precipitation of Nys was observed over the time due to the labile imine 
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linkage, the typical UV absorbance peak (λ = 305 nm) belonging to Nys from the 
mPEG-FBA Nys conjugate in water after a day was still 8 times larger than the native 
Nys, indicating the attachment of mPEG-FBA can provide a better solubility to Nys 
(Figure 6.8). 
An irreversibly modified conjugate was also synthesized by reductive amination 
in the presence of excess reducing agent (NaBH3CN) for comparison. MeOH was used 
as the solvent since it guaranteed a high reductive activity of NaBH3CN. Due to the 
poor solubility of Nys, the formation of the reduced conjugate did not reach full 
conversion when mixing the starting materials at near 1:1 ratio (Figure 6.9).  
As no further procedures could be made to improve the purity of the labile imine 
PEGylated product and the purities between the imine product and its reduced 
conjugate were similar, both products were used and evaluated for biological tests 
directly. 
 
Figure 6.9 HPLC traces of the reduced PEGylated Nys. Solid line: UV trace and dotted line: 
fluorescence trace. 
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6.2.3  The antifungal activity and the potential cytotoxicity of the 
labile PEGylated Nys (mPEG-FBA Nys) 
In order to evaluate the antifungal activity of the labile mPEG-FBA Nys 
conjugate, the minimum inhibitory concentration (MIC) and the minimum fungicidal 
concentration (MFC) assays were performed to determine its fungistatic and 
fungicidal endpoints. The reduced PEGylated Nys, the starting materials and a mixture 
of Nys and mPEG at a ratio of 1:1 were also tested for comparison. As Candida 
albicans is a human pathogen, Aspergillus carbonarius CICC 41254 was selected as 
a model for the tests.  
Both the labile mPEG-FBA Nys conjugate and the Nys/mPEG mixture showed 
a comparable antifungal activity to native Nys while neither the reduced PEG-Nys 
conjugate nor mPEG-FBA showed a reliable antifungal activity against Aspergillus 
carbonarius CICC 41254 (Table 6.1). The reduced PEG-Nys conjugate only showed 
some inhibition towards Aspergillus carbonarius CICC 41254 at 128 mg/L, which 
may be attributed to the remaining Nys impurity in the samples. This indicated the 
irreversible PEGylation of Nys would hinder the function of Nys, thus, the labile 
linkage between PEG and Nys is necessary to maintain the antifungal activity of Nys.  
Table 6.1 The MIC and MFC test of the labile mPEG-FBA-Nys conjugate, its reduced analogue and 
starting mateials. 
 
Although labile ligation can effectively release Nys in vitro, the concern of its 
potential toxicity has also been raised because the resulting conjugate would hydrolyse 
very rapidly and therefore not significantly reduce the toxicity of Nys. To investigate 
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the acute cytotoxicity of the mPEG-FBA Nys conjugate, a cytotoxicity experiment 
was then conducted using a mouse fibroblast cell line, L929, as a model. The cell 
viability was recorded through a cell count kit-8 (CCK-8) assay and the cytotoxicity 
of each compound was represented by the lethal concentration of 20% cell death 
(LC20). It turned out the mPEG-FBA Nys conjugate showed much less toxicity (LC20 
> 500 µg/mL) towards the L929 cell while both Nys and the Nys/mPEG mixture 
showed a significant toxicity at the same concentration (Figure 6.10).  
 
Figure 6.10 The acute cytotoxicity of Nys, mPEG-FBA Nys conjugate and mPEG/Nys 1:1 mixture.   
It can be estimated that the LC20 of Nys is around 125 µg/mL and the Nys/mPEG 
mixture is around 380 µg/mL. Considering there is only 1/3 of the mass belonging to 
Nys, it suggested the mPEG itself cannot reduce the toxicity of Nys, implying even 
though the linkage between Nys and mPEG-FBA is labile under physiological 
condition, the FBA unit on mPEG is important to reduce the acute cytotoxicity of Nys. 
As the poor solubility of Nys can act as the hydrophobic part when coupled to the 
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hydrophilic mPEG-FBA, the surfactant structure of mPEG-FBA Nys conjugate is 
likely to cause self-assembly in aqueous medium. This would limit the exposure of the 
labile imine linkage to the aqueous media and encapsulate unbound Nys remaining in 
the crude reaction mixture, leading to the reduction of the toxicity of Nys. 
6.3  Conclusions  
Thus far, an mPEG-FBA modified Nys conjugate was successfully synthesized 
through a dynamic imine bond. A small molecule model suggested the imine bond 
could form, although with limited stability, at physiological pH. The mPEG-FBA Nys 
conjugate was relatively stable in an anhydrous organic medium and can be 
characterised using HPLC with the help of a basic additive, TEA. Although the 
purification of this mPEG-FBA Nys conjugate was difficult due to the labile imine 
bond, it greatly improved the solubility of Nys. Furthermore, an excellent antifungal 
performance was found from the mPEG-FBA Nys conjugate that is close to the native 
Nys via the in vitro antifungal analysis against Aspergillus carbonarius compared to 
its analogue from reductive amination. Through the acute cytotoxicity experiments, it 
has proven that the FBA unit is crucial for the conjugate to reduce the overall toxicity 
of Nys. Although further evaluation is required to evaluate its toxicity to human cells, 
the mPEG-FBA-Nys conjugate with a labile imine linkage can increase the solubility 
for Nys and can be a potential formulation for Nys intravenous treatment. 
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6.4 Experimental  
6.4.1 Materials  
6.4.1.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich and used directly unless 
otherwise stated. HPLC solvents are obtained from VWR international, LLC. The 
synthesis and characterisation of mPEG-FBA was described in chapter 2. 
6.4.2 Cell line and fungal species 
Cell line: L929 fibroblast-like cell from mouse was used for the cytotoxicity 
tests. Cell culture was maintained in a 37oC incubator with 5% CO2, L929 cells was 
cultured in RPMI 1640 medium included 10% fetal bovine serum (FBS) and 1% 
penicillin and streptomycin. Culture medium was changed every one or two days. 
Fungus strain: Aspergillus carbonarius CICC 41254 (Institute of Microbiology 
Chinese Academy of Sciences, CICC) was used as a fungal infection model in this 
study. The culture of the isolates and the related MIC and MFC tests against 
Aspergillus carbonarius CICC 41254 were conducted following the developed 
precedure. 8 
6.4.3 Instruments 
6.4.3.1 NMR 
1H-NMR spectra were recorded on Bruker HD 400 spectrometers and referenced 
relative to deuterated solvent shifts using deuterated solvents obtained from Aldrich.  
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6.4.3.2 HPLC 
HPLC analysis was acquired from the Agilent 1260 infinity series stack 
equipped with an Agilent 1260 binary pump and a degasser. Samples (10-70 µL) were 
injected using Agilent 1260 auto-sampler. The HPLC was fitted with a ZORBAX 
Eclipse Plus C18 (4.6 x 100 mm, 3.5 µm).  Detection was achieved using an Agilent 
1260 variable wavelength detector monitoring at 260 nm and an Agilent 1260 
fluorescence detector with fluorescence detection at λex = 320 nm; λem = 410 nm.  
The mobile phase condition is as follows. 
Mobile phase A: 100% water, 0.2 % TEA; 
Mobile phase B: 100% ACN, 0.2% TEA. 
HPLC water and ‘far UV’ HPLC ACN were used as solvents and HPLC TEA 
was used as additive. 
The standard analysis method is as followed: 0-10 min 20%-60% B; 10-12 min 
60% B; 12-14 min 60-20% B; 14-30 min 20% B. The total flow rate was set to 1.0 
mL/min and the temperature for the column is set to 25 oC. 
For the separation, collection, and analysis of PEGylated Nys peak, a PREP 
HPLC system (Agilent 1260 infinity series stack) equipped with a 1260 Quat Pump 
VL, a degasser and a fraction collector (FC-AS) was used. Samples were injected 
using Agilent 1260 auto-sampler with a 900 μL injection volume. The HPLC was 
fitted with a ZORBAX Eclipse Plus C18 (4.6 x 100 mm, 3.5 µm).  Detection was 
achieved using an Agilent 1260 variable wavelength detector connected in series with 
UV detection monitored at 260 and 300 nm. 
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The method for purification is as followed: 0-20 min 20%-60% B; 20-25 min 
60% B; 25-26 min 60-20% B; 26-35 min 20% B. The total flow rate was set to 1.0 
mL/min and the temperature for the column is set to 25 oC. 
6.4.3.3 Ultraviolet-visible (UV-Vis) spectroscopy 
The UV-Vis absorption spectra of Nys and mPEG-FBA were measured on a 
Perkin Elmer Lambda-35 UV/VIS spectrometer using 1 cm path length quartz cuvettes 
using 1:1 water-ACN as a reference and solvent. 
6.4.4 Synthesis 
6.4.4.1 Synthesis of mPEG-FBA Nys conjugate 
9.2 mg of colistin (10 µmol, 1 equiv.) and 20 mg of mPEG-FBA (10 µmol, 1 
equiv.) were dissolved with 1 mL of solvent (d6-DMSO or DMF or DMAc) in a 2 mL 
glass vial with or without the addition of the dehydrating agent (Na2SO4, 140 mg). The 
vial was then sealed and left on a roller mixer (SRT9, Stuart) for 24 h. The crude was 
then precipitated from 40 mL diethyl ether. The precipitate was collected through 
centrifugation and washed with another 40 mL diethyl ether to get the product. The 
NMR, HPLC and UV characterisations of the conjugates were shown in Figure 6.2, 
6.4-6.8. 
6.4.4.2 Synthesis of reduced mPEG-FBA Nys conjugate 
9.2 mg of colistin (10 µmol, 1 equiv.) and 20 mg of mPEG-FBA (10 µmol, 1 
equiv.) were added into a 7 mL glass vial along with 5 mL of MeOH. After 5-10 min 
vortexing, 30 mg NaBH3CN (477 µmol, 47.7 equiv.) was dissolved in 1 mL of MeOH 
and added into the system. The reaction was vortexed for another 5-10 min and the 
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vial was then sealed and left on a roller mixer (SRT9, Stuart) for 24 h. The product 
was obtained through the same procedure as mPEG-FBA Nys conjugate. The HPLC 
analysis of the conjugate (6-7 min) was shown in Figure 6.9. 
6.4.5 Methods 
6.4.5.1 Small molecule model for 1H-NMR analysis 
 
Figure 6.11 1H-NMR of the mixture of mPEG-FBA and glucosamine at a ratio of 1:1 at various pH 
and the starting materials in D2O. The peaks belonged to aldehyde, imine and hydrate product are labled 
with , ▲, and ♦, repectively. 
The samples for 1H-NMR analysis were prepared as followed (Figure 6.11). 
mPEG-FBA (160 mg, 0.08 mmol) and glucosamine·HCl (43 mg, 0.2 mmol) were 
dissolved in 1 mL D2O, respectively. 125 µL mPEG-FBA solution and 50 µL 
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glucosamine solution was mixed together and with 200 µL D2O adjusted with 200 µL 
various buffers to desired pH. The pH was tested by a pH probe (Product Code: 
10237293, Thermo Scientific Orion) before analysed by 1H-NMR.  
6.4.5.2 Cell viability assay 
As modified from a developed method,9 the cytotoxicity of the labile PEGylated 
Nys conjugate to L929 cells was evaluated. Nys, mPEG-FBA and the mixture of 1:1 
Nys and mPEG were also tested for comparison. The cell viability was analysed 
through CCK-8 assay. Briefly, 100 μL cell suspension were seeded in a 96-well plate 
at a density of ~ 105 cells/mL. After the cell attachment, cells were washed with PBS 
(1X) and culture with different concentration of each sample in culture media at 37 oC 
for 1 h. Due to the poor solubility of Nys, 2% DMSO was added into all culture media 
to improve the sample solubility. Each well was then washed three times with PBS 
and incubated with 100 μL culture medium with 10% CCK-8 solution for 2 h. After 
the incubation, the UV absorbance of each sample was recorded with a microplate 
reader (VICTORTM X3 PerkinElmer 2030 Multilabel Plate Reader) with a UV 
wavelength of 450 nm. The cell viability was calculated by comparing to the positive 
control (cells in pure culture medium, 100% viability) and negative control (pure 
culture medium without cells, 0% viability). The results were showed as mean ± 
standard deviation. 
6.4.5.3 Aqueous solubility of Nys and mPEG-Nys conjugate 
determined by UV-Vis 
3 mg of mPEG-Nys conjugate and 1 mg of Nys was dissolved in a 2 mL glass 
vial with 1 mL of HPLC grade water, respectively. The samples were incubated at 
ambient temperature on a roller mixer (SRT9, Stuart) for 24 h before being centrifuged 
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at 10000 rpm for 30 min to remove the unsolubilised Nys. The supernatants were then 
diluted 10 times with PBS 1X. 200 µL of each sample was added into a 96-well plate 
and the UV scan (λ = 250 – 500 nm) of each sample was performed by a microplate 
reader (Synergy HTX Multi-Mode Reader) (Figure 6.8). 
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 Micellar Formulation for the Solubility 
Improvement of Nystatin and Its Potential Target 
Delivery 
 
In order to improve the aqueous solubility of Nys for intravenous antifungal 
applications, amphiphilic block copolymers (PBacidA20PPEGAx) containing boronic 
acid units on the side chains have been successfully synthesized via CP-LRP using a 
pinacol protected PBA containing acrylate monomer (BpinA) and a biocompatible 
monomer PEGA480. Comparing to the block copolymer analogues without the boronic 
acid groups generating from BzA monomer (PBzA20PPEGAx), the PBacidA20PPEGAx 
can greatly improve the Nys solubility (2.4-9.8 times), showing their potential as a 
Nys carrier. To develop an applicable Nys delivery system, the ongoing work will be 
focused on the investigation of the self-assembly and their bio-performances of each 
polymer in the presence/absence of Nys. 
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7.1 Introduction  
Although a prodrug formulation has been designed and demonstrated to have 
some potential to increase the solubility of nystatin (Nys), reduce toxicity and maintain 
activity in chapter 6, the incomplete modification and the difficulties in isolating pure 
products remain a concern for its application. Furthermore, the reason for the reduced 
toxicity using Nys ‘prodrug’ seems to be attributed to the self-assembly of the 
polymer-Nys complex, indicating the Nys solubility can be in theory improved and 
the toxicity of Nys can be reduced by the encapsulation of Nys into the right delivery 
system. Thus, to investigate this concept, the development of a suitable delivery 
system through encapsulation with targeted covalent attachement of Nys was 
attempted as discussed in this chapter as the chemical attachment of Nys onto a 
delivery system can provide a more stable and reliable performance comparing to the 
physical encapsulation. 
As described in chapter 1, the hydroxyl groups on Nys can be the potential 
modification sites for boronic acid containing compounds. The amphiphilic polymers 
that contains boronic acid groups can be a possible tool to improve the aqueous 
solubility of Nys through the formation of a polymer-Nys complex with Nys via 
dynamic boronate ester bonds. The formed boronate esters can be responsive not only 
to pH change but also to oxidation stress, which may be useful for the target antifungal 
treatments and has potential to reduce the oxidation stress produced during Nys 
administration. 
Thus, to investigate the possibility of the utilisation of the boronate linkage to 
covalently attach Nys, a small molecular model was initially tested. After that, the 
development and synthesis of boronic acid containing amphiphilic polymers was 
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targeted. With the help of copper-mediated photoinduced living radical polymerisation 
(CP-LRP), polymers with boronic acid on the side chains have been obtained with 
controlled molecular weight and narrow dispersities after optimisation. The obtained 
polymers were further used to test the binding with Nys via a UV study, demonstrating 
the possibility of improving solubility of Nys through the formation of boronate ester 
bonds. Although a slow response rate was found, the polymer-Nys complex showed a 
potential responsiveness towards the pH change of the environment.  
7.2 Results and Discussion 
7.2.1 A small molecule model for the boronate linker through 
the diol on Nys 
 
Figure 7.1 a) The chemical structure of Nys (left) and PBA (right). The possible conjugation sites for 
PBA are highlighted with a red rectangle. b-e) ESI-MS data of the three Nys containing products and 
their mass simulation found in the reaction mixture of Nys with PBA.  
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A small molecule model, phenylboronic acid (PBA), was initially reacted with 
Nys in an organic solvent (DMF) to test the feasibility of the boronate ester linkage 
formation. Through ESI-MS analysis, two Nys containing products were found from 
the reaction mixture in addition to unreacted Nys. The mass of each product along 
with the isotopic pattern indicated that one was the mono adduct and the other a double 
adduct of PBA on Nys (Figure 7.1). In order to confirm the formation of the PBA 
adducts and to identify the modification site(s) of the PBA, a further tandem mass 
spectrometry (ESI-MS/MS) was performed on the products (details of analysis please 
see Appendix). Indeed it as observed that the two PBA molecules can be attached on 
the 1,2-diol on position 3, 4 and/or 1,3-diol between positions 1, 3; 7, 9; or 9, 11 
(highlighted in Figure 7.1a). The possibility of two molecules of PBA binding to Nys 
suggests potential use of Nys as a cross-linker for the polymer containing multiple 
boronic acid side chains. 
7.2.2 Synthesis of the block copolymer containing PBA units on 
the side chains 
7.2.2.1 Synthesis of the monomer containing PBA unit for 
polymerisation 
In order to obtain the desired polymer, 4-(hydroxymethyl)phenylboronic acid 
(HBA) was used as the starting material for the synthesis of the PBA containing 
monomer suitable for polymerisation (Figure 7.2). The boronic acid group on HBA 
was protected using pinacol to improve the solubility of the PBA unit in organic 
solvents as well as to minimise the potential side reaction caused by the boronic acid 
during the polymerisation. The pinacol protected PBA containing acrylate monomer 
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(BpinA) was obtained through the substitution of hydroxyl group on HBA using 
acryloyl chloride in the presence of TEA. The peaks belonging to pinacol (g in Figure 
7.2b and g, i in Figure 7.2c) and the acrylate unit (c, d, e in Figure 7.2b and d, e in 
Figure 7.2c) have been successfully introduced onto the HBA as shown by 1H-NMR 
and 13C-NMR. Although the carbon adjacent to the boron atom is not detectable from 
13C-NMR due to the splitting by the boron atom, a sharp boron signal obtained from 
11B-NMR suggested the retention of the boron atom after the pinacol protection and 
the acrylate formation. A strong absorbance at 1724 cm-1 which belongs to the 
carbonyl stretch of the ester bond can clearly be found by FTIR, further confirming 
the formation of acrylate. 
 
Figure 7.2 Synthesis (a) and characterisation including 1H-NMR (b), 13C-NMR (c), 11B-NMR (d) and 
FTIR (e) of the BpinA monomer.  
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7.2.2.2 Synthesis of the PBzA homopolymer using copper-
mediated photoinduced living radical polymerisation (CP-LRP) 
Although the CP-LRP technique has been well developed and has proven to be 
applicable to polymerise various monomers with a good compatibility with biological 
agents as demonstrated in chapter 4,1 monomers with an aromoatic/phenyl ring have 
never been explored. It is uncertain whether this technique is feasible to polymerise 
the monomers with an aromatic ring as the monomer may absorb light which can 
potentially interfere with the polymerisation. Therefore, a benzyl acrylate (BzA) 
monomer was first used as a model to verify the possibility of using CP-LRP before 
the polymerisation of BpinA.  
 
Figure 7.3 a) Synthesis of PBzA using a standard CP-LRP condition. b) DMF GPC traces of the 
reaction mixture at 2 and 4 h. c) 1H-NMR of the reaction mixture at 4h. d) The conversion of the 
polymerisation at 2 and 4 h calculated from 1H-NMR. 
Using the standard CP-LRP condition, a poly(benzyl acrylate) homopolymer 
(PBzA) with DP = 10 was synthesised in DMSO under UV irradiation (λmax ~ 360 nm) 
with the initiator, ethyl α-bromoisobutyrate (EBiB), CuBr2 and the ligand (Me6TREN) 
([BzA]:[EBiB]:[Me6TREN]:[CuBr2] = 10:1:0.12:0.02). Samples were taken from the 
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reaction mixture at 2 and 4 hours. The polymerisation occurred smoothly and the 
conversion reached 90% after 4 h (Figure 7.3). The formed polymer stayed with a 
narrow Đ (Đ < 1.3) during the polymerisation process and an increased molecular 
weight was observed as a function of conversion, indicating the monomer with an 
aromatic ring can be polymerised using CP-LRP.  
Subsequently, the homopolymerisation of BpinA was conducted under a similar 
polymerisation condition and left overnight to examine the compatibility of BpinA 
monomer with CP-LRP. Unfortunately, although the polymerisation did occur, 
precipitation was obersved during the polymerisation, which was considered to be 
homopolymer of BpinA (PBpinA). Considering the low polarity of the pinacol 
protection group, the formed polymer may also have a low polarity which makes it 
immiscible with the DMSO solvent. Io order to obtain confirmation, the precipitate 
was then collected and dissolved in CDCl3 for 
1H-NMR analysis. The typical peaks 
on the BpinA monomer were all found from the precipitate (Figure 7.4c). The 
broadening of these peaks however indicated the formation of the BpinA homopolymer. 
A further GPC analysis revealed a peak with a broad Đ (Đ ~ 1.53) and a high molecular 
weight tail (Figure 7.4a), suggested the polymerisation lost control during the 
polymerisation as a result of the precipitation.  
Therefore, another trial of the homopolymerisation of BpinA was conducted 
under a similar polymerisation procedure using DMF as an alternative solvent. This 
time, no precipitation was found during the polymerisation process and the polymer 
was obtained with narrow dispersity (Đ ~1.14) analysed from the GPC, suggesting the 
monomer is compatible with the CP-LRP technique. However, unlike CP-LRP of 
other acrylate monomers, the conversion was limited to 90% even the reaction was 
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left overnight, indicating the polymerisation was slower when DMF was used as 
solvent.  
 
Figure 7.4 a) Homopolymerisation of PBpinA. DMF GPC traces of the overnight samples of the 
polymerisation of PBpinA under the UV light using b) DMSO or c) DMF as solvents. d) 1H-NMR of the 
overnight sample of the polymerisation of PBpinA in DMSO (red trace, CDCl3 as solvent) and in DMF 
(black trace, DMSO as solvent). 
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7.2.2.3 Synthesis of an amphiphilic block copolymer containing 
PBA units via CP-LRP 
 
Figure 7.5 a) Synthesis of PBzA20- PPEGA10 block copolymer. DMF GPC traces (b) and 1H-NMR (c) 
of the first block (black) and the copolymer (red). d) The conversion of each block calculated from 1H-
NMR. 
In order to form micelles under physiological condition, the synthesis of an 
amphiphilic block copolymer was required. The biocompatible water soluble 
monomer, PEGA480, was selected as the hydrophilic part of the molecule. Again, 
benzyl acrylate was first used to build up the hydrophobic block. DP = 10 and DP = 
20 was selected for each block. Due to the poor solubility of BpinA polymer in DMSO, 
the polymerisation of the block copolymer was performed in DMF. The 
polymerisation of BzA was first conducted, followed by the one-pot sequential 
addition of PEGA monomer (Figure 7.5). Due to the slow polymerisation rate in DMF, 
each block was left overnight to reach high conversion (Figure 7.5d). The 
disappearance of the protons from the double bonds along with the peak broadening 
from both monomers from 1H-NMR confirmed both BzA and PEGA were 
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polymerised during the process (Figure 7.5c). Through the GPC analysis, a clear 
molecular weight increase was observed after the polymerisation of the second block 
and the disperisty remained relatively narrow (Đ ~ 1.32), suggesting the successful 
synthesis of the PBzA-PPEGA block copolymer (Figure 7.5b). However, a notable 
small molecular weight peak which belonged to the first block remained in the product 
(Figure 7.5b highlighted by the arrow), suggesting some of the PBzA polymer chains 
were ‘dead’ that is unable to be reinitiated before the addition of the second block, 
which is likely to be attributed to the long reaction time. 
 
Figure 7.6 DMF GPC traces of the polymerisation of the first block using PEGA with various DPs 
(black) after 6h and the overnight polymerisation of the second block using hydrophobic monomers 
(BzA or BpinA) for the synthesis of the amphiphilic block copolymers. Black traces: homopolymer 
(PPEGA), red traces: block copolymers. 
To improve the yield of the block copolymer as well as to save the reaction time, 
DMSO was used for the polymerisation of the block copolymer for both BzA and 
BpinA monomers with PEGA. Due to the poor solubility of BpinA polymer in DMSO, 
the sequence of the monomer addition was adjusted so as to form a PPEGA 
macroinitiator followed by in situ chain extension with the hydrophobic monomer 
(BzA or BpinA) to improve the solubility of the formed copolymer during the 
polymerisation. The DP for the hydrophilic part was varied from DP 10, 20, 40 and 
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80, while the DP of the hydrophobic monomer was fixed as 20 for comparison. The 
polymerisation was performed again using the standard CP-LRP condition 
([PEGA]:[BzA/BpinA]:[EBiB]:[Me6TREN]:[CuBr2] = 10/20/40/80:20:1:0.12:0.02), 
of which the first block was polymerised for 6 h before the addition of the second 
block and the reaction was left overnight to ensure the high conversion for both blocks. 
Samples were taken at 6 h and overnight for 1H-NMR and GPC analysis. As shown in 
Figure 7.6, all the polymerisation were well controlled and relative narrow dispersities 
(Đ < 1.5) were obtained. The PEGA monomer was consumed nearly quantitatively in 
the first 6 h in all cases and the conversion of the second hydrophobic monomer was 
also high (~ 96 – 99%) after the overnight reaction (Table 7.1).   
Table 7.1 Summary of 1H-NMR and DMF GPC characterisation of the amphiphilic block copolymers, 
PBzA20PPEGAx and PBpinA20PPEGAx. 
 
All polymers showed an increase molecular weight after the polymerisation of 
the second block, with the exception of the copolymer prepared from PPEGA DP80, 
suggesting a successful polymerisation of the block copolymers. Due to the nature of 
the PEGA monomer and the large size of PPEGA DP80 macroinitiator, no significant 
change was observed from the GPC analysis before and after the polymerisation of 
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the second blocks via the addition of the hydrophobic monomers even though the 
conversions were nearly full (Table 7.1). In order to confirm the formation of the both 
block copolymers, PBzA20PPEGA80 and PBpinA20PPEGA80, a diffusion-ordered 
spectroscopy (DOSY) NMR was obtained. Through DOSY, the mixed compounds 
can be distinguished by their different diffusion coefficients while one distribution will 
be found in a block copolymer. As shown in Figure 7.7, the ester signals belonging to 
BzA/BpinA units (peak a and a’ in Figure 7.7) and PEGA units (peak b and b’ in Figure 
7.7) showed the same diffusion coefficient, indicating both monomers were attached 
on the same polymer, confirming the formation of a block copolymer. 
 
Figure 7.7 DOSY data of PBzA20PPEGA80 and PBpinA20PPEGA80 (in CDCl3).  
7.2.2.4 Recovery of the boronic acid groups from the 
PBpinA20PPEGAx block copolymer  
To regenerate the boronic acid groups from the pinacol protecting groups, as 
well to prevent the hydrolysis of the ester bonds on the monomer units, the 
BpinA20PPEGAx (x = 10, 20, 40, 80) block copolymers were dialysed separately under 
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weak acidic conditions (0.12 M HCl in 1:1 water/THF) for 2 days. The deprotected 
polymers were not very soluble in most of the common organic solvents due to the 
recovery of the boronic acid groups. In addition to the bulky size of the polymers and 
their amphiphilic behaviour, no reliable data with good signal-to-noise ratio was 
acquired from the deprotected polymers through 13C-NMR, 11B-NMR, or GPC 
analysis.  
 
Figure 7.8 a) Removal of the pinacol protection of BpinA20PPEGA40 through the dialysis under an acid 
condition. The zoomed-in 1H-NMR spectra (b, δ = 4 - 8 ppm) and (c, δ = 0 - 4 ppm) of the polymers 
before and after deprotection process in d8-THF. 
Fortunately, the deprotection efficiency could be determined through 1H-NMR 
analysis of the obtained polymers in d8-THF. As shown in Figure 7.8, the main 
structure of the polymers including both monomer ester bonds (peak d (d’), e (e’)) 
before and after the deprotection process remained unchanged, suggesting the polymer 
backbone and the ester linkage on the side chains survived during the deprotection 
process. The original pinacol peaks (peak f in Figure 7.8) disappeared nearly 
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completely and a new peak which represented to be the boronic acid groups (peak c’) 
appeared along with a slight shift of peak a to peak a’, indicating the successful 
removal of the protection groups. 
7.2.3 UV analysis for the interactions between the amphiphilc 
block copolymers and Nys 
7.2.3.1 Investigation on the increased solubility of Nys in the 
presence of PBacidA20PPEGAx or PBzA20PPEGAx through the UV 
spectroscopy 
After obtaining the boronic acid containing polymers, the interaction between 
Nys and the boronic acid groups on polymers was then investigated. As Nys has a UV 
absorbance pattern at a range of 280 - 350 nm, the UV absorbance of these peaks could 
be used to quantify the amount of Nys presented in the aqueous media. Therefore, a 
binding study was performed on the obtained polymers with Nys via UV spectroscopy. 
Excess of Nys (1-2 mg) was introduced into 1 mL of each polymer solution of the 
same concentration (10 mg/mL) and mixed well for 24 h. Each sample was then 
centrifuged (10000 rpm) to remove the non-bounded Nys. The supernatants were then 
diluted 10 fold by PBS (1X, pH = 7.4) and analysed by UV-Vis spectroscopy. As the 
block copolymers can be self-assembled into higher-ordered structures (Figure 7.11 
and 7.12), Nys can interact with the hydrophobic core of the assembly either through 
non-covalent encapsulation or through covalent ‘cross-linking’, resulting in a stronger 
UV response. As expected, the UV absorbance of Nys solution were all higher in the 
presence of polymers compared to the pure water (Figure 7.9). Interestingly, the UV 
aobsorbance of the Nys signal was much higher (2.4 - 9.8 times) in the presence of the 
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PBacidA20PPEGAx polymers than the PBzA20PPEGAx polymers with similar molecular 
weight. A notable UV shift of the highest peak of Nys (λmax = 305 nm→310 nm) was 
also observed from the samples with PBacidA20PPEGAx while it stayed the same as the 
Nys in water (λmax = 305 nm) for the samples with PBzA20PPEGAx. All these data 
implied that, beyond the hydrophobic interaction between Nys and the aromatic ring 
structure, the boronic acid groups on PBA units can react with the hydroxyl groups on 
Nys, forming a water-soluble Nys-polymer complex (PBacidA20PPEGAx-Nys 
complex). Notably, less Nys was solubilise in the presence of PBacidA20PPEGA10 
compared to the other PBacidA20PPEGAx. This can be explained by the large 
aggregates formed by the unstable self-assembly caused by the short hydrophilic 
PPEGA DP10 (Figure 7.11). 
 
Figure 7.9 a) UV spectra of the Nys in the presence of different polymers in aqueous media. b) The 
relative solubility of Nys in aqueous media with different polymers. 
Chapter 7 
Chongyu Zhu  185 
7.2.3.2 Stimuli release of Nys from PBacidA20PPEGAx-Nys complex in 
aqueous media 
 
Figure 7.10 Release percentage of Nys from the PBacidA20PPEGA20 using different stimuli in aqueous 
solution monitoring by the UV spectroscopy. 
After confirming the formation of PBacidA20PPEGAx-Nys complexes, a further 
investigation on the responsive release of Nys from the complexes was carried out. As 
the boronate is more stable in a basic condition rather than an acid pH,2 the effect of 
the pH of the environment upon the stability of the complex was conducted using 
PBacidA20PPEGA20-Nys as a model. Acidic pH (pH = 5), physiological pH (pH = 7.4) 
and a basic pH (pH = 10) were selected for comparison. As shown in Figure 7.10, the 
signals of Nys in the different pH solutions all decayed over the time, suggesting 
instability of the formed boronate between Nys and polymers in the presence of water. 
The decrease rate of the Nys signal was faster at a lower pH, which is consistent with 
the stability of the boronate bond at various pH. Since the boronate is a dynamic bond 
responsive to diols such as sugars,3, 4 two sugars (glucose and galactose, 50 mM) 
existing in the human body were also tested on PBacidA20PPEGA20-Nys complex. A 
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lower concentration of glucose (5 mM), mimicking the sugar concentration in the 
human blood was also tested for comparison. Surprisingly, although the Nys signal 
also decreased over the time, < 4% of the Nys signal decrease was observed during 
the 2 h test in all cases. Taking account that the release rates are similar to the one 
from PBS buffer and the difference among the sugars was not significant (< 1%), it 
was hard to draw a convincing conclusion at this stage. Although further experiments 
are needed, this may be explained by the fact that the sugar units are very hydrophilic 
so that it is difficult to interact with the formed boronate bonds between Nys and 
polymer that are buried in the hydrophobic core.   
7.3 Conclusions & Ongoing work 
In this chapter, it has been found that chemical reaction forming boronate ester 
bonds can occur on the hydroxyl groups, either on 1,2-diol or 1,3-diol, of Nys using 
boronic acid containing compounds. This founding has then been exploited to develop 
a dynamic delivery system for Nys to increase its aqueous solubility. In order to obtain 
a suitable boronic acid-rich self-assembly system, CP-LRP was intestigated to 
polymerise monomers with an aromatic ring. After the optimisation on CP-LRP, 
amphiphilic block copolymers with boronic acid side chains and various lengths of the 
hydrophilic part (PBacidA20PPEGAx) have been successfully synthesized. The similar 
block copolymers without the boronic acid groups (PBzA20PPEGAx) were also 
synthesized using BzA monomer for comparison. Although both types of block 
copolymers improved the Nys solubility, the PBacidA20PPEGAx showed a much 
greater improvement (2.4-9.8 times to Nys in pure water) thanks to the interaction 
between Nys and the boronic acid groups on the side chains. Although the Nys release 
rates from the PBacidA20PPEGAx polymers remained low at this stage, it showed a 
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potential to be responsive to some stimuli, at least pH, suggesting the possible targeted 
delivery of Nys using these polymers. The ongoing work will be focused on the 
possibility of increasing the release rate of Nys from the polymers and the 
investigation of the self-assembly and morphology change of each polymer in the 
presence/absence of Nys. The antifungal activity of each polymer-Nys complex and 
the related acute cytotoxicity are also needed to be analysis. 
7.4 Experimental  
7.4.1 Materials  
7.4.1.1 Chemicals 
All chemicals were purchased from Sigma-Aldrich and used directly unless 
otherwise stated. BzA monomer (97%, stab. with ca 150 ppm) was purchased from 
Alfa Aesar and used without purification. HBA was obtained from Apollo Scientific 
Ltd. HPLC solvents are obtained from VWR international, LLC. The dialysis 
membranes were purchased from Spectrum® Laboratories, Inc. 
7.4.2 Instruments  
7.4.2.1 NMR 
1H-NMR, 11B-NMR, 13C-NMR spectra were recorded on Bruker HD 400, HD 
500 and AV 500 spectrometers and referenced relative to deuterated solvent shifts 
using deuterated solvents obtained from Aldrich.  
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7.4.2.2 GPC 
GPC was acquired from an Agilent PL50 equipped with two Agilent Polargel 
Medium Columns eluting with DMF (0.1 M LiBr) as an additive at 50 °C. The flow 
rate was 1 mL/min and detection was achieved using differential refractive index 
detector. Molecular weights were calculated relative to narrow PMMA standards. 
7.4.2.3 FTIR 
Infrared absorption spectra were recorder on a Bruker VECTOR-22 FTIR 
spectrometer using a Golden Gate diamond attenuated total reflection (ATR) cell. 
7.4.2.4 ESI-(tandem) mass spectroscopy (ESI-MS and ESI-MS/MS)  
ESI-MS and ESI-MS/MS was done on the Bruker MaXis II instrument 
(equipped with ESI source) through direct infusion at 1 µL/min. The sample was 
dissolved and diluted in 50% ACN/water with 0.1% formic acid and run in the positive 
ion mode. 
7.4.2.5 Transmission electron microscopy (TEM) 
TEM data was obtained using either JEOL 2000FX TEM or JEOL 2100FX TEM 
at an acceleration voltage of 200 kV. All TEM samples were prepared on graphene 
oxide (GO) on lacey carbon (300 mesh) copper grids or GO on holey carbon (300 
mesh) copper grids to get high contrast images without staining. Typically, 10 μL 
sample was pipetted on a grid and left for 1 min before blotted away. Each grid was 
then air-dried for 15 minutes. 
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7.4.3 Synthesis 
7.4.3.1 Synthesis of BpinA monomer 
The synthesis of BpinA monomer was a two-step synthesis adapted from the 
literature. The pinacol protected HBA (HBpin) was synthesized as followed. HBA 
(9.14 g, 0.060 mol, 1 equiv.) and pinacol (10.42 g, 0.088 mol, 1.5 equiv.) were 
dissolved with 70 mL toluene in a 100 mL round-bottle flask and reflexed at 120 ºC 
using a Dean-Stark apparatus for 24 h until a homogeneous solution was obtained. The 
reaction solution was then evaporated to remove both toluene and most unreacted 
pinacol under reduced pressure. A further recrystalisation using hot hexane was 
conducted to remove the trace pinacol remaining in the products. The final product 
HBpin was a clear needle-like crystal with a yield of 85% (12.1g, 0.51 mmol). 
1H-NMR (500 MHz, CDCl3, 298 K)  (ppm) = 1.35 (s, C(CH3)2), 4.68 (br. s, 
HOCH2-), 7.35 (d, J = 8.1, HOCH2CCH), 7.80 (d, J = 7.9, -CHCB). 
13C-NMR (125 MHz, CDCl3, 298 K)  (ppm) = 24.75 (C(CH3)2), 65.06 
(HOCH2-), 83.76 (C(CH3)), 126.00 (-OCH2CCH), 134.95 (-CHCB), 144.00 
(HOCH2C). 
After obtaining the pure HBpin, HBpin (11.7 g, 0.050 mol, 1 equiv.) and 14 mL 
TEA (0.10 mol, 2 equiv.) was then dissolved with 60 mL anhydrous DCM into a 250 
mL round-bottom flask in an ice bath. 6 mL acryloyl chloride (0.075 mol, 1.5 equiv.) 
in 20 mL anhydrous DCM was added dropwise into the flask in 1 h under nitrigen. 
The reaction mixture was then stirred at ambient temperature for 24 h. After the 
reaction, the DCM was removed on a rotary evaporator and the crude mixture was 
redissolved by diethyl ether followed by the removal of the TEA salt by filtration. The 
filtrate was then washed with saturated ammonium chloride solution three times and 
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the organic phase was collected and dried with anhydrous MgSO4. The crude product 
was purified by flash chromatography (diethyl ether/hexane, 0%-7%). The product 
was obtained as an off-white solid with the yield of 60% (8.67 g, 0.30 mol). 1H-NMR, 
13C-NMR, 11B-NMR and IR were shown in Figure 7.2. 
7.4.3.2 Homopolymerisation of the PBzA10 and PBpinA10 polymer 
The polymerisation of BzA and BpinA was conducted using a standard CP-LRP 
condition. The ratio of initiator (EBiB), CuBr2, ligand (Me6TREN) and monomer 
(BzA or BpinA) was set as 1: 0.02: 0.12: 10. DMSO or DMF was used as solvent. 1-2 
volume equiv. of solvent was used for the synthesis. The reaction was left under UV 
with a cooling plate (CAMLAB, KP283, temperature was set to 5 oC, the actual 
temperature for the reaction mixture is ~ 20 oC) under a UV lamp (λmax ~ 360 nm) for 
4h or overnight. For example, the synthesis of PBzA10 in DMSO was conducted as 
followed. 1.5 mg CuBr2 (0.0067 mmol, 0.02 equiv.), 10 µL Me6TREN (0.037 mmol, 
0.12 equiv.), and 0.5 mL BzA (3.3 mmol, 10 equiv.) was dissolved in a 7 mL vial with 
0.5 mL DMSO. 48 µL EBiB (0.33 mmol, 1 equiv.) was then added and the reaction 
mixture was sealed, stirred and degassed under nitrogen for 15 min before the 
exposure to the UV. The characterisation of the products was shown in Figure 7.3 and 
Figure 7.4. 
7.4.3.3 Synthesis of the amphiphilic block copolymer, 
PBpinA20PPEGAx and PBzA20PPEGAx  
The block copolymer was synthesised in the similar condition as the 
polymerisation of BzA using a standard CP-LRP condition. 3 volume of DMSO was 
used in the second block to promote the solubility of BpinA monomer. For example, 
PBzA20PPEGA10 100 µL CuBr2 stock solution (7.3 mg/mL in DMSO, 0.0033 mmol, 
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0.02 equiv.), 5.24 µL Me6TREN (0.020 mmol, 0.12 equiv.), and 784.9 mg PEGA (1.6 
mmol, 10 equiv.) was dissolved in a 7 mL vial with 700 mL DMSO. 24 µL EBiB (0.16 
mmol, 1 equiv.) then added and the reaction mixture was sealed, stirred and degassed 
under nitrogen for 15 min before the exposure to the UV. After 6 h reaction, the BzA 
monomer (500 µL, 3.3 mmol, 20 equiv.) along with 1.5 mL DMSO was degassed and 
transferred into the sealed vial. The reaction mixture was left under the UV overnight 
for the completion of the second block. The 6h and overnight samples were taken for 
GPC and 1H-NMR analysis. The obtained polymers were then collected and dialysed 
(1000 MWCO) against THF to remove the DMSO and the trace unreacted monomer. 
The characterisation of the products was shown in Table 7.1 and Figure 7.8 (black 
trace). 
7.4.3.4 The deprotection of the pinacol groups from the 
BpinA20PPEGAx  
The deprotection of the PBpinA20PPEGAx was conducted in a dialysis tubing. 
Instead of THF, 4 L 1:1 water/THF mixture with 40 mL concentrated HCl (aq) (37%, 
~12 M) was used for dialysis. The solvent was changed every 12 hours. After 2 days 
dialysis, the products were quenched via the dialysis (1000 MWCO) against THF for 
another 2 days. The products were then collected and the remaining THF was then 
blowed off under nitrogen. The typical 1H-NMR of the products was shown in Figure 
7.8 (red trace). 
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7.4.4 Methods 
7.4.4.1 UV-Vis analysis for determining the increased amount of 
solubilised Nys in the precence of amphiphilic block copolymers 
10 mg of PBzA20PPEGAx and PBpinA20PPEGAx polymers was dissolved in a 2 
mL glass vial with 1 mL of HPLC grade water, respectively. Excess of Nys (normally 
1-2 mg) was added into each vial and all the vials were sealed and incubated at ambient 
temperature on a roller mixer (SRT9, Stuart) for 18 h. The samples were then collected 
and centrifuged at 10000 rpm for 30 min to remove the unsolubilised Nys. The 
supernatants were then diluted 10 times with PBS 1X. 200 µL of each sample was 
added into a 96-well plate and the UV-Vis scan (λ = 250 – 500 nm) of each sample 
was performed by a microplate reader (Synergy HTX Multi-Mode Reader). 
For the analysis of the responsiveness of the polymer-Nys complex towards 
stimuli, pH = 5 (NaAc-AcOH, 50 mM), pH = 7.4 (Na2HPO4-NaH2PO4, 50 mM), and 
pH = 10 (Na2CO3-NaHCO3, 50 mM) buffers and the sugar containing solutions: 
glucose (5 mM and 50 mM, in water) and galactose (50 mM, in water) were prepared. 
100 uL each solution was added into a 96-well plate along with 100 uL of 
PBpinA20PPEGA20 dilute prepared through the aboved procedure. The UV-Vis scan (λ 
= 250 – 500 nm) of each sample was collected at 0 min, 10 min, 30 min, 60 min, 90 
min and 120 min. The UV absorbance at λ = 310 nm was compared to the 0 min 
sample to obtaine the relative amount Nys remaining in the solution. 
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7.4.4.2 Sample preparation for  the self-assembly of block 
copolymers for TEM analysis 
 
Figure 7.11 TEM images of the two morphology found in the self-assembly of PBzA20PPEGA10 (a-b), 
and PBpinA20PPEGA10 (c-d) block copolymers in water (1 mg/mL). 
The samples for TEM were prepared by dissolving a certain amount of polymers 
(typically 5-10 mg) in a 14 mL vial using 1 mL DMF and followed by vigorous stirring 
(700 rpm) under nitrogen. 9 mL of HPLC grade water was added into the vial at a rate 
of 0.02 mL/min. Each sample was then dialysed against water (solvent changed 3 
times a day) for 2 days. After collecting each sample into a 50 mL Eppendorf tube, a 
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certain amount of water was added into the tube to reach a desired concentration 
(typically 5 mg/mL or 1 mg/mL).  
 
Figure 7.12 TEM images of the self-assembly of PBzA20PPEGA20, PBzA20PPEGA40, and 
PBzA20PPEGA80 block copolymers in water (5 mg/mL). 
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 Conclusions & Outlook 
Several strategies for the delivery of two antimicrobial agents, colistin and 
nystatin (Nys), have been described. It has demonstrated that the potential systemic 
toxicity of these biological agents to mammals can be reduced while their 
antimicrobial activity can be retained through the right choices of the polymeric 
delivery systems. 
The main focus of this work has been to modify polymyxin with polymers 
through a covalent linkage. It has been demonstrated that the polymer (PEG or PPEGA) 
modification of polymyxins can happen on the Dab or Thr residue(s) of the native 
colistin or the thiol group of the Thr10 →  Cys polymyxin B (Pol-SH), forming 
irreversible or releasable bonds under mild conditions. In particular, through a high 
efficient thiol-acrylate addition reaction, polymers can be introduced onto Pol-SH in 
aqueous media without the need for a catalyst. It has also been shown that copper-
mediated photoinduced living radical polymerisation technique (CP-LRP) is 
compatibility with polymyxin through the synthesis of polymer-polymyxin conjugates 
can be achieved through both ‘grafting-to’ and ‘grafting-from’ approaches. Due to the 
large size of the polymers, no antimicrobial activity was observed from the polymyxin 
conjugates with a single polymer chain attachment through the irreversible 
modification. However, the antimicrobial activity of polymyxins can be recovered 
from the colistin polymer conjugates with a releasable linker via hydrolysis. It is worth 
mentioning that the mono PEGylated colistin (col-aaPEG) showed a similar or better 
antibacterial activity as colistimethate sodium (CMS) and revealed no systemic 
toxicity, which can be a potential candidate as the alternative for CMS.  
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To demonstrate the concept that systemic toxicity of colistin can be reduced 
through a topical administration, a colistin-loaded antibacterial patch for burn wound 
infections treatment was developed through the encapsulation of colistin with a 
biocompatible and biodegradable hydrogel (HG-10). Through the dynamic imine bond 
formation and the ‘on-wound’ biodegradability of the hydrogel, colistin can be 
successfully encapsulated into the hydrogel and released effectively under 
physiological conditions, showing a similar antibacterial activity as the colistin 
solutions. Furthermore, even colistin-resistant Gram-negative bacterial can be greatly 
inhibited during the treatment while no overall systemic toxicity was revealed thanks 
to the localisation delivery of colistin. 
The delivery of Nys using polymers has also been described, aiming to improve 
its poor aqueous solubility and potential toxicity. The sugar amine and the 1,2-/1,3-
diol groups of Nys have proven to be possible modification sites for polymer 
modifications. Through the amine modification of Nys via a dynamic imine bond 
using an mPEG derivative (mPEG-FBA), an mPEG-FBA Nys conjugate can be 
achieved in an organic medium without a dehydrating agent. Although no pure product 
has been obtained, the crude mPEG-FBA Nys conjugate exhibited a comparible 
antifungal activity as native Nys with a reduced cytotoxicity. A polymeric micelle 
system to improve Nys solubility has also been prepared using a boronic acid 
containing amphiphilic polymer. Through the labile boronate ester formation between 
the polymer and the 1,2/1,3-diol groups on Nys, a water soluble Nys polymer complex 
has been formed and showed a much better solubility (~ 10 times) than native Nys. 
Although the actual morphology and the biological behaviour of the complex remain 
unknown, it showed a potential as a formulation to improve Nys chemical and 
biological performances.
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Appendix 
The Characterisation of PBA Modification Sites of Nys through 
Tandem Mass Spectroscopy 
The sample for tandem mass spectroscopy was prepared as below. 
Phenylboronic acid (PBA, 6 mg, 0.049 mmol, 4.5 equiv.) and Nystatin (Nys, 10 mg, 
0.011 mmol, 1 equiv.) were dissolved in a 7 mL glass vial with 2 mL DMF. The 
mixture was left on a roller mixer (SRT9, Stuart) for 18 h before the analysis from the 
tandem mass spectroscopy. The data and the related analysis were shown below. 
Though the ESI-MS data (SFigure 1-3), three Nys containing species charged 
with both proton and sodium ion were observed from the mixture. The mass of each 
species fitted perfectly with the Nys, Nys modified with one PBA (PBA1-Nys) and 
Nys modified with two PBA (PBA2-Nys), suggesting the formation of the Nys 
conjugate with PBA. To confirm that, tandem mass spectroscopy was then conducted. 
 
SFigure 1 The ESI-MS data of the mixture (above) and the simulation (below) of the isotopic pattern 
of Nys peaks, m/z 926 (proton adduct, left) and 948 (sodium adduct, right). 
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SFigure 2 The ESI-MS data (above) and the simulation (below) of the isotopic pattern of PBA1-Nys 
conjugate, m/z 1012 (proton adduct, left), 1034 (sodium adduct, right).  
 
SFigure 3 The ESI-MS data (above) and the simulation (below) of the isotopic pattern of PBA2- Nys 
conjugate, m/z 1098 (proton adduct, left), 1120 (sodium adduct, right).  
Through the comparison of the ESI-MS/MS data of the three species with proton 
(m/z 926, 1012, 1098) and sodium ion (m/z 948, 1034, 1120) (SFigure 4-8), it can be 
seen that similar patterns were observed in all these three species, suggesting all three 
species contained the structure of Nys. More importantly, extra sets of peaks that 
shared Nys pattern but with an increased molecular weight of one PBA and two PBA 
attachments along with a boron and two boron isotopic pattern, respectively, were 
observed from the MS/MS data of PBA1-Nys and PBA2-Nys peaks, suggesting one 
PBA was covalently attached onto Nys for PBA1-Nys and two for PBA2-Nys. 
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SFigure 4 Comparison of the MS/MS data of m/z 926, 1012, 1098 (full spectra). 
 
SFigure 5 Comparison of the MS/MS data of m/z 926, 1012, 1098 (zoom-in at high m/z). 
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SFigure 6 Comparison of the MS/MS data of m/z 926, 1012, 1098 (zoom-in at low m/z). 
 
SFigure 7 Comparison of the MS/MS data of m/z 948, 1034, 1120 (full spectra). 
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SFigure 8 Comparison of the MS/MS data of m/z 948, 1034, 1120 (zoom-in at high m/z). 
As shown in SFigure 9, m/z 723 was found in all the MS/MS data from the 
sodium adduct of three Nys species. This peak is possibly produced by the loss of the 
sugar unit, the carboxyl group and one water (can be from any one of the hydroxyl 
groups) from Nys. This implied that any modification will have to occur elsewhere on 
the lactone ring, rather than on the amino sugar unit. 
 
SFigure 9 a) Comparison of the MS/MS data of m/z 948, 1034, 1120 (zoom-in at m/z 723) and the 
simulation of m/z 723. b) The possible chemical structure of the fragment of m/z 723 (sodium adduct 
on the blue structure).  
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The fragment ion m/z 809 was found in both MS/MS data from the sodium 
adduct of PBA1-Nys and PBA2-Nys but not in native Nys (SFigure 10a). The isotopic 
pattern indicated there was one boron atom in m/z 809. Compared to m/z 723, 86 Da 
increased from m/z 809, indicating one PBA was attached. The fragment m/z 817 was 
only found in PBA2-Nys (SFigure 10b). The isotopic pattern indicated there were two 
boron atoms in the fragment ion m/z 817. On the other hand, a fragment ion m/z 645 
was only found in Nys, which is possible caused by the further loss of a part of the 
polyene structure (-C6H6) from m/z 723. The mass difference between m/z 817 and 
m/z 645 is 172 (= 2 × 86) Da (SFigure 11), implying two PBA were attached on PBA2-
Nys. Furthermore, the fragment m/z 895 with an isotopic pattern containing two boron 
atoms was only found in PBA2-Nys, which is 172 Da larger than the fragment ion m/z 
723, further confirming PBA2-Nys was the conjugation between Nys and two PBA. 
 
SFigure 10 Comparison of the MS/MS data of m/z 948, 1034, 1120 and the simulation of m/z 809 (a, 
zoom-in at m/z 809) and m/z 817 (b, zoom-in at m/z 817). 
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SFigure 11 Comparison of the MS/MS data of m/z 948, 1034, 1120 (zoom-in at m/z 645) and the 
simulation of m/z 645. b) The possible chemical structure of the fragment of m/z 645 (sodium adduct 
on the blue structure). 
 
SFigure 12 Comparison of the MS/MS data of m/z 948, 1034, 1120 (zoom-in at m/z 895) and the 
simulation of m/z 895. 
+MS2(948.0000), 40.0eV, 6.6-6.7min #296-298
+MS2(1033.5292), 42.0eV, 6.8-7.0min #302-307
893.4815
894.4778
895.4754
896.4784
897.4871
+MS2(1119.5635), 45.0eV, 7.8-7.9min #332-335
893.4820
1+
894.4789
1+
895.4764
1+
896.4790
1+
897.4818
1+
C₅₃H₆₂B₂N₄NaO₆, 895.4748
0
2000
4000
Intens.
0.0
0.5
1.0
4x10
0.00
0.25
0.50
0.75
4x10
0.00
0.25
0.50
0.75
4x10
892 894 896 898 900 902 m/z
Appendix 
Chongyu Zhu  204 
 
SFigure 13 Comparison of the MS/MS data of m/z 926, 1012, 1098 with the simulation of m/z 505 (a, 
zoom-in at m/z 505). b) The possible chemical structure of the fragment of m/z 645 (proton adduct 
with two PBA on the blue structure). 
The isotopic pattern indicated there were two boron atoms in the fragment ion 
m/z 505 (SFigure 13). The most likely chemical formula is C27H31B2O8. Thus, the 
chemical formula for the two PBA attachment is C15H24O8. Considering 8 oxygen 
atoms remain in that structure, the most likely modification is the hydrophilic hydroxyl 
group-rich part of Nys (highlighted as blue in SFigure 13). As the polyol structure is 
easy to dehydrate during the analysis and the dehydration could happen on any 
hydroxyl group. Therefore, a more accurate determination of the modification site was 
not possible at this stage. However, it can be determined that at most two PBA can be 
attached on to Nys molecule and the possible modification sites should happen at the 
hydroxyl groups within the area highlighted in Figure 7.1. 
Other m/z patterns with one boron or two boron atoms which were unable to be 
resolved were listed as below. 
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SFigure 14 The fragment ions of m/z 365, 383, 389, 401, 407, 443 found with the isotopic pattern 
containing one boron atoms from PBA-Nys and PBA2-Nys. 
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SFigure 15 The fragment ions of m/z 451 (a), 459 (b) and 511 (c) found with the isotopic pattern 
containing two boron atoms from PBA2-Nys. 
